# 专利文档

## 原始内容



  
    CN116555216A - Terminal transferase variant for controllable synthesis of single-stranded DNA and application 
        - Google Patents

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    

    
      
      #gb { top: 15px; left: auto; right: 0; width: auto; min-width: 135px !important; }   
      body { transition: none; }
    
    

    
      window.version = 'patent-search.search_20250707_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;
      window.experiments.plogs = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    

    
    
  
  
    
    
    
    
    
      
      

      
  CN116555216A - Terminal transferase variant for controllable synthesis of single-stranded DNA and application 
        - Google Patents
  Terminal transferase variant for controllable synthesis of single-stranded DNA and application 
       

  
  Download PDF
  ## Info

  
    Publication number
    CN116555216A
    
    
    
    CN116555216A
    CN202210107337.7A
    CN202210107337A
    CN116555216A
    CN 116555216 A
    CN116555216 A
    CN 116555216A
      
     
     
    CN 202210107337 A
    CN202210107337 A
    CN 202210107337A
    CN 116555216 A
    CN116555216 A
    CN 116555216A

    Authority
    CN
    China

    Prior art keywords
    leu
    lys
    glu
    ala
    variant

    Prior art date
    2022-01-28

    Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
    
      Pending
    
  

  Application number
  CN202210107337.7A

  Other languages
  
    
      Chinese (zh)
    
  

  

  Inventor
  æ±ä¼é
  é¯æäº
  æä»é¨
  ç¨å¥
  å¢ä¸½å¨
  å¨å©å©

  Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
  
    Tianjin Institute of Industrial Biotechnology of CAS
  

  Original Assignee
  Tianjin Institute of Industrial Biotechnology of CAS

  Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
  2022-01-28

  Filing date
  2022-01-28

  Publication date
  2023-08-08

  
  
    2022-01-28
    Application filed by Tianjin Institute of Industrial Biotechnology of CAS
    filed
    Critical
    
    
    
    Tianjin Institute of Industrial Biotechnology of CAS
  
  
    2022-01-28
    Priority to CN202210107337.7A
    priority
    Critical
    
    
    patent/CN116555216A/en
    
  
  
    2023-01-13
    Priority to US18/730,931
    priority
    
    
    
    patent/US20250101479A1/en
    
  
  
    2023-01-13
    Priority to EP23746005.0A
    priority
    
    
    
    patent/EP4450620A4/en
    
  
  
    2023-01-13
    Priority to PCT/CN2023/072086
    priority
    
    
    
    patent/WO2023143123A1/en
    
  
  
    2023-08-08
    Publication of CN116555216A
    publication
    Critical
    
    
    patent/CN116555216A/en
    
  
  
    Status
    Pending
    legal-status
    Critical
    Current
    
    
    
  

  ## Links
  
    

    
        
        Espacenet
      
      

    

    
      
      Global Dossier
    

    

      

      

      
      
        
        Discuss
      
  

  
    
      108010008286
      DNA nucleotidylexotransferase
      Proteins
      
      
      
      
      0.000
      title
      claims
      abstract
      description
      116
    
    
      230000015572
      biosynthetic process
      Effects
      
      
      
      
      0.000
      title
      claims
      abstract
      description
      26
    
    
      238000003786
      synthesis reaction
      Methods
      
      
      
      
      0.000
      title
      claims
      abstract
      description
      26
    
    
      108020004414
      DNA
      Proteins
      
      
      
      
      0.000
      title
      description
      22
    
    
      102100029764
      DNA-directed DNA/RNA polymerase mu
      Human genes
      
      
      
      
      0.000
      title
      description
      6
    
    
      102000053602
      DNA
      Human genes
      
      
      
      
      0.000
      title
      description
      5
    
    
      108020004682
      Single-Stranded DNA
      Proteins
      
      
      
      
      0.000
      title
      description
      5
    
    
      102100033215
      DNA nucleotidylexotransferase
      Human genes
      
      
      
      
      0.000
      claims
      abstract
      description
      110
    
    
      150000007523
      nucleic acids
      Chemical class
      
      
      
      
      0.000
      claims
      abstract
      description
      72
    
    
      102000039446
      nucleic acids
      Human genes
      
      
      
      
      0.000
      claims
      abstract
      description
      50
    
    
      108020004707
      nucleic acids
      Proteins
      
      
      
      
      0.000
      claims
      abstract
      description
      50
    
    
      125000000539
      amino acid group
      Chemical group
      
      
      
      
      0.000
      claims
      abstract
      description
      23
    
    
      125000003729
      nucleotide group
      Chemical group
      
      
      
      
      0.000
      claims
      description
      120
    
    
      239000002773
      nucleotide
      Substances
      
      
      
      
      0.000
      claims
      description
      69
    
    
      229910052720
      vanadium
      Inorganic materials
      
      
      
      
      0.000
      claims
      description
      32
    
    
      238000000034
      method
      Methods
      
      
      
      
      0.000
      claims
      description
      29
    
    
      230000035772
      mutation
      Effects
      
      
      
      
      0.000
      claims
      description
      27
    
    
      238000006467
      substitution reaction
      Methods
      
      
      
      
      0.000
      claims
      description
      25
    
    
      102000004190
      Enzymes
      Human genes
      
      
      
      
      0.000
      claims
      description
      22
    
    
      108090000790
      Enzymes
      Proteins
      
      
      
      
      0.000
      claims
      description
      22
    
    
      125000003275
      alpha amino acid group
      Chemical group
      
      
      
      
      0.000
      claims
      description
      22
    
    
      150000001413
      amino acids
      Chemical class
      
      
      
      
      0.000
      claims
      description
      21
    
    
      238000006243
      chemical reaction
      Methods
      
      
      
      
      0.000
      claims
      description
      18
    
    
      229910052731
      fluorine
      Inorganic materials
      
      
      
      
      0.000
      claims
      description
      18
    
    
      229910052799
      carbon
      Inorganic materials
      
      
      
      
      0.000
      claims
      description
      17
    
    
      229910052739
      hydrogen
      Inorganic materials
      
      
      
      
      0.000
      claims
      description
      17
    
    
      229910052698
      phosphorus
      Inorganic materials
      
      
      
      
      0.000
      claims
      description
      16
    
    
      229910052727
      yttrium
      Inorganic materials
      
      
      
      
      0.000
      claims
      description
      16
    
    
      239000000203
      mixture
      Substances
      
      
      
      
      0.000
      claims
      description
      10
    
    
      230000002194
      synthesizing effect
      Effects
      
      
      
      
      0.000
      claims
      description
      9
    
    
      238000010348
      incorporation
      Methods
      
      
      
      
      0.000
      claims
      description
      8
    
    
      239000013604
      expression vector
      Substances
      
      
      
      
      0.000
      claims
      description
      5
    
    
      238000004519
      manufacturing process
      Methods
      
      
      
      
      0.000
      claims
      description
      3
    
    
      230000004952
      protein activity
      Effects
      
      
      
      
      0.000
      claims
      description
      2
    
    
      108091033319
      polynucleotide
      Proteins
      
      
      
      
      0.000
      abstract
      description
      12
    
    
      102000040430
      polynucleotide
      Human genes
      
      
      
      
      0.000
      abstract
      description
      12
    
    
      239000002157
      polynucleotide
      Substances
      
      
      
      
      0.000
      abstract
      description
      12
    
    
      108020001778
      catalytic domains
      Proteins
      
      
      
      
      0.000
      abstract
      1
    
    
      239000012634
      fragment
      Substances
      
      
      
      
      0.000
      description
      45
    
    
      239000002777
      nucleoside
      Substances
      
      
      
      
      0.000
      description
      27
    
    
      -1
      nucleoside triphosphates
      Chemical class
      
      
      
      
      0.000
      description
      24
    
    
      238000012986
      modification
      Methods
      
      
      
      
      0.000
      description
      23
    
    
      235000001014
      amino acid
      Nutrition
      
      
      
      
      0.000
      description
      22
    
    
      229940024606
      amino acid
      Drugs
      
      
      
      
      0.000
      description
      21
    
    
      230000004048
      modification
      Effects
      
      
      
      
      0.000
      description
      19
    
    
      108090000623
      proteins and genes
      Proteins
      
      
      
      
      0.000
      description
      18
    
    
      230000003197
      catalytic effect
      Effects
      
      
      
      
      0.000
      description
      17
    
    
      239000001226
      triphosphate
      Substances
      
      
      
      
      0.000
      description
      17
    
    
      235000011178
      triphosphate
      Nutrition
      
      
      
      
      0.000
      description
      17
    
    
      230000002255
      enzymatic effect
      Effects
      
      
      
      
      0.000
      description
      16
    
    
      102000004169
      proteins and genes
      Human genes
      
      
      
      
      0.000
      description
      15
    
    
      238000003776
      cleavage reaction
      Methods
      
      
      
      
      0.000
      description
      14
    
    
      235000018102
      proteins
      Nutrition
      
      
      
      
      0.000
      description
      13
    
    
      239000007787
      solid
      Substances
      
      
      
      
      0.000
      description
      13
    
    
      FAPWRFPIFSIZLT-UHFFFAOYSA-M
      Sodium chloride
      Chemical compound
      
      
      [Na&#43;].[Cl-]
      FAPWRFPIFSIZLT-UHFFFAOYSA-M
      0.000
      description
      12
    
    
      KDXKERNSBIXSRK-UHFFFAOYSA-N
      Lysine
      Natural products
      
      
      NCCCCC(N)C(O)=O
      KDXKERNSBIXSRK-UHFFFAOYSA-N
      0.000
      description
      11
    
    
      239000003153
      chemical reaction reagent
      Substances
      
      
      
      
      0.000
      description
      11
    
    
      WHUUTDBJXJRKMK-UHFFFAOYSA-N
      Glutamic acid
      Natural products
      
      
      OC(=O)C(N)CCC(O)=O
      WHUUTDBJXJRKMK-UHFFFAOYSA-N
      0.000
      description
      9
    
    
      108010005233
      alanylglutamic acid
      Proteins
      
      
      
      
      0.000
      description
      9
    
    
      108010015792
      glycyllysine
      Proteins
      
      
      
      
      0.000
      description
      9
    
    
      230000002441
      reversible effect
      Effects
      
      
      
      
      0.000
      description
      9
    
    
      239000000758
      substrate
      Substances
      
      
      
      
      0.000
      description
      9
    
    
      NHSDEZURHWEZPN-SXTJYALSSA-N
      Asp-Ile-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CC(=O)O)N
      NHSDEZURHWEZPN-SXTJYALSSA-N
      0.000
      description
      8
    
    
      238000004422
      calculation algorithm
      Methods
      
      
      
      
      0.000
      description
      8
    
    
      239000005547
      deoxyribonucleotide
      Substances
      
      
      
      
      0.000
      description
      8
    
    
      108010073969
      valyllysine
      Proteins
      
      
      
      
      0.000
      description
      8
    
    
      108091034117
      Oligonucleotide
      Proteins
      
      
      
      
      0.000
      description
      7
    
    
      108010062796
      arginyllysine
      Proteins
      
      
      
      
      0.000
      description
      7
    
    
      238000001668
      nucleic acid synthesis
      Methods
      
      
      
      
      0.000
      description
      7
    
    
      150000003833
      nucleoside derivatives
      Chemical class
      
      
      
      
      0.000
      description
      7
    
    
      ACRYGQFHAQHDSF-ZLUOBGJFSA-N
      Asn-Asn-Asn
      Chemical compound
      
      
      NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O
      ACRYGQFHAQHDSF-ZLUOBGJFSA-N
      0.000
      description
      6
    
    
      PEDCQBHIVMGVHV-UHFFFAOYSA-N
      Glycerine
      Chemical compound
      
      
      OCC(O)CO
      PEDCQBHIVMGVHV-UHFFFAOYSA-N
      0.000
      description
      6
    
    
      XFIHDSBIPWEYJJ-YUMQZZPRSA-N
      Lys-Ala-Gly
      Chemical compound
      
      
      OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN
      XFIHDSBIPWEYJJ-YUMQZZPRSA-N
      0.000
      description
      6
    
    
      108010092854
      aspartyllysine
      Proteins
      
      
      
      
      0.000
      description
      6
    
    
      230000000903
      blocking effect
      Effects
      
      
      
      
      0.000
      description
      6
    
    
      239000003795
      chemical substances by application
      Substances
      
      
      
      
      0.000
      description
      6
    
    
      238000012217
      deletion
      Methods
      
      
      
      
      0.000
      description
      6
    
    
      230000037430
      deletion
      Effects
      
      
      
      
      0.000
      description
      6
    
    
      108010055341
      glutamyl-glutamic acid
      Proteins
      
      
      
      
      0.000
      description
      6
    
    
      230000007017
      scission
      Effects
      
      
      
      
      0.000
      description
      6
    
    
      239000011780
      sodium chloride
      Substances
      
      
      
      
      0.000
      description
      6
    
    
      239000000126
      substance
      Substances
      
      
      
      
      0.000
      description
      6
    
    
      239000013598
      vector
      Substances
      
      
      
      
      0.000
      description
      6
    
    
      QKNYBSVHEMOAJP-UHFFFAOYSA-N
      2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride
      Chemical compound
      
      
      Cl.OCC(N)(CO)CO
      QKNYBSVHEMOAJP-UHFFFAOYSA-N
      0.000
      description
      5
    
    
      YYSWCHMLFJLLBJ-ZLUOBGJFSA-N
      Ala-Ala-Ser
      Chemical compound
      
      
      C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O
      YYSWCHMLFJLLBJ-ZLUOBGJFSA-N
      0.000
      description
      5
    
    
      PVBBEKPHARMPHX-DCAQKATOSA-N
      Glu-Gln-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O
      PVBBEKPHARMPHX-DCAQKATOSA-N
      0.000
      description
      5
    
    
      DHMQDGOQFOQNFH-UHFFFAOYSA-N
      Glycine
      Chemical compound
      
      
      NCC(O)=O
      DHMQDGOQFOQNFH-UHFFFAOYSA-N
      0.000
      description
      5
    
    
      125000000217
      alkyl group
      Chemical group
      
      
      
      
      0.000
      description
      5
    
    
      230000003321
      amplification
      Effects
      
      
      
      
      0.000
      description
      5
    
    
      239000000872
      buffer
      Substances
      
      
      
      
      0.000
      description
      5
    
    
      210000004027
      cell
      Anatomy
      
      
      
      
      0.000
      description
      5
    
    
      230000000875
      corresponding effect
      Effects
      
      
      
      
      0.000
      description
      5
    
    
      239000000499
      gel
      Substances
      
      
      
      
      0.000
      description
      5
    
    
      108010017391
      lysylvaline
      Proteins
      
      
      
      
      0.000
      description
      5
    
    
      238000003199
      nucleic acid amplification method
      Methods
      
      
      
      
      0.000
      description
      5
    
    
      230000003287
      optical effect
      Effects
      
      
      
      
      0.000
      description
      5
    
    
      108090000765
      processed proteins &amp; peptides
      Proteins
      
      
      
      
      0.000
      description
      5
    
    
      YBJHBAHKTGYVGT-ZKWXMUAHSA-N
      (&#43;)-Biotin
      Chemical compound
      
      
      N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21
      YBJHBAHKTGYVGT-ZKWXMUAHSA-N
      0.000
      description
      4
    
    
      ASJSAQIRZKANQN-CRCLSJGQSA-N
      2-deoxy-D-ribose
      Chemical compound
      
      
      OC[C@@H](O)[C@@H](O)CC=O
      ASJSAQIRZKANQN-CRCLSJGQSA-N
      0.000
      description
      4
    
    
      FTSAJSADJCMDHH-CIUDSAMLSA-N
      Asn-Lys-Asp
      Chemical compound
      
      
      C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N
      FTSAJSADJCMDHH-CIUDSAMLSA-N
      0.000
      description
      4
    
    
      241000894006
      Bacteria
      Species
      
      
      
      
      0.000
      description
      4
    
    
      HMFHBZSHGGEWLO-SOOFDHNKSA-N
      D-ribofuranose
      Chemical compound
      
      
      OC[C@H]1OC(O)[C@H](O)[C@@H]1O
      HMFHBZSHGGEWLO-SOOFDHNKSA-N
      0.000
      description
      4
    
    
      241000588724
      Escherichia coli
      Species
      
      
      
      
      0.000
      description
      4
    
    
      SJPMNHCEWPTRBR-BQBZGAKWSA-N
      Glu-Glu-Gly
      Chemical compound
      
      
      OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O
      SJPMNHCEWPTRBR-BQBZGAKWSA-N
      0.000
      description
      4
    
    
      QNJNPKSWAHPYGI-JYJNAYRXSA-N
      Glu-Phe-Leu
      Chemical compound
      
      
      OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1
      QNJNPKSWAHPYGI-JYJNAYRXSA-N
      0.000
      description
      4
    
    
      JWNZHMSRZXXGTM-XKBZYTNZSA-N
      Glu-Ser-Thr
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      JWNZHMSRZXXGTM-XKBZYTNZSA-N
      0.000
      description
      4
    
    
      XLXPYSDGMXTTNQ-UHFFFAOYSA-N
      Ile-Phe-Leu
      Natural products
      
      
      CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1
      XLXPYSDGMXTTNQ-UHFFFAOYSA-N
      0.000
      description
      4
    
    
      PMGDADKJMCOXHX-UHFFFAOYSA-N
      L-Arginyl-L-glutamin-acetat
      Natural products
      
      
      NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O
      PMGDADKJMCOXHX-UHFFFAOYSA-N
      0.000
      description
      4
    
    
      QNAYBMKLOCPYGJ-REOHCLBHSA-N
      L-alanine
      Chemical compound
      
      
      C[C@H](N)C(O)=O
      QNAYBMKLOCPYGJ-REOHCLBHSA-N
      0.000
      description
      4
    
    
      AGPKZVBTJJNPAG-WHFBIAKZSA-N
      L-isoleucine
      Chemical compound
      
      
      CC[C@H](C)[C@H](N)C(O)=O
      AGPKZVBTJJNPAG-WHFBIAKZSA-N
      0.000
      description
      4
    
    
      ROHFNLRQFUQHCH-YFKPBYRVSA-N
      L-leucine
      Chemical compound
      
      
      CC(C)C[C@H](N)C(O)=O
      ROHFNLRQFUQHCH-YFKPBYRVSA-N
      0.000
      description
      4
    
    
      PRZVBIAOPFGAQF-SRVKXCTJSA-N
      Leu-Glu-Met
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O
      PRZVBIAOPFGAQF-SRVKXCTJSA-N
      0.000
      description
      4
    
    
      VCHVSKNMTXWIIP-SRVKXCTJSA-N
      Leu-Lys-Ser
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O
      VCHVSKNMTXWIIP-SRVKXCTJSA-N
      0.000
      description
      4
    
    
      SXOFUVGLPHCPRQ-KKUMJFAQSA-N
      Leu-Tyr-Cys
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(O)=O
      SXOFUVGLPHCPRQ-KKUMJFAQSA-N
      0.000
      description
      4
    
    
      ATNKHRAIZCMCCN-BZSNNMDCSA-N
      Lys-Lys-Phe
      Chemical compound
      
      
      C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N
      ATNKHRAIZCMCCN-BZSNNMDCSA-N
      0.000
      description
      4
    
    
      VQILILSLEFDECU-GUBZILKMSA-N
      Met-Pro-Ala
      Chemical compound
      
      
      [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O
      VQILILSLEFDECU-GUBZILKMSA-N
      0.000
      description
      4
    
    
      YBAFDPFAUTYYRW-UHFFFAOYSA-N
      N-L-alpha-glutamyl-L-leucine
      Natural products
      
      
      CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O
      YBAFDPFAUTYYRW-UHFFFAOYSA-N
      0.000
      description
      4
    
    
      XMBSYZWANAQXEV-UHFFFAOYSA-N
      N-alpha-L-glutamyl-L-phenylalanine
      Natural products
      
      
      OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1
      XMBSYZWANAQXEV-UHFFFAOYSA-N
      0.000
      description
      4
    
    
      KDLHZDBZIXYQEI-UHFFFAOYSA-N
      Palladium
      Chemical compound
      
      
      [Pd]
      KDLHZDBZIXYQEI-UHFFFAOYSA-N
      0.000
      description
      4
    
    
      ABEFOXGAIIJDCL-SFJXLCSZSA-N
      Phe-Thr-Trp
      Chemical compound
      
      
      C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1
      ABEFOXGAIIJDCL-SFJXLCSZSA-N
      0.000
      description
      4
    
    
      RGMLUHANLDVMPB-ULQDDVLXSA-N
      Phe-Val-Lys
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N
      RGMLUHANLDVMPB-ULQDDVLXSA-N
      0.000
      description
      4
    
    
      PYMYPHUHKUWMLA-LMVFSUKVSA-N
      Ribose
      Natural products
      
      
      OC[C@@H](O)[C@@H](O)[C@@H](O)C=O
      PYMYPHUHKUWMLA-LMVFSUKVSA-N
      0.000
      description
      4
    
    
      XXROXFHCMVXETG-UWVGGRQHSA-N
      Val-Gly-Val
      Chemical compound
      
      
      CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O
      XXROXFHCMVXETG-UWVGGRQHSA-N
      0.000
      description
      4
    
    
      JQTYTBPCSOAZHI-FXQIFTODSA-N
      Val-Ser-Cys
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N
      JQTYTBPCSOAZHI-FXQIFTODSA-N
      0.000
      description
      4
    
    
      QTPQHINADBYBNA-DCAQKATOSA-N
      Val-Ser-Lys
      Chemical compound
      
      
      CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN
      QTPQHINADBYBNA-DCAQKATOSA-N
      0.000
      description
      4
    
    
      KZSNJWFQEVHDMF-UHFFFAOYSA-N
      Valine
      Natural products
      
      
      CC(C)C(N)C(O)=O
      KZSNJWFQEVHDMF-UHFFFAOYSA-N
      0.000
      description
      4
    
    
      235000004279
      alanine
      Nutrition
      
      
      
      
      0.000
      description
      4
    
    
      108010069490
      alanyl-glycyl-seryl-glutamic acid
      Proteins
      
      
      
      
      0.000
      description
      4
    
    
      HMFHBZSHGGEWLO-UHFFFAOYSA-N
      alpha-D-Furanose-Ribose
      Natural products
      
      
      OCC1OC(O)C(O)C1O
      HMFHBZSHGGEWLO-UHFFFAOYSA-N
      0.000
      description
      4
    
    
      KOSRFJWDECSPRO-UHFFFAOYSA-N
      alpha-L-glutamyl-L-glutamic acid
      Natural products
      
      
      OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O
      KOSRFJWDECSPRO-UHFFFAOYSA-N
      0.000
      description
      4
    
    
      108010008355
      arginyl-glutamine
      Proteins
      
      
      
      
      0.000
      description
      4
    
    
      125000004432
      carbon atom
      Chemical group
      
      
      C*
      
      0.000
      description
      4
    
    
      125000002637
      deoxyribonucleotide group
      Chemical group
      
      
      
      
      0.000
      description
      4
    
    
      230000000694
      effects
      Effects
      
      
      
      
      0.000
      description
      4
    
    
      238000006911
      enzymatic reaction
      Methods
      
      
      
      
      0.000
      description
      4
    
    
      108010057083
      glutamyl-aspartyl-leucine
      Proteins
      
      
      
      
      0.000
      description
      4
    
    
      108010050848
      glycylleucine
      Proteins
      
      
      
      
      0.000
      description
      4
    
    
      108010034529
      leucyl-lysine
      Proteins
      
      
      
      
      0.000
      description
      4
    
    
      108010057821
      leucylproline
      Proteins
      
      
      
      
      0.000
      description
      4
    
    
      108010064235
      lysylglycine
      Proteins
      
      
      
      
      0.000
      description
      4
    
    
      125000003835
      nucleoside group
      Chemical group
      
      
      
      
      0.000
      description
      4
    
    
      238000002515
      oligonucleotide synthesis
      Methods
      
      
      
      
      0.000
      description
      4
    
    
      125000002467
      phosphate group
      Chemical group
      
      
      [H]OP(=O)(O[H])O[*]
      
      0.000
      description
      4
    
    
      238000002264
      polyacrylamide gel electrophoresis
      Methods
      
      
      
      
      0.000
      description
      4
    
    
      238000000746
      purification
      Methods
      
      
      
      
      0.000
      description
      4
    
    
      238000002864
      sequence alignment
      Methods
      
      
      
      
      0.000
      description
      4
    
    
      LPXPTNMVRIOKMN-UHFFFAOYSA-M
      sodium nitrite
      Chemical compound
      
      
      [Na&#43;].[O-]N=O
      LPXPTNMVRIOKMN-UHFFFAOYSA-M
      0.000
      description
      4
    
    
      235000000346
      sugar
      Nutrition
      
      
      
      
      0.000
      description
      4
    
    
      125000003903
      2-propenyl group
      Chemical group
      
      
      [H]C([*])([H])C([H])=C([H])[H]
      
      0.000
      description
      3
    
    
      FUSPCLTUKXQREV-ACZMJKKPSA-N
      Ala-Glu-Ala
      Chemical compound
      
      
      [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O
      FUSPCLTUKXQREV-ACZMJKKPSA-N
      0.000
      description
      3
    
    
      FSNVAJOPUDVQAR-AVGNSLFASA-N
      Arg-Lys-Arg
      Chemical compound
      
      
      NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      FSNVAJOPUDVQAR-AVGNSLFASA-N
      0.000
      description
      3
    
    
      MTYLORHAQXVQOW-AVGNSLFASA-N
      Arg-Lys-Met
      Chemical compound
      
      
      [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O
      MTYLORHAQXVQOW-AVGNSLFASA-N
      0.000
      description
      3
    
    
      230000006820
      DNA synthesis
      Effects
      
      
      
      
      0.000
      description
      3
    
    
      108010014303
      DNA-directed DNA polymerase
      Proteins
      
      
      
      
      0.000
      description
      3
    
    
      102000016928
      DNA-directed DNA polymerase
      Human genes
      
      
      
      
      0.000
      description
      3
    
    
      JFOKLAPFYCTNHW-SRVKXCTJSA-N
      Gln-Arg-Lys
      Chemical compound
      
      
      C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N
      JFOKLAPFYCTNHW-SRVKXCTJSA-N
      0.000
      description
      3
    
    
      ZJICFHQSPWFBKP-AVGNSLFASA-N
      Glu-Asn-Tyr
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
      ZJICFHQSPWFBKP-AVGNSLFASA-N
      0.000
      description
      3
    
    
      AUTNXSQEVVHSJK-YVNDNENWSA-N
      Glu-Glu-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O
      AUTNXSQEVVHSJK-YVNDNENWSA-N
      0.000
      description
      3
    
    
      WTMZXOPHTIVFCP-QEWYBTABSA-N
      Glu-Ile-Phe
      Chemical compound
      
      
      OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1
      WTMZXOPHTIVFCP-QEWYBTABSA-N
      0.000
      description
      3
    
    
      MWMJCGBSIORNCD-AVGNSLFASA-N
      Glu-Leu-Leu
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O
      MWMJCGBSIORNCD-AVGNSLFASA-N
      0.000
      description
      3
    
    
      ZYRXTRTUCAVNBQ-GVXVVHGQSA-N
      Glu-Val-Lys
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N
      ZYRXTRTUCAVNBQ-GVXVVHGQSA-N
      0.000
      description
      3
    
    
      PHIXPNQDGGILMP-YVNDNENWSA-N
      Ile-Glu-Glu
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N
      PHIXPNQDGGILMP-YVNDNENWSA-N
      0.000
      description
      3
    
    
      DCXYFEDJOCDNAF-REOHCLBHSA-N
      L-asparagine
      Chemical compound
      
      
      OC(=O)[C@@H](N)CC(N)=O
      DCXYFEDJOCDNAF-REOHCLBHSA-N
      0.000
      description
      3
    
    
      CKLJMWTZIZZHCS-REOHCLBHSA-N
      L-aspartic acid
      Chemical compound
      
      
      OC(=O)[C@@H](N)CC(O)=O
      CKLJMWTZIZZHCS-REOHCLBHSA-N
      0.000
      description
      3
    
    
      FFEARJCKVFRZRR-BYPYZUCNSA-N
      L-methionine
      Chemical compound
      
      
      CSCC[C@H](N)C(O)=O
      FFEARJCKVFRZRR-BYPYZUCNSA-N
      0.000
      description
      3
    
    
      COLNVLDHVKWLRT-QMMMGPOBSA-N
      L-phenylalanine
      Chemical compound
      
      
      OC(=O)[C@@H](N)CC1=CC=CC=C1
      COLNVLDHVKWLRT-QMMMGPOBSA-N
      0.000
      description
      3
    
    
      AYFVYJQAPQTCCC-GBXIJSLDSA-N
      L-threonine
      Chemical compound
      
      
      C[C@@H](O)[C@H](N)C(O)=O
      AYFVYJQAPQTCCC-GBXIJSLDSA-N
      0.000
      description
      3
    
    
      OUYCCCASQSFEME-QMMMGPOBSA-N
      L-tyrosine
      Chemical compound
      
      
      OC(=O)[C@@H](N)CC1=CC=C(O)C=C1
      OUYCCCASQSFEME-QMMMGPOBSA-N
      0.000
      description
      3
    
    
      KZSNJWFQEVHDMF-BYPYZUCNSA-N
      L-valine
      Chemical compound
      
      
      CC(C)[C@H](N)C(O)=O
      KZSNJWFQEVHDMF-BYPYZUCNSA-N
      0.000
      description
      3
    
    
      241000880493
      Leptailurus serval
      Species
      
      
      
      
      0.000
      description
      3
    
    
      YOKVEHGYYQEQOP-QWRGUYRKSA-N
      Leu-Leu-Gly
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O
      YOKVEHGYYQEQOP-QWRGUYRKSA-N
      0.000
      description
      3
    
    
      BGZCJDGBBUUBHA-KKUMJFAQSA-N
      Leu-Lys-Leu
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O
      BGZCJDGBBUUBHA-KKUMJFAQSA-N
      0.000
      description
      3
    
    
      WRODMZBHNNPRLN-SRVKXCTJSA-N
      Lys-Leu-Ser
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O
      WRODMZBHNNPRLN-SRVKXCTJSA-N
      0.000
      description
      3
    
    
      SITLTJHOQZFJGG-UHFFFAOYSA-N
      N-L-alpha-glutamyl-L-valine
      Natural products
      
      
      CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O
      SITLTJHOQZFJGG-UHFFFAOYSA-N
      0.000
      description
      3
    
    
      RFEXGCASCQGGHZ-STQMWFEESA-N
      Phe-Gly-Arg
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      RFEXGCASCQGGHZ-STQMWFEESA-N
      0.000
      description
      3
    
    
      QWZIOCFPXMAXET-CIUDSAMLSA-N
      Ser-Arg-Gln
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O
      QWZIOCFPXMAXET-CIUDSAMLSA-N
      0.000
      description
      3
    
    
      UOLGINIHBRIECN-FXQIFTODSA-N
      Ser-Glu-Glu
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      UOLGINIHBRIECN-FXQIFTODSA-N
      0.000
      description
      3
    
    
      PZBFGYYEXUXCOF-UHFFFAOYSA-N
      TCEP
      Chemical compound
      
      
      OC(=O)CCP(CCC(O)=O)CCC(O)=O
      PZBFGYYEXUXCOF-UHFFFAOYSA-N
      0.000
      description
      3
    
    
      SEXRBCGSZRCIPE-LYSGOOTNSA-N
      Trp-Thr-Gly
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O
      SEXRBCGSZRCIPE-LYSGOOTNSA-N
      0.000
      description
      3
    
    
      108010047495
      alanylglycine
      Proteins
      
      
      
      
      0.000
      description
      3
    
    
      230000008878
      coupling
      Effects
      
      
      
      
      0.000
      description
      3
    
    
      238000010168
      coupling process
      Methods
      
      
      
      
      0.000
      description
      3
    
    
      238000005859
      coupling reaction
      Methods
      
      
      
      
      0.000
      description
      3
    
    
      238000005336
      cracking
      Methods
      
      
      
      
      0.000
      description
      3
    
    
      238000001514
      detection method
      Methods
      
      
      
      
      0.000
      description
      3
    
    
      238000005516
      engineering process
      Methods
      
      
      
      
      0.000
      description
      3
    
    
      230000006870
      function
      Effects
      
      
      
      
      0.000
      description
      3
    
    
      JYPCXBJRLBHWME-UHFFFAOYSA-N
      glycyl-L-prolyl-L-arginine
      Natural products
      
      
      NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O
      JYPCXBJRLBHWME-UHFFFAOYSA-N
      0.000
      description
      3
    
    
      108010025801
      glycyl-prolyl-arginine
      Proteins
      
      
      
      
      0.000
      description
      3
    
    
      108010037850
      glycylvaline
      Proteins
      
      
      
      
      0.000
      description
      3
    
    
      125000005842
      heteroatom
      Chemical group
      
      
      
      
      0.000
      description
      3
    
    
      RAXXELZNTBOGNW-UHFFFAOYSA-N
      imidazole
      Natural products
      
      
      C1=CNC=N1
      RAXXELZNTBOGNW-UHFFFAOYSA-N
      0.000
      description
      3
    
    
      150000002460
      imidazoles
      Chemical class
      
      
      
      
      0.000
      description
      3
    
    
      230000006872
      improvement
      Effects
      
      
      
      
      0.000
      description
      3
    
    
      AGPKZVBTJJNPAG-UHFFFAOYSA-N
      isoleucine
      Natural products
      
      
      CCC(C)C(N)C(O)=O
      AGPKZVBTJJNPAG-UHFFFAOYSA-N
      0.000
      description
      3
    
    
      229960000310
      isoleucine
      Drugs
      
      
      
      
      0.000
      description
      3
    
    
      108010038320
      lysylphenylalanine
      Proteins
      
      
      
      
      0.000
      description
      3
    
    
      230000007246
      mechanism
      Effects
      
      
      
      
      0.000
      description
      3
    
    
      229930182817
      methionine
      Natural products
      
      
      
      
      0.000
      description
      3
    
    
      108010005942
      methionylglycine
      Proteins
      
      
      
      
      0.000
      description
      3
    
    
      239000008188
      pellet
      Substances
      
      
      
      
      0.000
      description
      3
    
    
      229920001184
      polypeptide
      Polymers
      
      
      
      
      0.000
      description
      3
    
    
      230000008569
      process
      Effects
      
      
      
      
      0.000
      description
      3
    
    
      102000004196
      processed proteins &amp; peptides
      Human genes
      
      
      
      
      0.000
      description
      3
    
    
      239000012429
      reaction media
      Substances
      
      
      
      
      0.000
      description
      3
    
    
      239000000523
      sample
      Substances
      
      
      
      
      0.000
      description
      3
    
    
      125000000547
      substituted alkyl group
      Chemical group
      
      
      
      
      0.000
      description
      3
    
    
      238000001308
      synthesis method
      Methods
      
      
      
      
      0.000
      description
      3
    
    
      108010061238
      threonyl-glycine
      Proteins
      
      
      
      
      0.000
      description
      3
    
    
      239000004474
      valine
      Substances
      
      
      
      
      0.000
      description
      3
    
    
      XVZCXCTYGHPNEM-IHRRRGAJSA-N
      (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O
      XVZCXCTYGHPNEM-IHRRRGAJSA-N
      0.000
      description
      2
    
    
      BRPMXFSTKXXNHF-IUCAKERBSA-N
      (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid
      Chemical compound
      
      
      OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1
      BRPMXFSTKXXNHF-IUCAKERBSA-N
      0.000
      description
      2
    
    
      IAOXXKYIZHCAQJ-ACZMJKKPSA-N
      (2s)-2-[[2-[[(2s)-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]acetyl]amino]propanoic acid
      Chemical compound
      
      
      OC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O
      IAOXXKYIZHCAQJ-ACZMJKKPSA-N
      0.000
      description
      2
    
    
      ZKHQWZAMYRWXGA-KQYNXXCUSA-J
      ATP(4-)
      Chemical compound
      
      
      C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O
      ZKHQWZAMYRWXGA-KQYNXXCUSA-J
      0.000
      description
      2
    
    
      ZKHQWZAMYRWXGA-UHFFFAOYSA-N
      Adenosine triphosphate
      Natural products
      
      
      C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O
      ZKHQWZAMYRWXGA-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      JBVSSSZFNTXJDX-YTLHQDLWSA-N
      Ala-Ala-Thr
      Chemical compound
      
      
      C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N
      JBVSSSZFNTXJDX-YTLHQDLWSA-N
      0.000
      description
      2
    
    
      KIUYPHAMDKDICO-WHFBIAKZSA-N
      Ala-Asp-Gly
      Chemical compound
      
      
      C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O
      KIUYPHAMDKDICO-WHFBIAKZSA-N
      0.000
      description
      2
    
    
      SFNFGFDRYJKZKN-XQXXSGGOSA-N
      Ala-Gln-Thr
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)N)O
      SFNFGFDRYJKZKN-XQXXSGGOSA-N
      0.000
      description
      2
    
    
      OMMDTNGURYRDAC-NRPADANISA-N
      Ala-Glu-Val
      Chemical compound
      
      
      [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O
      OMMDTNGURYRDAC-NRPADANISA-N
      0.000
      description
      2
    
    
      GRPHQEMIFDPKOE-HGNGGELXSA-N
      Ala-His-Glu
      Chemical compound
      
      
      [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      GRPHQEMIFDPKOE-HGNGGELXSA-N
      0.000
      description
      2
    
    
      NYDBKUNVSALYPX-NAKRPEOUSA-N
      Ala-Ile-Arg
      Chemical compound
      
      
      C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N
      NYDBKUNVSALYPX-NAKRPEOUSA-N
      0.000
      description
      2
    
    
      CCDFBRZVTDDJNM-GUBZILKMSA-N
      Ala-Leu-Glu
      Chemical compound
      
      
      [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      CCDFBRZVTDDJNM-GUBZILKMSA-N
      0.000
      description
      2
    
    
      SOBIAADAMRHGKH-CIUDSAMLSA-N
      Ala-Leu-Ser
      Chemical compound
      
      
      [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O
      SOBIAADAMRHGKH-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      SUHLZMHFRALVSY-YUMQZZPRSA-N
      Ala-Lys-Gly
      Chemical compound
      
      
      NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O
      SUHLZMHFRALVSY-YUMQZZPRSA-N
      0.000
      description
      2
    
    
      VHEVVUZDDUCAKU-FXQIFTODSA-N
      Ala-Met-Asp
      Chemical compound
      
      
      [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O
      VHEVVUZDDUCAKU-FXQIFTODSA-N
      0.000
      description
      2
    
    
      CNQAFFMNJIQYGX-DRZSPHRISA-N
      Ala-Phe-Glu
      Chemical compound
      
      
      OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1
      CNQAFFMNJIQYGX-DRZSPHRISA-N
      0.000
      description
      2
    
    
      WEZNQZHACPSMEF-QEJZJMRPSA-N
      Ala-Phe-Lys
      Chemical compound
      
      
      NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1
      WEZNQZHACPSMEF-QEJZJMRPSA-N
      0.000
      description
      2
    
    
      ZXKNLCPUNZPFGY-LEWSCRJBSA-N
      Ala-Tyr-Pro
      Chemical compound
      
      
      C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N
      ZXKNLCPUNZPFGY-LEWSCRJBSA-N
      0.000
      description
      2
    
    
      IYKVSFNGSWTTNZ-GUBZILKMSA-N
      Ala-Val-Arg
      Chemical compound
      
      
      C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N
      IYKVSFNGSWTTNZ-GUBZILKMSA-N
      0.000
      description
      2
    
    
      REWSWYIDQIELBE-FXQIFTODSA-N
      Ala-Val-Ser
      Chemical compound
      
      
      [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O
      REWSWYIDQIELBE-FXQIFTODSA-N
      0.000
      description
      2
    
    
      YUIGJDNAGKJLDO-JYJNAYRXSA-N
      Arg-Arg-Tyr
      Chemical compound
      
      
      [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
      YUIGJDNAGKJLDO-JYJNAYRXSA-N
      0.000
      description
      2
    
    
      JSHVMZANPXCDTL-GMOBBJLQSA-N
      Arg-Asp-Ile
      Chemical compound
      
      
      [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O
      JSHVMZANPXCDTL-GMOBBJLQSA-N
      0.000
      description
      2
    
    
      XLWSGICNBZGYTA-CIUDSAMLSA-N
      Arg-Glu-Asp
      Chemical compound
      
      
      NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O
      XLWSGICNBZGYTA-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      PHHRSPBBQUFULD-UWVGGRQHSA-N
      Arg-Gly-Lys
      Chemical compound
      
      
      C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N
      PHHRSPBBQUFULD-UWVGGRQHSA-N
      0.000
      description
      2
    
    
      UBCPNBUIQNMDNH-NAKRPEOUSA-N
      Arg-Ile-Ala
      Chemical compound
      
      
      [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O
      UBCPNBUIQNMDNH-NAKRPEOUSA-N
      0.000
      description
      2
    
    
      VVJTWSRNMJNDPN-IUCAKERBSA-N
      Arg-Met-Gly
      Chemical compound
      
      
      [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O
      VVJTWSRNMJNDPN-IUCAKERBSA-N
      0.000
      description
      2
    
    
      NYDIVDKTULRINZ-AVGNSLFASA-N
      Arg-Met-Lys
      Chemical compound
      
      
      CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N
      NYDIVDKTULRINZ-AVGNSLFASA-N
      0.000
      description
      2
    
    
      NMTANZXPDAHUKU-ULQDDVLXSA-N
      Arg-Tyr-Lys
      Chemical compound
      
      
      NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1
      NMTANZXPDAHUKU-ULQDDVLXSA-N
      0.000
      description
      2
    
    
      PSUXEQYPYZLNER-QXEWZRGKSA-N
      Arg-Val-Asn
      Chemical compound
      
      
      [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O
      PSUXEQYPYZLNER-QXEWZRGKSA-N
      0.000
      description
      2
    
    
      239000004475
      Arginine
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      PDQBXRSOSCTGKY-ACZMJKKPSA-N
      Asn-Ala-Gln
      Chemical compound
      
      
      C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N
      PDQBXRSOSCTGKY-ACZMJKKPSA-N
      0.000
      description
      2
    
    
      BVLIJXXSXBUGEC-SRVKXCTJSA-N
      Asn-Asn-Tyr
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
      BVLIJXXSXBUGEC-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      BHQQRVARKXWXPP-ACZMJKKPSA-N
      Asn-Asp-Glu
      Chemical compound
      
      
      C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N
      BHQQRVARKXWXPP-ACZMJKKPSA-N
      0.000
      description
      2
    
    
      MSBDSTRUMZFSEU-PEFMBERDSA-N
      Asn-Glu-Ile
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O
      MSBDSTRUMZFSEU-PEFMBERDSA-N
      0.000
      description
      2
    
    
      DMLSCRJBWUEALP-LAEOZQHASA-N
      Asn-Glu-Val
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O
      DMLSCRJBWUEALP-LAEOZQHASA-N
      0.000
      description
      2
    
    
      IICZCLFBILYRCU-WHFBIAKZSA-N
      Asn-Gly-Asp
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O
      IICZCLFBILYRCU-WHFBIAKZSA-N
      0.000
      description
      2
    
    
      GJFYPBDMUGGLFR-NKWVEPMBSA-N
      Asn-Gly-Pro
      Chemical compound
      
      
      C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC(=O)N)N)C(=O)O
      GJFYPBDMUGGLFR-NKWVEPMBSA-N
      0.000
      description
      2
    
    
      VXLBDJWTONZHJN-YUMQZZPRSA-N
      Asn-His-Gly
      Chemical compound
      
      
      C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N
      VXLBDJWTONZHJN-YUMQZZPRSA-N
      0.000
      description
      2
    
    
      NVWJMQNYLYWVNQ-BYULHYEWSA-N
      Asn-Ile-Gly
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O
      NVWJMQNYLYWVNQ-BYULHYEWSA-N
      0.000
      description
      2
    
    
      LTZIRYMWOJHRCH-GUDRVLHUSA-N
      Asn-Ile-Pro
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N
      LTZIRYMWOJHRCH-GUDRVLHUSA-N
      0.000
      description
      2
    
    
      HFPXZWPUVFVNLL-GUBZILKMSA-N
      Asn-Leu-Gln
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O
      HFPXZWPUVFVNLL-GUBZILKMSA-N
      0.000
      description
      2
    
    
      WIDVAWAQBRAKTI-YUMQZZPRSA-N
      Asn-Leu-Gly
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O
      WIDVAWAQBRAKTI-YUMQZZPRSA-N
      0.000
      description
      2
    
    
      FBODFHMLALOPHP-GUBZILKMSA-N
      Asn-Lys-Glu
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      FBODFHMLALOPHP-GUBZILKMSA-N
      0.000
      description
      2
    
    
      RZNAMKZJPBQWDJ-SRVKXCTJSA-N
      Asn-Lys-His
      Chemical compound
      
      
      C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N
      RZNAMKZJPBQWDJ-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      ZYPWIUFLYMQZBS-SRVKXCTJSA-N
      Asn-Lys-Lys
      Chemical compound
      
      
      C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N
      ZYPWIUFLYMQZBS-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      WCRQQIPFSXFIRN-LPEHRKFASA-N
      Asn-Met-Pro
      Chemical compound
      
      
      CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N
      WCRQQIPFSXFIRN-LPEHRKFASA-N
      0.000
      description
      2
    
    
      GKKUBLFXKRDMFC-BQBZGAKWSA-N
      Asn-Pro-Gly
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O
      GKKUBLFXKRDMFC-BQBZGAKWSA-N
      0.000
      description
      2
    
    
      VCJCPARXDBEGNE-GUBZILKMSA-N
      Asn-Pro-Pro
      Chemical compound
      
      
      NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1
      VCJCPARXDBEGNE-GUBZILKMSA-N
      0.000
      description
      2
    
    
      AMGQTNHANMRPOE-LKXGYXEUSA-N
      Asn-Thr-Ser
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O
      AMGQTNHANMRPOE-LKXGYXEUSA-N
      0.000
      description
      2
    
    
      NSTBNYOKCZKOMI-AVGNSLFASA-N
      Asn-Tyr-Glu
      Chemical compound
      
      
      C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O
      NSTBNYOKCZKOMI-AVGNSLFASA-N
      0.000
      description
      2
    
    
      RGKKALNPOYURGE-ZKWXMUAHSA-N
      Asp-Ala-Val
      Chemical compound
      
      
      N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O
      RGKKALNPOYURGE-ZKWXMUAHSA-N
      0.000
      description
      2
    
    
      ZSJFGGSPCCHMNE-LAEOZQHASA-N
      Asp-Gln-Val
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N
      ZSJFGGSPCCHMNE-LAEOZQHASA-N
      0.000
      description
      2
    
    
      VAWNQIGQPUOPQW-ACZMJKKPSA-N
      Asp-Glu-Ala
      Chemical compound
      
      
      [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O
      VAWNQIGQPUOPQW-ACZMJKKPSA-N
      0.000
      description
      2
    
    
      PDECQIHABNQRHN-GUBZILKMSA-N
      Asp-Glu-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O
      PDECQIHABNQRHN-GUBZILKMSA-N
      0.000
      description
      2
    
    
      POTCZYQVVNXUIG-BQBZGAKWSA-N
      Asp-Gly-Pro
      Chemical compound
      
      
      OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O
      POTCZYQVVNXUIG-BQBZGAKWSA-N
      0.000
      description
      2
    
    
      QNFRBNZGVVKBNJ-PEFMBERDSA-N
      Asp-Ile-Gln
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N
      QNFRBNZGVVKBNJ-PEFMBERDSA-N
      0.000
      description
      2
    
    
      GKWFMNNNYZHJHV-SRVKXCTJSA-N
      Asp-Lys-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O
      GKWFMNNNYZHJHV-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      DONWIPDSZZJHHK-HJGDQZAQSA-N
      Asp-Lys-Thr
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O
      DONWIPDSZZJHHK-HJGDQZAQSA-N
      0.000
      description
      2
    
    
      LTCKTLYKRMCFOC-KKUMJFAQSA-N
      Asp-Phe-Leu
      Chemical compound
      
      
      [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O
      LTCKTLYKRMCFOC-KKUMJFAQSA-N
      0.000
      description
      2
    
    
      GCACQYDBDHRVGE-LKXGYXEUSA-N
      Asp-Thr-Ser
      Chemical compound
      
      
      OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O
      GCACQYDBDHRVGE-LKXGYXEUSA-N
      0.000
      description
      2
    
    
      FIRWLDUOFOULCA-XIRDDKMYSA-N
      Asp-Trp-Lys
      Chemical compound
      
      
      C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N
      FIRWLDUOFOULCA-XIRDDKMYSA-N
      0.000
      description
      2
    
    
      BYLPQJAWXJWUCJ-YDHLFZDLSA-N
      Asp-Tyr-Val
      Chemical compound
      
      
      [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O
      BYLPQJAWXJWUCJ-YDHLFZDLSA-N
      0.000
      description
      2
    
    
      DCXYFEDJOCDNAF-UHFFFAOYSA-N
      Asparagine
      Natural products
      
      
      OC(=O)C(N)CC(N)=O
      DCXYFEDJOCDNAF-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      ZVNFONSZVUBRAV-CIUDSAMLSA-N
      Cys-Gln-Arg
      Chemical compound
      
      
      C(C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N)CN=C(N)N
      ZVNFONSZVUBRAV-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      XLLSMEFANRROJE-GUBZILKMSA-N
      Cys-Leu-Glu
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N
      XLLSMEFANRROJE-GUBZILKMSA-N
      0.000
      description
      2
    
    
      AZDQAZRURQMSQD-XPUUQOCRSA-N
      Cys-Val-Gly
      Chemical compound
      
      
      [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O
      AZDQAZRURQMSQD-XPUUQOCRSA-N
      0.000
      description
      2
    
    
      PCDQPRRSZKQHHS-CCXZUQQUSA-N
      Cytarabine Triphosphate
      Chemical compound
      
      
      O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1
      PCDQPRRSZKQHHS-CCXZUQQUSA-N
      0.000
      description
      2
    
    
      ZHNUHDYFZUAESO-UHFFFAOYSA-N
      Formamide
      Chemical compound
      
      
      NC=O
      ZHNUHDYFZUAESO-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      JSYULGSPLTZDHM-NRPADANISA-N
      Gln-Ala-Val
      Chemical compound
      
      
      [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O
      JSYULGSPLTZDHM-NRPADANISA-N
      0.000
      description
      2
    
    
      KZEUVLLVULIPNX-GUBZILKMSA-N
      Gln-Asp-Lys
      Chemical compound
      
      
      C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N
      KZEUVLLVULIPNX-GUBZILKMSA-N
      0.000
      description
      2
    
    
      FGYPOQPQTUNESW-IUCAKERBSA-N
      Gln-Gly-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N
      FGYPOQPQTUNESW-IUCAKERBSA-N
      0.000
      description
      2
    
    
      DRNMNLKUUKKPIA-HTUGSXCWSA-N
      Gln-Phe-Thr
      Chemical compound
      
      
      C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCC(N)=O)C(O)=O
      DRNMNLKUUKKPIA-HTUGSXCWSA-N
      0.000
      description
      2
    
    
      HLRLXVPRJJITSK-IFFSRLJSSA-N
      Gln-Thr-Val
      Chemical compound
      
      
      [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O
      HLRLXVPRJJITSK-IFFSRLJSSA-N
      0.000
      description
      2
    
    
      JTWZNMUVQWWGOX-SOUVJXGZSA-N
      Gln-Tyr-Pro
      Chemical compound
      
      
      C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O
      JTWZNMUVQWWGOX-SOUVJXGZSA-N
      0.000
      description
      2
    
    
      UBRQJXFDVZNYJP-AVGNSLFASA-N
      Gln-Tyr-Ser
      Chemical compound
      
      
      C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O
      UBRQJXFDVZNYJP-AVGNSLFASA-N
      0.000
      description
      2
    
    
      OACPJRQRAHMQEQ-NHCYSSNCSA-N
      Gln-Val-Arg
      Chemical compound
      
      
      NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O
      OACPJRQRAHMQEQ-NHCYSSNCSA-N
      0.000
      description
      2
    
    
      RUFHOVYUYSNDNY-ACZMJKKPSA-N
      Glu-Ala-Ala
      Chemical compound
      
      
      OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O
      RUFHOVYUYSNDNY-ACZMJKKPSA-N
      0.000
      description
      2
    
    
      NCWOMXABNYEPLY-NRPADANISA-N
      Glu-Ala-Val
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O
      NCWOMXABNYEPLY-NRPADANISA-N
      0.000
      description
      2
    
    
      CVPXINNKRTZBMO-CIUDSAMLSA-N
      Glu-Arg-Asn
      Chemical compound
      
      
      C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)CN=C(N)N
      CVPXINNKRTZBMO-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      CKRUHITYRFNUKW-WDSKDSINSA-N
      Glu-Asn-Gly
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O
      CKRUHITYRFNUKW-WDSKDSINSA-N
      0.000
      description
      2
    
    
      JVSBYEDSSRZQGV-GUBZILKMSA-N
      Glu-Asp-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O
      JVSBYEDSSRZQGV-GUBZILKMSA-N
      0.000
      description
      2
    
    
      LGYZYFFDELZWRS-DCAQKATOSA-N
      Glu-Glu-Lys
      Chemical compound
      
      
      NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O
      LGYZYFFDELZWRS-DCAQKATOSA-N
      0.000
      description
      2
    
    
      LRPXYSGPOBVBEH-IUCAKERBSA-N
      Glu-Gly-Leu
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O
      LRPXYSGPOBVBEH-IUCAKERBSA-N
      0.000
      description
      2
    
    
      VGOFRWOTSXVPAU-SDDRHHMPSA-N
      Glu-His-Pro
      Chemical compound
      
      
      C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)O)N)C(=O)O
      VGOFRWOTSXVPAU-SDDRHHMPSA-N
      0.000
      description
      2
    
    
      GXMXPCXXKVWOSM-KQXIARHKSA-N
      Glu-Ile-Pro
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N
      GXMXPCXXKVWOSM-KQXIARHKSA-N
      0.000
      description
      2
    
    
      IVGJYOOGJLFKQE-AVGNSLFASA-N
      Glu-Leu-Lys
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N
      IVGJYOOGJLFKQE-AVGNSLFASA-N
      0.000
      description
      2
    
    
      GJBUAAAIZSRCDC-GVXVVHGQSA-N
      Glu-Leu-Val
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O
      GJBUAAAIZSRCDC-GVXVVHGQSA-N
      0.000
      description
      2
    
    
      CUPSDFQZTVVTSK-GUBZILKMSA-N
      Glu-Lys-Asp
      Chemical compound
      
      
      OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O
      CUPSDFQZTVVTSK-GUBZILKMSA-N
      0.000
      description
      2
    
    
      OFIHURVSQXAZIR-SZMVWBNQSA-N
      Glu-Lys-Trp
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
      OFIHURVSQXAZIR-SZMVWBNQSA-N
      0.000
      description
      2
    
    
      ZQYZDDXTNQXUJH-CIUDSAMLSA-N
      Glu-Met-Ala
      Chemical compound
      
      
      C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)N
      ZQYZDDXTNQXUJH-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      JPUNZXVHHRZMNL-XIRDDKMYSA-N
      Glu-Pro-Trp
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
      JPUNZXVHHRZMNL-XIRDDKMYSA-N
      0.000
      description
      2
    
    
      ARIORLIIMJACKZ-KKUMJFAQSA-N
      Glu-Pro-Tyr
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
      ARIORLIIMJACKZ-KKUMJFAQSA-N
      0.000
      description
      2
    
    
      VNCNWQPIQYAMAK-ACZMJKKPSA-N
      Glu-Ser-Ser
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O
      VNCNWQPIQYAMAK-ACZMJKKPSA-N
      0.000
      description
      2
    
    
      HQTDNEZTGZUWSY-XVKPBYJWSA-N
      Glu-Val-Gly
      Chemical compound
      
      
      CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)NCC(O)=O
      HQTDNEZTGZUWSY-XVKPBYJWSA-N
      0.000
      description
      2
    
    
      VIPDPMHGICREIS-GVXVVHGQSA-N
      Glu-Val-Leu
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O
      VIPDPMHGICREIS-GVXVVHGQSA-N
      0.000
      description
      2
    
    
      JRDYDYXZKFNNRQ-XPUUQOCRSA-N
      Gly-Ala-Val
      Chemical compound
      
      
      CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN
      JRDYDYXZKFNNRQ-XPUUQOCRSA-N
      0.000
      description
      2
    
    
      KKBWDNZXYLGJEY-UHFFFAOYSA-N
      Gly-Arg-Pro
      Natural products
      
      
      NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O
      KKBWDNZXYLGJEY-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      LCNXZQROPKFGQK-WHFBIAKZSA-N
      Gly-Asp-Ser
      Chemical compound
      
      
      NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O
      LCNXZQROPKFGQK-WHFBIAKZSA-N
      0.000
      description
      2
    
    
      PABFFPWEJMEVEC-JGVFFNPUSA-N
      Gly-Gln-Pro
      Chemical compound
      
      
      C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O
      PABFFPWEJMEVEC-JGVFFNPUSA-N
      0.000
      description
      2
    
    
      QSVCIFZPGLOZGH-WDSKDSINSA-N
      Gly-Glu-Ser
      Chemical compound
      
      
      NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O
      QSVCIFZPGLOZGH-WDSKDSINSA-N
      0.000
      description
      2
    
    
      MBOAPAXLTUSMQI-JHEQGTHGSA-N
      Gly-Glu-Thr
      Chemical compound
      
      
      [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      MBOAPAXLTUSMQI-JHEQGTHGSA-N
      0.000
      description
      2
    
    
      VAXIVIPMCTYSHI-YUMQZZPRSA-N
      Gly-His-Asp
      Chemical compound
      
      
      C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN
      VAXIVIPMCTYSHI-YUMQZZPRSA-N
      0.000
      description
      2
    
    
      DGKBSGNCMCLDSL-BYULHYEWSA-N
      Gly-Ile-Asn
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN
      DGKBSGNCMCLDSL-BYULHYEWSA-N
      0.000
      description
      2
    
    
      ITZOBNKQDZEOCE-NHCYSSNCSA-N
      Gly-Ile-Lys
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN
      ITZOBNKQDZEOCE-NHCYSSNCSA-N
      0.000
      description
      2
    
    
      PAWIVEIWWYGBAM-YUMQZZPRSA-N
      Gly-Leu-Ala
      Chemical compound
      
      
      NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O
      PAWIVEIWWYGBAM-YUMQZZPRSA-N
      0.000
      description
      2
    
    
      NSTUFLGQJCOCDL-UWVGGRQHSA-N
      Gly-Leu-Arg
      Chemical compound
      
      
      NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N
      NSTUFLGQJCOCDL-UWVGGRQHSA-N
      0.000
      description
      2
    
    
      UUYBFNKHOCJCHT-VHSXEESVSA-N
      Gly-Leu-Pro
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN
      UUYBFNKHOCJCHT-VHSXEESVSA-N
      0.000
      description
      2
    
    
      FXLVSYVJDPCIHH-STQMWFEESA-N
      Gly-Phe-Arg
      Chemical compound
      
      
      [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      FXLVSYVJDPCIHH-STQMWFEESA-N
      0.000
      description
      2
    
    
      UIQGJYUEQDOODF-KWQFWETISA-N
      Gly-Tyr-Ala
      Chemical compound
      
      
      OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1
      UIQGJYUEQDOODF-KWQFWETISA-N
      0.000
      description
      2
    
    
      YJDALMUYJIENAG-QWRGUYRKSA-N
      Gly-Tyr-Asn
      Chemical compound
      
      
      C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN)O
      YJDALMUYJIENAG-QWRGUYRKSA-N
      0.000
      description
      2
    
    
      DNVDEMWIYLVIQU-RCOVLWMOSA-N
      Gly-Val-Asp
      Chemical compound
      
      
      NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O
      DNVDEMWIYLVIQU-RCOVLWMOSA-N
      0.000
      description
      2
    
    
      AFMOTCMSEBITOE-YEPSODPASA-N
      Gly-Val-Thr
      Chemical compound
      
      
      NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      AFMOTCMSEBITOE-YEPSODPASA-N
      0.000
      description
      2
    
    
      239000004471
      Glycine
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      XKMLYUALXHKNFT-UUOKFMHZSA-N
      Guanosine-5&#39;-triphosphate
      Chemical compound
      
      
      C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
      XKMLYUALXHKNFT-UUOKFMHZSA-N
      0.000
      description
      2
    
    
      JBCLFWXMTIKCCB-UHFFFAOYSA-N
      H-Gly-Phe-OH
      Natural products
      
      
      NCC(=O)NC(C(O)=O)CC1=CC=CC=C1
      JBCLFWXMTIKCCB-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      LYSMQLXUCAKELQ-DCAQKATOSA-N
      His-Asp-Arg
      Chemical compound
      
      
      C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N
      LYSMQLXUCAKELQ-DCAQKATOSA-N
      0.000
      description
      2
    
    
      ZJSMFRTVYSLKQU-DJFWLOJKSA-N
      His-Asp-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N
      ZJSMFRTVYSLKQU-DJFWLOJKSA-N
      0.000
      description
      2
    
    
      IMCHNUANCIGUKS-SRVKXCTJSA-N
      His-Glu-Arg
      Chemical compound
      
      
      [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      IMCHNUANCIGUKS-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      RGPWUJOMKFYFSR-QWRGUYRKSA-N
      His-Gly-Leu
      Chemical compound
      
      
      [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O
      RGPWUJOMKFYFSR-QWRGUYRKSA-N
      0.000
      description
      2
    
    
      AIPUZFXMXAHZKY-QWRGUYRKSA-N
      His-Leu-Gly
      Chemical compound
      
      
      [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O
      AIPUZFXMXAHZKY-QWRGUYRKSA-N
      0.000
      description
      2
    
    
      TVMNTHXFRSXZGR-IHRRRGAJSA-N
      His-Lys-Val
      Chemical compound
      
      
      [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O
      TVMNTHXFRSXZGR-IHRRRGAJSA-N
      0.000
      description
      2
    
    
      FBCURAVMSXNOLP-JYJNAYRXSA-N
      His-Phe-Gln
      Chemical compound
      
      
      C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N
      FBCURAVMSXNOLP-JYJNAYRXSA-N
      0.000
      description
      2
    
    
      CYHYBSGMHMHKOA-CIQUZCHMSA-N
      Ile-Ala-Thr
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N
      CYHYBSGMHMHKOA-CIQUZCHMSA-N
      0.000
      description
      2
    
    
      MKWSZEHGHSLNPF-NAKRPEOUSA-N
      Ile-Ala-Val
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N
      MKWSZEHGHSLNPF-NAKRPEOUSA-N
      0.000
      description
      2
    
    
      RGSOCXHDOPQREB-ZPFDUUQYSA-N
      Ile-Asp-Leu
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N
      RGSOCXHDOPQREB-ZPFDUUQYSA-N
      0.000
      description
      2
    
    
      HGNUKGZQASSBKQ-PCBIJLKTSA-N
      Ile-Asp-Phe
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N
      HGNUKGZQASSBKQ-PCBIJLKTSA-N
      0.000
      description
      2
    
    
      OUUCIIJSBIBCHB-ZPFDUUQYSA-N
      Ile-Leu-Asp
      Chemical compound
      
      
      CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O
      OUUCIIJSBIBCHB-ZPFDUUQYSA-N
      0.000
      description
      2
    
    
      FTUZWJVSNZMLPI-RVMXOQNASA-N
      Ile-Met-Pro
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N
      FTUZWJVSNZMLPI-RVMXOQNASA-N
      0.000
      description
      2
    
    
      XLXPYSDGMXTTNQ-DKIMLUQUSA-N
      Ile-Phe-Leu
      Chemical compound
      
      
      CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(O)=O
      XLXPYSDGMXTTNQ-DKIMLUQUSA-N
      0.000
      description
      2
    
    
      SAEWJTCJQVZQNZ-IUKAMOBKSA-N
      Ile-Thr-Asn
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N
      SAEWJTCJQVZQNZ-IUKAMOBKSA-N
      0.000
      description
      2
    
    
      YBKKLDBBPFIXBQ-MBLNEYKQSA-N
      Ile-Thr-Gly
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N
      YBKKLDBBPFIXBQ-MBLNEYKQSA-N
      0.000
      description
      2
    
    
      XVUAQNRNFMVWBR-BLMTYFJBSA-N
      Ile-Trp-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N
      XVUAQNRNFMVWBR-BLMTYFJBSA-N
      0.000
      description
      2
    
    
      HNDVDQJCIGZPNO-YFKPBYRVSA-N
      L-histidine
      Chemical compound
      
      
      OC(=O)[C@@H](N)CC1=CN=CN1
      HNDVDQJCIGZPNO-YFKPBYRVSA-N
      0.000
      description
      2
    
    
      RCFDOSNHHZGBOY-UHFFFAOYSA-N
      L-isoleucyl-L-alanine
      Natural products
      
      
      CCC(C)C(N)C(=O)NC(C)C(O)=O
      RCFDOSNHHZGBOY-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      QIVBCDIJIAJPQS-VIFPVBQESA-N
      L-tryptophane
      Chemical compound
      
      
      C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1
      QIVBCDIJIAJPQS-VIFPVBQESA-N
      0.000
      description
      2
    
    
      CQQGCWPXDHTTNF-GUBZILKMSA-N
      Leu-Ala-Glu
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O
      CQQGCWPXDHTTNF-GUBZILKMSA-N
      0.000
      description
      2
    
    
      KWTVLKBOQATPHJ-SRVKXCTJSA-N
      Leu-Ala-Lys
      Chemical compound
      
      
      C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N
      KWTVLKBOQATPHJ-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      STAVRDQLZOTNKJ-RHYQMDGZSA-N
      Leu-Arg-Thr
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      STAVRDQLZOTNKJ-RHYQMDGZSA-N
      0.000
      description
      2
    
    
      ZURHXHNAEJJRNU-CIUDSAMLSA-N
      Leu-Asp-Asn
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O
      ZURHXHNAEJJRNU-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      MYGQXVYRZMKRDB-SRVKXCTJSA-N
      Leu-Asp-Lys
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN
      MYGQXVYRZMKRDB-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      GBDMISNMNXVTNV-XIRDDKMYSA-N
      Leu-Asp-Trp
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
      GBDMISNMNXVTNV-XIRDDKMYSA-N
      0.000
      description
      2
    
    
      QLQHWWCSCLZUMA-KKUMJFAQSA-N
      Leu-Asp-Tyr
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1
      QLQHWWCSCLZUMA-KKUMJFAQSA-N
      0.000
      description
      2
    
    
      HYIFFZAQXPUEAU-QWRGUYRKSA-N
      Leu-Gly-Leu
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C
      HYIFFZAQXPUEAU-QWRGUYRKSA-N
      0.000
      description
      2
    
    
      KVOFSTUWVSQMDK-KKUMJFAQSA-N
      Leu-His-Lys
      Chemical compound
      
      
      NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CN=CN1
      KVOFSTUWVSQMDK-KKUMJFAQSA-N
      0.000
      description
      2
    
    
      DBSLVQBXKVKDKJ-BJDJZHNGSA-N
      Leu-Ile-Ala
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O
      DBSLVQBXKVKDKJ-BJDJZHNGSA-N
      0.000
      description
      2
    
    
      HNDWYLYAYNBWMP-AJNGGQMLSA-N
      Leu-Ile-Lys
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N
      HNDWYLYAYNBWMP-AJNGGQMLSA-N
      0.000
      description
      2
    
    
      LIINDKYIGYTDLG-PPCPHDFISA-N
      Leu-Ile-Thr
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      LIINDKYIGYTDLG-PPCPHDFISA-N
      0.000
      description
      2
    
    
      NRFGTHFONZYFNY-MGHWNKPDSA-N
      Leu-Ile-Tyr
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1
      NRFGTHFONZYFNY-MGHWNKPDSA-N
      0.000
      description
      2
    
    
      JKSIBWITFMQTOA-XUXIUFHCSA-N
      Leu-Ile-Val
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O
      JKSIBWITFMQTOA-XUXIUFHCSA-N
      0.000
      description
      2
    
    
      LXKNSJLSGPNHSK-KKUMJFAQSA-N
      Leu-Leu-Lys
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N
      LXKNSJLSGPNHSK-KKUMJFAQSA-N
      0.000
      description
      2
    
    
      XVZCXCTYGHPNEM-UHFFFAOYSA-N
      Leu-Leu-Pro
      Natural products
      
      
      CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O
      XVZCXCTYGHPNEM-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      IEWBEPKLKUXQBU-VOAKCMCISA-N
      Leu-Leu-Thr
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      IEWBEPKLKUXQBU-VOAKCMCISA-N
      0.000
      description
      2
    
    
      UCNNZELZXFXXJQ-BZSNNMDCSA-N
      Leu-Leu-Tyr
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1
      UCNNZELZXFXXJQ-BZSNNMDCSA-N
      0.000
      description
      2
    
    
      RZXLZBIUTDQHJQ-SRVKXCTJSA-N
      Leu-Lys-Asp
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O
      RZXLZBIUTDQHJQ-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      LVTJJOJKDCVZGP-QWRGUYRKSA-N
      Leu-Lys-Gly
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O
      LVTJJOJKDCVZGP-QWRGUYRKSA-N
      0.000
      description
      2
    
    
      BJWKOATWNQJPSK-SRVKXCTJSA-N
      Leu-Met-Glu
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N
      BJWKOATWNQJPSK-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      MJTOYIHCKVQICL-ULQDDVLXSA-N
      Leu-Met-Phe
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N
      MJTOYIHCKVQICL-ULQDDVLXSA-N
      0.000
      description
      2
    
    
      HGUUMQWGYCVPKG-DCAQKATOSA-N
      Leu-Pro-Cys
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N
      HGUUMQWGYCVPKG-DCAQKATOSA-N
      0.000
      description
      2
    
    
      KWLWZYMNUZJKMZ-IHRRRGAJSA-N
      Leu-Pro-Leu
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O
      KWLWZYMNUZJKMZ-IHRRRGAJSA-N
      0.000
      description
      2
    
    
      XXXXOVFBXRERQL-ULQDDVLXSA-N
      Leu-Pro-Phe
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1
      XXXXOVFBXRERQL-ULQDDVLXSA-N
      0.000
      description
      2
    
    
      IRMLZWSRWSGTOP-CIUDSAMLSA-N
      Leu-Ser-Ala
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O
      IRMLZWSRWSGTOP-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      ODRREERHVHMIPT-OEAJRASXSA-N
      Leu-Thr-Phe
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1
      ODRREERHVHMIPT-OEAJRASXSA-N
      0.000
      description
      2
    
    
      ZGGVHTQAPHVMKM-IHPCNDPISA-N
      Leu-Trp-Lys
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)O)N
      ZGGVHTQAPHVMKM-IHPCNDPISA-N
      0.000
      description
      2
    
    
      AXVIGSRGTMNSJU-YESZJQIVSA-N
      Leu-Tyr-Pro
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N
      AXVIGSRGTMNSJU-YESZJQIVSA-N
      0.000
      description
      2
    
    
      YIRIDPUGZKHMHT-ACRUOGEOSA-N
      Leu-Tyr-Tyr
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
      YIRIDPUGZKHMHT-ACRUOGEOSA-N
      0.000
      description
      2
    
    
      CGHXMODRYJISSK-NHCYSSNCSA-N
      Leu-Val-Asp
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O
      CGHXMODRYJISSK-NHCYSSNCSA-N
      0.000
      description
      2
    
    
      QESXLSQLQHHTIX-RHYQMDGZSA-N
      Leu-Val-Thr
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      QESXLSQLQHHTIX-RHYQMDGZSA-N
      0.000
      description
      2
    
    
      ROHFNLRQFUQHCH-UHFFFAOYSA-N
      Leucine
      Natural products
      
      
      CC(C)CC(N)C(O)=O
      ROHFNLRQFUQHCH-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      MPGHETGWWWUHPY-CIUDSAMLSA-N
      Lys-Ala-Asp
      Chemical compound
      
      
      OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN
      MPGHETGWWWUHPY-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      YIBOAHAOAWACDK-QEJZJMRPSA-N
      Lys-Ala-Phe
      Chemical compound
      
      
      NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1
      YIBOAHAOAWACDK-QEJZJMRPSA-N
      0.000
      description
      2
    
    
      DEFGUIIUYAUEDU-ZPFDUUQYSA-N
      Lys-Asn-Ile
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O
      DEFGUIIUYAUEDU-ZPFDUUQYSA-N
      0.000
      description
      2
    
    
      QUCDKEKDPYISNX-HJGDQZAQSA-N
      Lys-Asn-Thr
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      QUCDKEKDPYISNX-HJGDQZAQSA-N
      0.000
      description
      2
    
    
      YEIYAQQKADPIBJ-GARJFASQSA-N
      Lys-Asp-Pro
      Chemical compound
      
      
      C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O
      YEIYAQQKADPIBJ-GARJFASQSA-N
      0.000
      description
      2
    
    
      PHHYNOUOUWYQRO-XIRDDKMYSA-N
      Lys-Asp-Trp
      Chemical compound
      
      
      C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N
      PHHYNOUOUWYQRO-XIRDDKMYSA-N
      0.000
      description
      2
    
    
      GKFNXYMAMKJSKD-NHCYSSNCSA-N
      Lys-Asp-Val
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O
      GKFNXYMAMKJSKD-NHCYSSNCSA-N
      0.000
      description
      2
    
    
      ZXEUFAVXODIPHC-GUBZILKMSA-N
      Lys-Glu-Asn
      Chemical compound
      
      
      NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O
      ZXEUFAVXODIPHC-GUBZILKMSA-N
      0.000
      description
      2
    
    
      LCMWVZLBCUVDAZ-IUCAKERBSA-N
      Lys-Gly-Glu
      Chemical compound
      
      
      [NH3&#43;]CCCC[C@H]([NH3&#43;])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O
      LCMWVZLBCUVDAZ-IUCAKERBSA-N
      0.000
      description
      2
    
    
      WVJNGSFKBKOKRV-AJNGGQMLSA-N
      Lys-Leu-Ile
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O
      WVJNGSFKBKOKRV-AJNGGQMLSA-N
      0.000
      description
      2
    
    
      LJADEBULDNKJNK-IHRRRGAJSA-N
      Lys-Leu-Val
      Chemical compound
      
      
      CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O
      LJADEBULDNKJNK-IHRRRGAJSA-N
      0.000
      description
      2
    
    
      WKUXWMWQTOYTFI-SRVKXCTJSA-N
      Lys-Met-Gln
      Chemical compound
      
      
      CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N
      WKUXWMWQTOYTFI-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      WWEWGPOLIJXGNX-XUXIUFHCSA-N
      Lys-Met-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)N
      WWEWGPOLIJXGNX-XUXIUFHCSA-N
      0.000
      description
      2
    
    
      HYSVGEAWTGPMOA-IHRRRGAJSA-N
      Lys-Pro-Leu
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O
      HYSVGEAWTGPMOA-IHRRRGAJSA-N
      0.000
      description
      2
    
    
      LECIJRIRMVOFMH-ULQDDVLXSA-N
      Lys-Pro-Phe
      Chemical compound
      
      
      NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1
      LECIJRIRMVOFMH-ULQDDVLXSA-N
      0.000
      description
      2
    
    
      HKXSZKJMDBHOTG-CIUDSAMLSA-N
      Lys-Ser-Ala
      Chemical compound
      
      
      OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN
      HKXSZKJMDBHOTG-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      RPWTZTBIFGENIA-VOAKCMCISA-N
      Lys-Thr-Leu
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O
      RPWTZTBIFGENIA-VOAKCMCISA-N
      0.000
      description
      2
    
    
      RMOKGALPSPOYKE-KATARQTJSA-N
      Lys-Thr-Ser
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O
      RMOKGALPSPOYKE-KATARQTJSA-N
      0.000
      description
      2
    
    
      CAVRAQIDHUPECU-UVOCVTCTSA-N
      Lys-Thr-Thr
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      CAVRAQIDHUPECU-UVOCVTCTSA-N
      0.000
      description
      2
    
    
      NROQVSYLPRLJIP-PMVMPFDFSA-N
      Lys-Trp-Tyr
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
      NROQVSYLPRLJIP-PMVMPFDFSA-N
      0.000
      description
      2
    
    
      QLFAPXUXEBAWEK-NHCYSSNCSA-N
      Lys-Val-Asp
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O
      QLFAPXUXEBAWEK-NHCYSSNCSA-N
      0.000
      description
      2
    
    
      GILLQRYAWOMHED-DCAQKATOSA-N
      Lys-Val-Ser
      Chemical compound
      
      
      OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN
      GILLQRYAWOMHED-DCAQKATOSA-N
      0.000
      description
      2
    
    
      239000004472
      Lysine
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      ONGCSGVHCSAATF-CIUDSAMLSA-N
      Met-Ala-Glu
      Chemical compound
      
      
      CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O
      ONGCSGVHCSAATF-CIUDSAMLSA-N
      0.000
      description
      2
    
    
      DCHHUGLTVLJYKA-FXQIFTODSA-N
      Met-Asn-Ala
      Chemical compound
      
      
      CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O
      DCHHUGLTVLJYKA-FXQIFTODSA-N
      0.000
      description
      2
    
    
      DRINJBAHUGXNFC-DCAQKATOSA-N
      Met-Asp-His
      Chemical compound
      
      
      [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O
      DRINJBAHUGXNFC-DCAQKATOSA-N
      0.000
      description
      2
    
    
      HOZNVKDCKZPRER-XUXIUFHCSA-N
      Met-Lys-Ile
      Chemical compound
      
      
      [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O
      HOZNVKDCKZPRER-XUXIUFHCSA-N
      0.000
      description
      2
    
    
      WXJLBSXNUHIGSS-OSUNSFLBSA-N
      Met-Thr-Ile
      Chemical compound
      
      
      [H]N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O
      WXJLBSXNUHIGSS-OSUNSFLBSA-N
      0.000
      description
      2
    
    
      AUEJLPRZGVVDNU-UHFFFAOYSA-N
      N-L-tyrosyl-L-leucine
      Natural products
      
      
      CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1
      AUEJLPRZGVVDNU-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      AJHCSUXXECOXOY-UHFFFAOYSA-N
      N-glycyl-L-tryptophan
      Natural products
      
      
      C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1
      AJHCSUXXECOXOY-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      108010002311
      N-glycylglutamic acid
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      KSPIYJQBLVDRRI-UHFFFAOYSA-N
      N-methylisoleucine
      Chemical compound
      
      
      CCC(C)C(NC)C(O)=O
      KSPIYJQBLVDRRI-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      125000001429
      N-terminal alpha-amino-acid group
      Chemical group
      
      
      
      
      0.000
      description
      2
    
    
      BQVUABVGYYSDCJ-UHFFFAOYSA-N
      Nalpha-L-Leucyl-L-tryptophan
      Natural products
      
      
      C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1
      BQVUABVGYYSDCJ-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      YRKFKTQRVBJYLT-CQDKDKBSSA-N
      Phe-Ala-His
      Chemical compound
      
      
      C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1
      YRKFKTQRVBJYLT-CQDKDKBSSA-N
      0.000
      description
      2
    
    
      KAHUBGWSIQNZQQ-KKUMJFAQSA-N
      Phe-Asn-Lys
      Chemical compound
      
      
      NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1
      KAHUBGWSIQNZQQ-KKUMJFAQSA-N
      0.000
      description
      2
    
    
      LXUJDHOKVUYHRC-KKUMJFAQSA-N
      Phe-Cys-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N
      LXUJDHOKVUYHRC-KKUMJFAQSA-N
      0.000
      description
      2
    
    
      WYPVCIACUMJRIB-JYJNAYRXSA-N
      Phe-Gln-Lys
      Chemical compound
      
      
      C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N
      WYPVCIACUMJRIB-JYJNAYRXSA-N
      0.000
      description
      2
    
    
      LWPMGKSZPKFKJD-DZKIICNBSA-N
      Phe-Glu-Val
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O
      LWPMGKSZPKFKJD-DZKIICNBSA-N
      0.000
      description
      2
    
    
      NAXPHWZXEXNDIW-JTQLQIEISA-N
      Phe-Gly-Gly
      Chemical compound
      
      
      OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1
      NAXPHWZXEXNDIW-JTQLQIEISA-N
      0.000
      description
      2
    
    
      XMQSOOJRRVEHRO-ULQDDVLXSA-N
      Phe-Leu-Arg
      Chemical compound
      
      
      NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1
      XMQSOOJRRVEHRO-ULQDDVLXSA-N
      0.000
      description
      2
    
    
      MJAYDXWQQUOURZ-JYJNAYRXSA-N
      Phe-Lys-Gln
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O
      MJAYDXWQQUOURZ-JYJNAYRXSA-N
      0.000
      description
      2
    
    
      WLYPRKLMRIYGPP-JYJNAYRXSA-N
      Phe-Lys-Glu
      Chemical compound
      
      
      OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1
      WLYPRKLMRIYGPP-JYJNAYRXSA-N
      0.000
      description
      2
    
    
      BSHMIVKDJQGLNT-ACRUOGEOSA-N
      Phe-Lys-Tyr
      Chemical compound
      
      
      C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1
      BSHMIVKDJQGLNT-ACRUOGEOSA-N
      0.000
      description
      2
    
    
      MVIJMIZJPHQGEN-IHRRRGAJSA-N
      Phe-Ser-Val
      Chemical compound
      
      
      CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3&#43;])CC1=CC=CC=C1
      MVIJMIZJPHQGEN-IHRRRGAJSA-N
      0.000
      description
      2
    
    
      RAGOJJCBGXARPO-XVSYOHENSA-N
      Phe-Thr-Asp
      Chemical compound
      
      
      OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=CC=C1
      RAGOJJCBGXARPO-XVSYOHENSA-N
      0.000
      description
      2
    
    
      GNRMAQSIROFNMI-IXOXFDKPSA-N
      Phe-Thr-Ser
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O
      GNRMAQSIROFNMI-IXOXFDKPSA-N
      0.000
      description
      2
    
    
      BPIFSOUEUYDJRM-DCPHZVHLSA-N
      Phe-Trp-Ala
      Chemical compound
      
      
      C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(O)=O)C1=CC=CC=C1
      BPIFSOUEUYDJRM-DCPHZVHLSA-N
      0.000
      description
      2
    
    
      CQZNGNCAIXMAIQ-UBHSHLNASA-N
      Pro-Ala-Phe
      Chemical compound
      
      
      C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
      CQZNGNCAIXMAIQ-UBHSHLNASA-N
      0.000
      description
      2
    
    
      UAYHMOIGIQZLFR-NHCYSSNCSA-N
      Pro-Gln-Val
      Chemical compound
      
      
      [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O
      UAYHMOIGIQZLFR-NHCYSSNCSA-N
      0.000
      description
      2
    
    
      RUDOLGWDSKQQFF-DCAQKATOSA-N
      Pro-Leu-Asn
      Chemical compound
      
      
      [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O
      RUDOLGWDSKQQFF-DCAQKATOSA-N
      0.000
      description
      2
    
    
      JIWJRKNYLSHONY-KKUMJFAQSA-N
      Pro-Phe-Glu
      Chemical compound
      
      
      [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      JIWJRKNYLSHONY-KKUMJFAQSA-N
      0.000
      description
      2
    
    
      GOMUXSCOIWIJFP-GUBZILKMSA-N
      Pro-Ser-Arg
      Chemical compound
      
      
      [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      GOMUXSCOIWIJFP-GUBZILKMSA-N
      0.000
      description
      2
    
    
      101100012902
      Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      101100233916
      Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR5 gene
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      QFBNNYNWKYKVJO-DCAQKATOSA-N
      Ser-Arg-Lys
      Chemical compound
      
      
      NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N
      QFBNNYNWKYKVJO-DCAQKATOSA-N
      0.000
      description
      2
    
    
      HBOABDXGTMMDSE-GUBZILKMSA-N
      Ser-Arg-Val
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O
      HBOABDXGTMMDSE-GUBZILKMSA-N
      0.000
      description
      2
    
    
      YMEXHZTVKDAKIY-GHCJXIJMSA-N
      Ser-Asn-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)C(O)=O
      YMEXHZTVKDAKIY-GHCJXIJMSA-N
      0.000
      description
      2
    
    
      YQQKYAZABFEYAF-FXQIFTODSA-N
      Ser-Glu-Gln
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O
      YQQKYAZABFEYAF-FXQIFTODSA-N
      0.000
      description
      2
    
    
      AEGUWTFAQQWVLC-BQBZGAKWSA-N
      Ser-Gly-Arg
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      AEGUWTFAQQWVLC-BQBZGAKWSA-N
      0.000
      description
      2
    
    
      GZFAWAQTEYDKII-YUMQZZPRSA-N
      Ser-Gly-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO
      GZFAWAQTEYDKII-YUMQZZPRSA-N
      0.000
      description
      2
    
    
      SFTZTYBXIXLRGQ-JBDRJPRFSA-N
      Ser-Ile-Ala
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O
      SFTZTYBXIXLRGQ-JBDRJPRFSA-N
      0.000
      description
      2
    
    
      HEUVHBXOVZONPU-BJDJZHNGSA-N
      Ser-Leu-Ile
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O
      HEUVHBXOVZONPU-BJDJZHNGSA-N
      0.000
      description
      2
    
    
      KCGIREHVWRXNDH-GARJFASQSA-N
      Ser-Leu-Pro
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N
      KCGIREHVWRXNDH-GARJFASQSA-N
      0.000
      description
      2
    
    
      OCWWJBZQXGYQCA-DCAQKATOSA-N
      Ser-Lys-Met
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O
      OCWWJBZQXGYQCA-DCAQKATOSA-N
      0.000
      description
      2
    
    
      XQJCEKXQUJQNNK-ZLUOBGJFSA-N
      Ser-Ser-Ser
      Chemical compound
      
      
      OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O
      XQJCEKXQUJQNNK-ZLUOBGJFSA-N
      0.000
      description
      2
    
    
      HNDMFDBQXYZSRM-IHRRRGAJSA-N
      Ser-Val-Phe
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
      HNDMFDBQXYZSRM-IHRRRGAJSA-N
      0.000
      description
      2
    
    
      SIEBDTCABMZCLF-XGEHTFHBSA-N
      Ser-Val-Thr
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      SIEBDTCABMZCLF-XGEHTFHBSA-N
      0.000
      description
      2
    
    
      MTCFGRXMJLQNBG-UHFFFAOYSA-N
      Serine
      Natural products
      
      
      OCC(N)C(O)=O
      MTCFGRXMJLQNBG-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      108091027568
      Single-stranded nucleotide
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      XVNZSJIKGJLQLH-RCWTZXSCSA-N
      Thr-Arg-Met
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)O)N)O
      XVNZSJIKGJLQLH-RCWTZXSCSA-N
      0.000
      description
      2
    
    
      LMMDEZPNUTZJAY-GCJQMDKQSA-N
      Thr-Asp-Ala
      Chemical compound
      
      
      [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O
      LMMDEZPNUTZJAY-GCJQMDKQSA-N
      0.000
      description
      2
    
    
      DCLBXIWHLVEPMQ-JRQIVUDYSA-N
      Thr-Asp-Tyr
      Chemical compound
      
      
      C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1
      DCLBXIWHLVEPMQ-JRQIVUDYSA-N
      0.000
      description
      2
    
    
      MCDVZTRGHNXTGK-HJGDQZAQSA-N
      Thr-Met-Glu
      Chemical compound
      
      
      [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      MCDVZTRGHNXTGK-HJGDQZAQSA-N
      0.000
      description
      2
    
    
      VGYVVSQFSSKZRJ-OEAJRASXSA-N
      Thr-Phe-Lys
      Chemical compound
      
      
      NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1
      VGYVVSQFSSKZRJ-OEAJRASXSA-N
      0.000
      description
      2
    
    
      NDXSOKGYKCGYKT-VEVYYDQMSA-N
      Thr-Pro-Asp
      Chemical compound
      
      
      C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O
      NDXSOKGYKCGYKT-VEVYYDQMSA-N
      0.000
      description
      2
    
    
      XHWCDRUPDNSDAZ-XKBZYTNZSA-N
      Thr-Ser-Glu
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O
      XHWCDRUPDNSDAZ-XKBZYTNZSA-N
      0.000
      description
      2
    
    
      BBPCSGKKPJUYRB-UVOCVTCTSA-N
      Thr-Thr-Leu
      Chemical compound
      
      
      [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O
      BBPCSGKKPJUYRB-UVOCVTCTSA-N
      0.000
      description
      2
    
    
      XGUAUKUYQHBUNY-SWRJLBSHSA-N
      Thr-Trp-Glu
      Chemical compound
      
      
      [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      XGUAUKUYQHBUNY-SWRJLBSHSA-N
      0.000
      description
      2
    
    
      AXEJRUGTOJPZKG-XGEHTFHBSA-N
      Thr-Val-Cys
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O
      AXEJRUGTOJPZKG-XGEHTFHBSA-N
      0.000
      description
      2
    
    
      AYFVYJQAPQTCCC-UHFFFAOYSA-N
      Threonine
      Natural products
      
      
      CC(O)C(N)C(O)=O
      AYFVYJQAPQTCCC-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      239000004473
      Threonine
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      HJWVPKJHHLZCNH-DVXDUOKCSA-N
      Trp-Ala-Trp
      Chemical compound
      
      
      C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=3C4=CC=CC=C4NC=3)C)C(O)=O)=CNC2=C1
      HJWVPKJHHLZCNH-DVXDUOKCSA-N
      0.000
      description
      2
    
    
      PKUJMYZNJMRHEZ-XIRDDKMYSA-N
      Trp-Glu-Arg
      Chemical compound
      
      
      [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      PKUJMYZNJMRHEZ-XIRDDKMYSA-N
      0.000
      description
      2
    
    
      UUIYFDAWNBSWPG-IHPCNDPISA-N
      Trp-Lys-Lys
      Chemical compound
      
      
      C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N
      UUIYFDAWNBSWPG-IHPCNDPISA-N
      0.000
      description
      2
    
    
      QIVBCDIJIAJPQS-UHFFFAOYSA-N
      Tryptophan
      Natural products
      
      
      C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1
      QIVBCDIJIAJPQS-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      XLMDWQNAOKLKCP-XDTLVQLUSA-N
      Tyr-Ala-Gln
      Chemical compound
      
      
      C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
      XLMDWQNAOKLKCP-XDTLVQLUSA-N
      0.000
      description
      2
    
    
      JBBYKPZAPOLCPK-JYJNAYRXSA-N
      Tyr-Arg-Met
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O
      JBBYKPZAPOLCPK-JYJNAYRXSA-N
      0.000
      description
      2
    
    
      GFHYISDTIWZUSU-QWRGUYRKSA-N
      Tyr-Asn-Gly
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O
      GFHYISDTIWZUSU-QWRGUYRKSA-N
      0.000
      description
      2
    
    
      BARBHMSSVWPKPZ-IHRRRGAJSA-N
      Tyr-Asp-Arg
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      BARBHMSSVWPKPZ-IHRRRGAJSA-N
      0.000
      description
      2
    
    
      NLMXVDDEQFKQQU-CFMVVWHZSA-N
      Tyr-Asp-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1
      NLMXVDDEQFKQQU-CFMVVWHZSA-N
      0.000
      description
      2
    
    
      HKYTWJOWZTWBQB-AVGNSLFASA-N
      Tyr-Glu-Asp
      Chemical compound
      
      
      OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1
      HKYTWJOWZTWBQB-AVGNSLFASA-N
      0.000
      description
      2
    
    
      WVRUKYLYMFGKAN-IHRRRGAJSA-N
      Tyr-Glu-Glu
      Chemical compound
      
      
      OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1
      WVRUKYLYMFGKAN-IHRRRGAJSA-N
      0.000
      description
      2
    
    
      JAGGEZACYAAMIL-CQDKDKBSSA-N
      Tyr-Lys-Ala
      Chemical compound
      
      
      C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
      JAGGEZACYAAMIL-CQDKDKBSSA-N
      0.000
      description
      2
    
    
      KWKJGBHDYJOVCR-SRVKXCTJSA-N
      Tyr-Ser-Cys
      Chemical compound
      
      
      C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O
      KWKJGBHDYJOVCR-SRVKXCTJSA-N
      0.000
      description
      2
    
    
      102000006943
      Uracil-DNA Glycosidase
      Human genes
      
      
      
      
      0.000
      description
      2
    
    
      108010072685
      Uracil-DNA Glycosidase
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      XSQUKJJJFZCRTK-UHFFFAOYSA-N
      Urea
      Chemical compound
      
      
      NC(N)=O
      XSQUKJJJFZCRTK-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      DRTQHJPVMGBUCF-XVFCMESISA-N
      Uridine
      Chemical compound
      
      
      O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1
      DRTQHJPVMGBUCF-XVFCMESISA-N
      0.000
      description
      2
    
    
      IQQYYFPCWKWUHW-YDHLFZDLSA-N
      Val-Asn-Tyr
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N
      IQQYYFPCWKWUHW-YDHLFZDLSA-N
      0.000
      description
      2
    
    
      ISERLACIZUGCDX-ZKWXMUAHSA-N
      Val-Asp-Ala
      Chemical compound
      
      
      C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N
      ISERLACIZUGCDX-ZKWXMUAHSA-N
      0.000
      description
      2
    
    
      TZVUSFMQWPWHON-NHCYSSNCSA-N
      Val-Asp-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N
      TZVUSFMQWPWHON-NHCYSSNCSA-N
      0.000
      description
      2
    
    
      IRLYZKKNBFPQBW-XGEHTFHBSA-N
      Val-Cys-Thr
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N)O
      IRLYZKKNBFPQBW-XGEHTFHBSA-N
      0.000
      description
      2
    
    
      SZTTYWIUCGSURQ-AUTRQRHGSA-N
      Val-Glu-Glu
      Chemical compound
      
      
      CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      SZTTYWIUCGSURQ-AUTRQRHGSA-N
      0.000
      description
      2
    
    
      WDIGUPHXPBMODF-UMNHJUIQSA-N
      Val-Glu-Pro
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N
      WDIGUPHXPBMODF-UMNHJUIQSA-N
      0.000
      description
      2
    
    
      DJEVQCWNMQOABE-RCOVLWMOSA-N
      Val-Gly-Asp
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N
      DJEVQCWNMQOABE-RCOVLWMOSA-N
      0.000
      description
      2
    
    
      LKUDRJSNRWVGMS-QSFUFRPTSA-N
      Val-Ile-Asp
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N
      LKUDRJSNRWVGMS-QSFUFRPTSA-N
      0.000
      description
      2
    
    
      APQIVBCUIUDSMB-OSUNSFLBSA-N
      Val-Ile-Thr
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N
      APQIVBCUIUDSMB-OSUNSFLBSA-N
      0.000
      description
      2
    
    
      ZHQWPWQNVRCXAX-XQQFMLRXSA-N
      Val-Leu-Pro
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N
      ZHQWPWQNVRCXAX-XQQFMLRXSA-N
      0.000
      description
      2
    
    
      RWOGENDAOGMHLX-DCAQKATOSA-N
      Val-Lys-Ala
      Chemical compound
      
      
      C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N
      RWOGENDAOGMHLX-DCAQKATOSA-N
      0.000
      description
      2
    
    
      XXWBHOWRARMUOC-NHCYSSNCSA-N
      Val-Lys-Asn
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N
      XXWBHOWRARMUOC-NHCYSSNCSA-N
      0.000
      description
      2
    
    
      MBGFDZDWMDLXHQ-GUBZILKMSA-N
      Val-Met-Ala
      Chemical compound
      
      
      C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C(C)C)N
      MBGFDZDWMDLXHQ-GUBZILKMSA-N
      0.000
      description
      2
    
    
      CKTMJBPRVQWPHU-JSGCOSHPSA-N
      Val-Phe-Gly
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N
      CKTMJBPRVQWPHU-JSGCOSHPSA-N
      0.000
      description
      2
    
    
      RYHUIHUOYRNNIE-NRPADANISA-N
      Val-Ser-Gln
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
      RYHUIHUOYRNNIE-NRPADANISA-N
      0.000
      description
      2
    
    
      HTONZBWRYUKUKC-RCWTZXSCSA-N
      Val-Thr-Val
      Chemical compound
      
      
      CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O
      HTONZBWRYUKUKC-RCWTZXSCSA-N
      0.000
      description
      2
    
    
      241000179387
      Zonotrichia albicollis
      Species
      
      
      
      
      0.000
      description
      2
    
    
      108010081404
      acein-2
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      239000002253
      acid
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      150000007513
      acids
      Chemical class
      
      
      
      
      0.000
      description
      2
    
    
      108010070944
      alanylhistidine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      ODKSFYDXXFIFQN-UHFFFAOYSA-N
      arginine
      Natural products
      
      
      OC(=O)C(N)CCCNC(N)=N
      ODKSFYDXXFIFQN-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      108010068380
      arginylarginine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      235000009582
      asparagine
      Nutrition
      
      
      
      
      0.000
      description
      2
    
    
      229960001230
      asparagine
      Drugs
      
      
      
      
      0.000
      description
      2
    
    
      108010066988
      asparaginyl-alanyl-glycyl-alanine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      108010077245
      asparaginyl-proline
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      235000003704
      aspartic acid
      Nutrition
      
      
      
      
      0.000
      description
      2
    
    
      108010038633
      aspartylglutamate
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      QVGXLLKOCUKJST-UHFFFAOYSA-N
      atomic oxygen
      Chemical compound
      
      
      [O]
      QVGXLLKOCUKJST-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      239000011324
      bead
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      OQFSQFPPLPISGP-UHFFFAOYSA-N
      beta-carboxyaspartic acid
      Natural products
      
      
      OC(=O)C(N)C(C(O)=O)C(O)=O
      OQFSQFPPLPISGP-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      229960002685
      biotin
      Drugs
      
      
      
      
      0.000
      description
      2
    
    
      235000020958
      biotin
      Nutrition
      
      
      
      
      0.000
      description
      2
    
    
      239000011616
      biotin
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      238000005119
      centrifugation
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      230000008859
      change
      Effects
      
      
      
      
      0.000
      description
      2
    
    
      238000010276
      construction
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      238000007796
      conventional method
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      239000013078
      crystal
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      XUJNEKJLAYXESH-UHFFFAOYSA-N
      cysteine
      Natural products
      
      
      SCC(N)C(O)=O
      XUJNEKJLAYXESH-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      235000018417
      cysteine
      Nutrition
      
      
      
      
      0.000
      description
      2
    
    
      108010081447
      cytochrophin-4
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      RGWHQCVHVJXOKC-SHYZEUOFSA-N
      dCTP
      Chemical compound
      
      
      O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1
      RGWHQCVHVJXOKC-SHYZEUOFSA-N
      0.000
      description
      2
    
    
      HAAZLUGHYHWQIW-KVQBGUIXSA-N
      dGTP
      Chemical compound
      
      
      C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1
      HAAZLUGHYHWQIW-KVQBGUIXSA-N
      0.000
      description
      2
    
    
      NHVNXKFIZYSCEB-XLPZGREQSA-N
      dTTP
      Chemical compound
      
      
      O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1
      NHVNXKFIZYSCEB-XLPZGREQSA-N
      0.000
      description
      2
    
    
      230000001419
      dependent effect
      Effects
      
      
      
      
      0.000
      description
      2
    
    
      238000010511
      deprotection reaction
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      238000010586
      diagram
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      230000004049
      epigenetic modification
      Effects
      
      
      
      
      0.000
      description
      2
    
    
      235000013922
      glutamic acid
      Nutrition
      
      
      
      
      0.000
      description
      2
    
    
      239000004220
      glutamic acid
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      ZDXPYRJPNDTMRX-UHFFFAOYSA-N
      glutamine
      Natural products
      
      
      OC(=O)C(N)CCC(N)=O
      ZDXPYRJPNDTMRX-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      108010078144
      glutaminyl-glycine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      108010079547
      glutamylmethionine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      XBGGUPMXALFZOT-UHFFFAOYSA-N
      glycyl-L-tyrosine hemihydrate
      Natural products
      
      
      NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1
      XBGGUPMXALFZOT-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      108010048994
      glycyl-tyrosyl-alanine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      PCHJSUWPFVWCPO-UHFFFAOYSA-N
      gold
      Chemical compound
      
      
      [Au]
      PCHJSUWPFVWCPO-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      229910052737
      gold
      Inorganic materials
      
      
      
      
      0.000
      description
      2
    
    
      239000010931
      gold
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      HNDVDQJCIGZPNO-UHFFFAOYSA-N
      histidine
      Natural products
      
      
      OC(=O)C(N)CC1=CN=CN1
      HNDVDQJCIGZPNO-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      108010092114
      histidylphenylalanine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      238000000338
      in vitro
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      239000003999
      initiator
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      238000003780
      insertion
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      230000037431
      insertion
      Effects
      
      
      
      
      0.000
      description
      2
    
    
      108010053037
      kyotorphin
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      108010003700
      lysyl aspartic acid
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      108010009298
      lysylglutamic acid
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      108010054155
      lysyllysine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      238000001823
      molecular biology technique
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      QJGQUHMNIGDVPM-UHFFFAOYSA-N
      nitrogen group
      Chemical group
      
      
      [N]
      QJGQUHMNIGDVPM-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      238000001216
      nucleic acid method
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      229910052760
      oxygen
      Inorganic materials
      
      
      
      
      0.000
      description
      2
    
    
      239000001301
      oxygen
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      229910052763
      palladium
      Inorganic materials
      
      
      
      
      0.000
      description
      2
    
    
      COLNVLDHVKWLRT-UHFFFAOYSA-N
      phenylalanine
      Natural products
      
      
      OC(=O)C(N)CC1=CC=CC=C1
      COLNVLDHVKWLRT-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      108010070409
      phenylalanyl-glycyl-glycine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      108010051242
      phenylalanylserine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      229920002401
      polyacrylamide
      Polymers
      
      
      
      
      0.000
      description
      2
    
    
      229920000642
      polymer
      Polymers
      
      
      
      
      0.000
      description
      2
    
    
      239000000047
      product
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      108010031719
      prolyl-serine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      125000006239
      protecting group
      Chemical group
      
      
      
      
      0.000
      description
      2
    
    
      108091008146
      restriction endonucleases
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      FSYKKLYZXJSNPZ-UHFFFAOYSA-N
      sarcosine
      Chemical compound
      
      
      C[NH2&#43;]CC([O-])=O
      FSYKKLYZXJSNPZ-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      108010026333
      seryl-proline
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      235000010288
      sodium nitrite
      Nutrition
      
      
      
      
      0.000
      description
      2
    
    
      239000000243
      solution
      Substances
      
      
      
      
      0.000
      description
      2
    
    
      241000894007
      species
      Species
      
      
      
      
      0.000
      description
      2
    
    
      108010033670
      threonyl-aspartyl-tyrosine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      108010072986
      threonyl-seryl-lysine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      108010080629
      tryptophan-leucine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      108010084932
      tryptophyl-proline
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      OUYCCCASQSFEME-UHFFFAOYSA-N
      tyrosine
      Natural products
      
      
      OC(=O)C(N)CC1=CC=C(O)C=C1
      OUYCCCASQSFEME-UHFFFAOYSA-N
      0.000
      description
      2
    
    
      108010078580
      tyrosylleucine
      Proteins
      
      
      
      
      0.000
      description
      2
    
    
      238000005406
      washing
      Methods
      
      
      
      
      0.000
      description
      2
    
    
      MTCFGRXMJLQNBG-REOHCLBHSA-N
      (2S)-2-Amino-3-hydroxypropansÃ¤ure
      Chemical compound
      
      
      OC[C@H](N)C(O)=O
      MTCFGRXMJLQNBG-REOHCLBHSA-N
      0.000
      description
      1
    
    
      BVAUMRCGVHUWOZ-ZETCQYMHSA-N
      (2s)-2-(cyclohexylazaniumyl)propanoate
      Chemical compound
      
      
      OC(=O)[C@H](C)NC1CCCCC1
      BVAUMRCGVHUWOZ-ZETCQYMHSA-N
      0.000
      description
      1
    
    
      VLAFRQCSFRYCLC-FXQIFTODSA-N
      (2s)-2-[[(2s)-2-[[2-[[(2s)-2-aminopropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]pentanedioic acid
      Chemical compound
      
      
      C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O
      VLAFRQCSFRYCLC-FXQIFTODSA-N
      0.000
      description
      1
    
    
      NPWMTBZSRRLQNJ-VKHMYHEASA-N
      (3s)-3-aminopiperidine-2,6-dione
      Chemical compound
      
      
      N[C@H]1CCC(=O)NC1=O
      NPWMTBZSRRLQNJ-VKHMYHEASA-N
      0.000
      description
      1
    
    
      DLZKEQQWXODGGZ-KCJUWKMLSA-N
      2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid
      Chemical compound
      
      
      OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1
      DLZKEQQWXODGGZ-KCJUWKMLSA-N
      0.000
      description
      1
    
    
      125000001494
      2-propynyl group
      Chemical group
      
      
      [H]C#CC([H])([H])*
      
      0.000
      description
      1
    
    
      KDCGOANMDULRCW-UHFFFAOYSA-N
      7H-purine
      Chemical compound
      
      
      N1=CNC2=NC=NC2=C1
      KDCGOANMDULRCW-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      208000035657
      Abasia
      Diseases
      
      
      
      
      0.000
      description
      1
    
    
      229930024421
      Adenine
      Natural products
      
      
      
      
      0.000
      description
      1
    
    
      XYKDZXKKYOOTGC-FXQIFTODSA-N
      Ala-Cys-Met
      Chemical compound
      
      
      C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)O)N
      XYKDZXKKYOOTGC-FXQIFTODSA-N
      0.000
      description
      1
    
    
      WGDNWOMKBUXFHR-BQBZGAKWSA-N
      Ala-Gly-Arg
      Chemical compound
      
      
      C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N
      WGDNWOMKBUXFHR-BQBZGAKWSA-N
      0.000
      description
      1
    
    
      PCIFXPRIFWKWLK-YUMQZZPRSA-N
      Ala-Gly-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N
      PCIFXPRIFWKWLK-YUMQZZPRSA-N
      0.000
      description
      1
    
    
      HOVPGJUNRLMIOZ-CIUDSAMLSA-N
      Ala-Ser-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N
      HOVPGJUNRLMIOZ-CIUDSAMLSA-N
      0.000
      description
      1
    
    
      SAHQGRZIQVEJPF-JXUBOQSCSA-N
      Ala-Thr-Lys
      Chemical compound
      
      
      C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN
      SAHQGRZIQVEJPF-JXUBOQSCSA-N
      0.000
      description
      1
    
    
      108091023037
      Aptamer
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      IASNWHAGGYTEKX-IUCAKERBSA-N
      Arg-Arg-Gly
      Chemical compound
      
      
      NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O
      IASNWHAGGYTEKX-IUCAKERBSA-N
      0.000
      description
      1
    
    
      HJVGMOYJDDXLMI-AVGNSLFASA-N
      Arg-Arg-Lys
      Chemical compound
      
      
      NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N
      HJVGMOYJDDXLMI-AVGNSLFASA-N
      0.000
      description
      1
    
    
      OTCJMMRQBVDQRK-DCAQKATOSA-N
      Arg-Asp-Leu
      Chemical compound
      
      
      [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O
      OTCJMMRQBVDQRK-DCAQKATOSA-N
      0.000
      description
      1
    
    
      OBFTYSPXDRROQO-SRVKXCTJSA-N
      Arg-Gln-Lys
      Chemical compound
      
      
      NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCN=C(N)N
      OBFTYSPXDRROQO-SRVKXCTJSA-N
      0.000
      description
      1
    
    
      OFIYLHVAAJYRBC-HJWJTTGWSA-N
      Arg-Ile-Phe
      Chemical compound
      
      
      CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O
      OFIYLHVAAJYRBC-HJWJTTGWSA-N
      0.000
      description
      1
    
    
      NGTYEHIRESTSRX-UWVGGRQHSA-N
      Arg-Lys-Gly
      Chemical compound
      
      
      NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N
      NGTYEHIRESTSRX-UWVGGRQHSA-N
      0.000
      description
      1
    
    
      DTBPLQNKYCYUOM-JYJNAYRXSA-N
      Arg-Met-Phe
      Chemical compound
      
      
      NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1
      DTBPLQNKYCYUOM-JYJNAYRXSA-N
      0.000
      description
      1
    
    
      DPLFNLDACGGBAK-KKUMJFAQSA-N
      Arg-Phe-Glu
      Chemical compound
      
      
      C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N
      DPLFNLDACGGBAK-KKUMJFAQSA-N
      0.000
      description
      1
    
    
      NVPHRWNWTKYIST-BPNCWPANSA-N
      Arg-Tyr-Ala
      Chemical compound
      
      
      NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1
      NVPHRWNWTKYIST-BPNCWPANSA-N
      0.000
      description
      1
    
    
      ULBHWNVWSCJLCO-NHCYSSNCSA-N
      Arg-Val-Glu
      Chemical compound
      
      
      OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N
      ULBHWNVWSCJLCO-NHCYSSNCSA-N
      0.000
      description
      1
    
    
      KXFCBAHYSLJCCY-ZLUOBGJFSA-N
      Asn-Asn-Ser
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O
      KXFCBAHYSLJCCY-ZLUOBGJFSA-N
      0.000
      description
      1
    
    
      UYCPJVYQYARFGB-YDHLFZDLSA-N
      Asn-Phe-Val
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O
      UYCPJVYQYARFGB-YDHLFZDLSA-N
      0.000
      description
      1
    
    
      RTFXPCYMDYBZNQ-SRVKXCTJSA-N
      Asn-Tyr-Asn
      Chemical compound
      
      
      [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O
      RTFXPCYMDYBZNQ-SRVKXCTJSA-N
      0.000
      description
      1
    
    
      PBVLJOIPOGUQQP-CIUDSAMLSA-N
      Asp-Ala-Leu
      Chemical compound
      
      
      [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O
      PBVLJOIPOGUQQP-CIUDSAMLSA-N
      0.000
      description
      1
    
    
      MRQQMVZUHXUPEV-IHRRRGAJSA-N
      Asp-Arg-Phe
      Chemical compound
      
      
      [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
      MRQQMVZUHXUPEV-IHRRRGAJSA-N
      0.000
      description
      1
    
    
      KNMRXHIAVXHCLW-ZLUOBGJFSA-N
      Asp-Asn-Ser
      Chemical compound
      
      
      C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O
      KNMRXHIAVXHCLW-ZLUOBGJFSA-N
      0.000
      description
      1
    
    
      IJHUZMGJRGNXIW-CIUDSAMLSA-N
      Asp-Glu-Arg
      Chemical compound
      
      
      [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      IJHUZMGJRGNXIW-CIUDSAMLSA-N
      0.000
      description
      1
    
    
      KLYPOCBLKMPBIQ-GHCJXIJMSA-N
      Asp-Ile-Ser
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N
      KLYPOCBLKMPBIQ-GHCJXIJMSA-N
      0.000
      description
      1
    
    
      QNMKWNONJGKJJC-NHCYSSNCSA-N
      Asp-Leu-Val
      Chemical compound
      
      
      [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O
      QNMKWNONJGKJJC-NHCYSSNCSA-N
      0.000
      description
      1
    
    
      JSHWXQIZOCVWIA-ZKWXMUAHSA-N
      Asp-Ser-Val
      Chemical compound
      
      
      [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O
      JSHWXQIZOCVWIA-ZKWXMUAHSA-N
      0.000
      description
      1
    
    
      KWIUHFFTVRNATP-UHFFFAOYSA-N
      Betaine
      Natural products
      
      
      C[N&#43;](C)(C)CC([O-])=O
      KWIUHFFTVRNATP-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      NQSUTVRXXBGVDQ-LKXGYXEUSA-N
      Cys-Asn-Thr
      Chemical compound
      
      
      [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      NQSUTVRXXBGVDQ-LKXGYXEUSA-N
      0.000
      description
      1
    
    
      POSRGGKLRWCUBE-CIUDSAMLSA-N
      Cys-Met-Glu
      Chemical compound
      
      
      CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N
      POSRGGKLRWCUBE-CIUDSAMLSA-N
      0.000
      description
      1
    
    
      UIKLEGZPIOXFHJ-DLOVCJGASA-N
      Cys-Phe-Ala
      Chemical compound
      
      
      [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O
      UIKLEGZPIOXFHJ-DLOVCJGASA-N
      0.000
      description
      1
    
    
      IXPSSIBVVKSOIE-SRVKXCTJSA-N
      Cys-Ser-Tyr
      Chemical compound
      
      
      C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O
      IXPSSIBVVKSOIE-SRVKXCTJSA-N
      0.000
      description
      1
    
    
      230000005971
      DNA damage repair
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      102100029765
      DNA polymerase lambda
      Human genes
      
      
      
      
      0.000
      description
      1
    
    
      101710177421
      DNA polymerase lambda
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      108010061914
      DNA polymerase mu
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      230000008265
      DNA repair mechanism
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      BWGNESOTFCXPMA-UHFFFAOYSA-N
      Dihydrogen disulfide
      Chemical compound
      
      
      SS
      BWGNESOTFCXPMA-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      102100031780
      Endonuclease
      Human genes
      
      
      
      
      0.000
      description
      1
    
    
      108010042407
      Endonucleases
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      241001198387
      Escherichia coli BL21(DE3)
      Species
      
      
      
      
      0.000
      description
      1
    
    
      ZBKUIQNCRIYVGH-SDDRHHMPSA-N
      Gln-Leu-Pro
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N
      ZBKUIQNCRIYVGH-SDDRHHMPSA-N
      0.000
      description
      1
    
    
      IHSGESFHTMFHRB-GUBZILKMSA-N
      Gln-Lys-Ala
      Chemical compound
      
      
      OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O
      IHSGESFHTMFHRB-GUBZILKMSA-N
      0.000
      description
      1
    
    
      QBEWLBKBGXVVPD-RYUDHWBXSA-N
      Gln-Phe-Gly
      Chemical compound
      
      
      C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N
      QBEWLBKBGXVVPD-RYUDHWBXSA-N
      0.000
      description
      1
    
    
      LPIKVBWNNVFHCQ-GUBZILKMSA-N
      Gln-Ser-Leu
      Chemical compound
      
      
      [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O
      LPIKVBWNNVFHCQ-GUBZILKMSA-N
      0.000
      description
      1
    
    
      WZZSKAJIHTUUSG-ACZMJKKPSA-N
      Glu-Ala-Asp
      Chemical compound
      
      
      OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O
      WZZSKAJIHTUUSG-ACZMJKKPSA-N
      0.000
      description
      1
    
    
      GLWXKFRTOHKGIT-ACZMJKKPSA-N
      Glu-Asn-Asn
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O
      GLWXKFRTOHKGIT-ACZMJKKPSA-N
      0.000
      description
      1
    
    
      JPHYJQHPILOKHC-ACZMJKKPSA-N
      Glu-Asp-Asp
      Chemical compound
      
      
      OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O
      JPHYJQHPILOKHC-ACZMJKKPSA-N
      0.000
      description
      1
    
    
      QJCKNLPMTPXXEM-AUTRQRHGSA-N
      Glu-Glu-Val
      Chemical compound
      
      
      CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O
      QJCKNLPMTPXXEM-AUTRQRHGSA-N
      0.000
      description
      1
    
    
      ZCOJVESMNGBGLF-GRLWGSQLSA-N
      Glu-Ile-Ile
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O
      ZCOJVESMNGBGLF-GRLWGSQLSA-N
      0.000
      description
      1
    
    
      XTZDZAXYPDISRR-MNXVOIDGSA-N
      Glu-Ile-Lys
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N
      XTZDZAXYPDISRR-MNXVOIDGSA-N
      0.000
      description
      1
    
    
      FBEJIDRSQCGFJI-GUBZILKMSA-N
      Glu-Leu-Ser
      Chemical compound
      
      
      [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O
      FBEJIDRSQCGFJI-GUBZILKMSA-N
      0.000
      description
      1
    
    
      UPOJUWHGMDJUQZ-IUCAKERBSA-N
      Gly-Arg-Arg
      Chemical compound
      
      
      NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      UPOJUWHGMDJUQZ-IUCAKERBSA-N
      0.000
      description
      1
    
    
      VXKCPBPQEKKERH-IUCAKERBSA-N
      Gly-Arg-Pro
      Chemical compound
      
      
      NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O
      VXKCPBPQEKKERH-IUCAKERBSA-N
      0.000
      description
      1
    
    
      LIXWIUAORXJNBH-QWRGUYRKSA-N
      Gly-Leu-His
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN
      LIXWIUAORXJNBH-QWRGUYRKSA-N
      0.000
      description
      1
    
    
      UHPAZODVFFYEEL-QWRGUYRKSA-N
      Gly-Leu-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN
      UHPAZODVFFYEEL-QWRGUYRKSA-N
      0.000
      description
      1
    
    
      LHYJCVCQPWRMKZ-WEDXCCLWSA-N
      Gly-Leu-Thr
      Chemical compound
      
      
      [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O
      LHYJCVCQPWRMKZ-WEDXCCLWSA-N
      0.000
      description
      1
    
    
      YOBGUCWZPXJHTN-BQBZGAKWSA-N
      Gly-Ser-Arg
      Chemical compound
      
      
      NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N
      YOBGUCWZPXJHTN-BQBZGAKWSA-N
      0.000
      description
      1
    
    
      UMBDRSMLCUYIRI-DVJZZOLTSA-N
      Gly-Trp-Thr
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN)O
      UMBDRSMLCUYIRI-DVJZZOLTSA-N
      0.000
      description
      1
    
    
      RYAOJUMWLWUGNW-QMMMGPOBSA-N
      Gly-Val-Gly
      Chemical compound
      
      
      NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O
      RYAOJUMWLWUGNW-QMMMGPOBSA-N
      0.000
      description
      1
    
    
      FNXSYBOHALPRHV-ONGXEEELSA-N
      Gly-Val-Lys
      Chemical compound
      
      
      NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN
      FNXSYBOHALPRHV-ONGXEEELSA-N
      0.000
      description
      1
    
    
      UYTPUPDQBNUYGX-UHFFFAOYSA-N
      Guanine
      Natural products
      
      
      O=C1NC(N)=NC2=C1N=CN2
      UYTPUPDQBNUYGX-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      GIRSNERMXCMDBO-GARJFASQSA-N
      His-Ser-Pro
      Chemical compound
      
      
      C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O
      GIRSNERMXCMDBO-GARJFASQSA-N
      0.000
      description
      1
    
    
      101001121408
      Homo sapiens L-amino-acid oxidase
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      UFHFLCQGNIYNRP-UHFFFAOYSA-N
      Hydrogen
      Chemical compound
      
      
      [H][H]
      UFHFLCQGNIYNRP-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      LCWXJXMHJVIJFK-UHFFFAOYSA-N
      Hydroxylysine
      Natural products
      
      
      NCC(O)CC(N)CC(O)=O
      LCWXJXMHJVIJFK-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      PMMYEEVYMWASQN-DMTCNVIQSA-N
      Hydroxyproline
      Chemical compound
      
      
      O[C@H]1CN[C@H](C(O)=O)C1
      PMMYEEVYMWASQN-DMTCNVIQSA-N
      0.000
      description
      1
    
    
      CYHJCEKUMCNDFG-LAEOZQHASA-N
      Ile-Gln-Gly
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N
      CYHJCEKUMCNDFG-LAEOZQHASA-N
      0.000
      description
      1
    
    
      TVYWVSJGSHQWMT-AJNGGQMLSA-N
      Ile-Leu-Lys
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N
      TVYWVSJGSHQWMT-AJNGGQMLSA-N
      0.000
      description
      1
    
    
      IDMNOFVUXYYZPF-DKIMLUQUSA-N
      Ile-Lys-Phe
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N
      IDMNOFVUXYYZPF-DKIMLUQUSA-N
      0.000
      description
      1
    
    
      IMRKCLXPYOIHIF-ZPFDUUQYSA-N
      Ile-Met-Gln
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
      IMRKCLXPYOIHIF-ZPFDUUQYSA-N
      0.000
      description
      1
    
    
      HQEPKOFULQTSFV-JURCDPSOSA-N
      Ile-Phe-Ala
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)O)N
      HQEPKOFULQTSFV-JURCDPSOSA-N
      0.000
      description
      1
    
    
      WYUHAXJAMDTOAU-IAVJCBSLSA-N
      Ile-Phe-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N
      WYUHAXJAMDTOAU-IAVJCBSLSA-N
      0.000
      description
      1
    
    
      XMYURPUVJSKTMC-KBIXCLLPSA-N
      Ile-Ser-Gln
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
      XMYURPUVJSKTMC-KBIXCLLPSA-N
      0.000
      description
      1
    
    
      JDCQDJVYUXNCGF-SPOWBLRKSA-N
      Ile-Ser-Trp
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N
      JDCQDJVYUXNCGF-SPOWBLRKSA-N
      0.000
      description
      1
    
    
      ANTFEOSJMAUGIB-KNZXXDILSA-N
      Ile-Thr-Pro
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N
      ANTFEOSJMAUGIB-KNZXXDILSA-N
      0.000
      description
      1
    
    
      YJRSIJZUIUANHO-NAKRPEOUSA-N
      Ile-Val-Ala
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N
      YJRSIJZUIUANHO-NAKRPEOUSA-N
      0.000
      description
      1
    
    
      SNDPXSYFESPGGJ-BYPYZUCNSA-N
      L-2-aminopentanoic acid
      Chemical compound
      
      
      CCC[C@H](N)C(O)=O
      SNDPXSYFESPGGJ-BYPYZUCNSA-N
      0.000
      description
      1
    
    
      XUJNEKJLAYXESH-REOHCLBHSA-N
      L-Cysteine
      Chemical compound
      
      
      SC[C@H](N)C(O)=O
      XUJNEKJLAYXESH-REOHCLBHSA-N
      0.000
      description
      1
    
    
      AHLPHDHHMVZTML-BYPYZUCNSA-N
      L-Ornithine
      Chemical compound
      
      
      NCCC[C@H](N)C(O)=O
      AHLPHDHHMVZTML-BYPYZUCNSA-N
      0.000
      description
      1
    
    
      FADYJNXDPBKVCA-UHFFFAOYSA-N
      L-Phenylalanyl-L-lysin
      Natural products
      
      
      NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1
      FADYJNXDPBKVCA-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      AGPKZVBTJJNPAG-UHNVWZDZSA-N
      L-allo-Isoleucine
      Chemical compound
      
      
      CC[C@@H](C)[C@H](N)C(O)=O
      AGPKZVBTJJNPAG-UHNVWZDZSA-N
      0.000
      description
      1
    
    
      102100026388
      L-amino-acid oxidase
      Human genes
      
      
      
      
      0.000
      description
      1
    
    
      ODKSFYDXXFIFQN-BYPYZUCNSA-P
      L-argininium(2&#43;)
      Chemical compound
      
      
      NC(=[NH2&#43;])NCCC[C@H]([NH3&#43;])C(O)=O
      ODKSFYDXXFIFQN-BYPYZUCNSA-P
      0.000
      description
      1
    
    
      WHUUTDBJXJRKMK-VKHMYHEASA-N
      L-glutamic acid
      Chemical compound
      
      
      OC(=O)[C@@H](N)CCC(O)=O
      WHUUTDBJXJRKMK-VKHMYHEASA-N
      0.000
      description
      1
    
    
      ZDXPYRJPNDTMRX-VKHMYHEASA-N
      L-glutamine
      Chemical compound
      
      
      OC(=O)[C@@H](N)CCC(N)=O
      ZDXPYRJPNDTMRX-VKHMYHEASA-N
      0.000
      description
      1
    
    
      LHSGPCFBGJHPCY-UHFFFAOYSA-N
      L-leucine-L-tyrosine
      Natural products
      
      
      CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1
      LHSGPCFBGJHPCY-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      KDXKERNSBIXSRK-YFKPBYRVSA-N
      L-lysine
      Chemical compound
      
      
      NCCCC[C@H](N)C(O)=O
      KDXKERNSBIXSRK-YFKPBYRVSA-N
      0.000
      description
      1
    
    
      SNDPXSYFESPGGJ-UHFFFAOYSA-N
      L-norVal-OH
      Natural products
      
      
      CCCC(N)C(O)=O
      SNDPXSYFESPGGJ-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      LRQKBLKVPFOOQJ-YFKPBYRVSA-N
      L-norleucine
      Chemical compound
      
      
      CCCC[C@H]([NH3&#43;])C([O-])=O
      LRQKBLKVPFOOQJ-YFKPBYRVSA-N
      0.000
      description
      1
    
    
      DBVWMYGBVFCRBE-CIUDSAMLSA-N
      Leu-Asn-Asn
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O
      DBVWMYGBVFCRBE-CIUDSAMLSA-N
      0.000
      description
      1
    
    
      VCSBGUACOYUIGD-CIUDSAMLSA-N
      Leu-Asn-Asp
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O
      VCSBGUACOYUIGD-CIUDSAMLSA-N
      0.000
      description
      1
    
    
      HVJVUYQWFYMGJS-GVXVVHGQSA-N
      Leu-Glu-Val
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O
      HVJVUYQWFYMGJS-GVXVVHGQSA-N
      0.000
      description
      1
    
    
      BABSVXFGKFLIGW-UWVGGRQHSA-N
      Leu-Gly-Arg
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N
      BABSVXFGKFLIGW-UWVGGRQHSA-N
      0.000
      description
      1
    
    
      PDQDCFBVYXEFSD-SRVKXCTJSA-N
      Leu-Leu-Asp
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O
      PDQDCFBVYXEFSD-SRVKXCTJSA-N
      0.000
      description
      1
    
    
      ZRHDPZAAWLXXIR-SRVKXCTJSA-N
      Leu-Lys-Ala
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O
      ZRHDPZAAWLXXIR-SRVKXCTJSA-N
      0.000
      description
      1
    
    
      BMVFXOQHDQZAQU-DCAQKATOSA-N
      Leu-Pro-Asp
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N
      BMVFXOQHDQZAQU-DCAQKATOSA-N
      0.000
      description
      1
    
    
      KIZIOFNVSOSKJI-CIUDSAMLSA-N
      Leu-Ser-Cys
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N
      KIZIOFNVSOSKJI-CIUDSAMLSA-N
      0.000
      description
      1
    
    
      ZDJQVSIPFLMNOX-RHYQMDGZSA-N
      Leu-Thr-Arg
      Chemical compound
      
      
      CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N
      ZDJQVSIPFLMNOX-RHYQMDGZSA-N
      0.000
      description
      1
    
    
      ISSAURVGLGAPDK-KKUMJFAQSA-N
      Leu-Tyr-Asp
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O
      ISSAURVGLGAPDK-KKUMJFAQSA-N
      0.000
      description
      1
    
    
      VHTIZYYHIUHMCA-JYJNAYRXSA-N
      Leu-Tyr-Gln
      Chemical compound
      
      
      [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O
      VHTIZYYHIUHMCA-JYJNAYRXSA-N
      0.000
      description
      1
    
    
      NFLFJGGKOHYZJF-BJDJZHNGSA-N
      Lys-Ala-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN
      NFLFJGGKOHYZJF-BJDJZHNGSA-N
      0.000
      description
      1
    
    
      IXHKPDJKKCUKHS-GARJFASQSA-N
      Lys-Ala-Pro
      Chemical compound
      
      
      C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N
      IXHKPDJKKCUKHS-GARJFASQSA-N
      0.000
      description
      1
    
    
      VHNOAIFVYUQOOY-XUXIUFHCSA-N
      Lys-Arg-Ile
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O
      VHNOAIFVYUQOOY-XUXIUFHCSA-N
      0.000
      description
      1
    
    
      WGCKDDHUFPQSMZ-ZPFDUUQYSA-N
      Lys-Asp-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN
      WGCKDDHUFPQSMZ-ZPFDUUQYSA-N
      0.000
      description
      1
    
    
      AIPHUKOBUXJNKM-KKUMJFAQSA-N
      Lys-Cys-Phe
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
      AIPHUKOBUXJNKM-KKUMJFAQSA-N
      0.000
      description
      1
    
    
      VSRXPEHZMHSFKU-IUCAKERBSA-N
      Lys-Gln-Gly
      Chemical compound
      
      
      NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O
      VSRXPEHZMHSFKU-IUCAKERBSA-N
      0.000
      description
      1
    
    
      GQFDWEDHOQRNLC-QWRGUYRKSA-N
      Lys-Gly-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN
      GQFDWEDHOQRNLC-QWRGUYRKSA-N
      0.000
      description
      1
    
    
      PBLLTSKBTAHDNA-KBPBESRZSA-N
      Lys-Gly-Phe
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
      PBLLTSKBTAHDNA-KBPBESRZSA-N
      0.000
      description
      1
    
    
      DAHQKYYIXPBESV-UWVGGRQHSA-N
      Lys-Met-Gly
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O
      DAHQKYYIXPBESV-UWVGGRQHSA-N
      0.000
      description
      1
    
    
      ZVZRQKJOQQAFCF-ULQDDVLXSA-N
      Lys-Tyr-Arg
      Chemical compound
      
      
      [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      ZVZRQKJOQQAFCF-ULQDDVLXSA-N
      0.000
      description
      1
    
    
      SQUTUWHAAWJYES-GUBZILKMSA-N
      Met-Asp-Arg
      Chemical compound
      
      
      [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      SQUTUWHAAWJYES-GUBZILKMSA-N
      0.000
      description
      1
    
    
      OXHSZBRPUGNMKW-DCAQKATOSA-N
      Met-Gln-Arg
      Chemical compound
      
      
      [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
      OXHSZBRPUGNMKW-DCAQKATOSA-N
      0.000
      description
      1
    
    
      DJDFBVNNDAUPRW-GUBZILKMSA-N
      Met-Glu-Gln
      Chemical compound
      
      
      CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O
      DJDFBVNNDAUPRW-GUBZILKMSA-N
      0.000
      description
      1
    
    
      SJDQOYTYNGZZJX-SRVKXCTJSA-N
      Met-Glu-Leu
      Chemical compound
      
      
      CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O
      SJDQOYTYNGZZJX-SRVKXCTJSA-N
      0.000
      description
      1
    
    
      OIFHHODAXVWKJN-ULQDDVLXSA-N
      Met-Phe-Leu
      Chemical compound
      
      
      CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1
      OIFHHODAXVWKJN-ULQDDVLXSA-N
      0.000
      description
      1
    
    
      KWIUHFFTVRNATP-UHFFFAOYSA-O
      N,N,N-trimethylglycinium
      Chemical compound
      
      
      C[N&#43;](C)(C)CC(O)=O
      KWIUHFFTVRNATP-UHFFFAOYSA-O
      0.000
      description
      1
    
    
      OLNLSTNFRUFTLM-UHFFFAOYSA-N
      N-ethylasparagine
      Chemical compound
      
      
      CCNC(C(O)=O)CC(N)=O
      OLNLSTNFRUFTLM-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      YPIGGYHFMKJNKV-UHFFFAOYSA-N
      N-ethylglycine
      Chemical compound
      
      
      CC[NH2&#43;]CC([O-])=O
      YPIGGYHFMKJNKV-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      108010065338
      N-ethylglycine
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      KZNQNBZMBZJQJO-UHFFFAOYSA-N
      N-glycyl-L-proline
      Natural products
      
      
      NCC(=O)N1CCCC1C(O)=O
      KZNQNBZMBZJQJO-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      AKCRVYNORCOYQT-YFKPBYRVSA-N
      N-methyl-L-valine
      Chemical compound
      
      
      CN[C@@H](C(C)C)C(O)=O
      AKCRVYNORCOYQT-YFKPBYRVSA-N
      0.000
      description
      1
    
    
      IOVCWXUNBOPUCH-UHFFFAOYSA-N
      Nitrous acid
      Chemical compound
      
      
      ON=O
      IOVCWXUNBOPUCH-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      108091028043
      Nucleic acid sequence
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      AHLPHDHHMVZTML-UHFFFAOYSA-N
      Orn-delta-NH2
      Natural products
      
      
      NCCCC(N)C(O)=O
      AHLPHDHHMVZTML-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      UTJLXEIPEHZYQJ-UHFFFAOYSA-N
      Ornithine
      Natural products
      
      
      OC(=O)C(C)CCCN
      UTJLXEIPEHZYQJ-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      229910019142
      PO4
      Inorganic materials
      
      
      
      
      0.000
      description
      1
    
    
      108091005804
      Peptidases
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      LJUUGSWZPQOJKD-JYJNAYRXSA-N
      Phe-Arg-Val
      Chemical compound
      
      
      CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O
      LJUUGSWZPQOJKD-JYJNAYRXSA-N
      0.000
      description
      1
    
    
      CDQCFGOQNYOICK-IHRRRGAJSA-N
      Phe-Glu-Gln
      Chemical compound
      
      
      NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1
      CDQCFGOQNYOICK-IHRRRGAJSA-N
      0.000
      description
      1
    
    
      VZFPYFRVHMSSNA-JURCDPSOSA-N
      Phe-Ile-Ala
      Chemical compound
      
      
      OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=CC=C1
      VZFPYFRVHMSSNA-JURCDPSOSA-N
      0.000
      description
      1
    
    
      LRBSWBVUCLLRLU-BZSNNMDCSA-N
      Phe-Leu-Lys
      Chemical compound
      
      
      CC(C)C[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(O)=O
      LRBSWBVUCLLRLU-BZSNNMDCSA-N
      0.000
      description
      1
    
    
      OSBADCBXAMSPQD-YESZJQIVSA-N
      Phe-Leu-Pro
      Chemical compound
      
      
      CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N
      OSBADCBXAMSPQD-YESZJQIVSA-N
      0.000
      description
      1
    
    
      DNAXXTQSTKOHFO-QEJZJMRPSA-N
      Phe-Lys-Ala
      Chemical compound
      
      
      OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1
      DNAXXTQSTKOHFO-QEJZJMRPSA-N
      0.000
      description
      1
    
    
      GMWNQSGWWGKTSF-LFSVMHDDSA-N
      Phe-Thr-Ala
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O
      GMWNQSGWWGKTSF-LFSVMHDDSA-N
      0.000
      description
      1
    
    
      OOLOTUZJUBOMAX-GUBZILKMSA-N
      Pro-Ala-Val
      Chemical compound
      
      
      [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O
      OOLOTUZJUBOMAX-GUBZILKMSA-N
      0.000
      description
      1
    
    
      IHCXPSYCHXFXKT-DCAQKATOSA-N
      Pro-Arg-Glu
      Chemical compound
      
      
      [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      IHCXPSYCHXFXKT-DCAQKATOSA-N
      0.000
      description
      1
    
    
      ORPZXBQTEHINPB-SRVKXCTJSA-N
      Pro-Arg-Val
      Chemical compound
      
      
      CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1)C(O)=O
      ORPZXBQTEHINPB-SRVKXCTJSA-N
      0.000
      description
      1
    
    
      OOZJHTXCLJUODH-QXEWZRGKSA-N
      Pro-Val-Asp
      Chemical compound
      
      
      OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1
      OOZJHTXCLJUODH-QXEWZRGKSA-N
      0.000
      description
      1
    
    
      ONIBWKKTOPOVIA-UHFFFAOYSA-N
      Proline
      Natural products
      
      
      OC(=O)C1CCCN1
      ONIBWKKTOPOVIA-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      239000004365
      Protease
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      CZPWVGJYEJSRLH-UHFFFAOYSA-N
      Pyrimidine
      Chemical compound
      
      
      C1=CN=CN=C1
      CZPWVGJYEJSRLH-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      102100037486
      Reverse transcriptase/ribonuclease H
      Human genes
      
      
      
      
      0.000
      description
      1
    
    
      240000004808
      Saccharomyces cerevisiae
      Species
      
      
      
      
      0.000
      description
      1
    
    
      108010077895
      Sarcosine
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      QGMLKFGTGXWAHF-IHRRRGAJSA-N
      Ser-Arg-Phe
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
      QGMLKFGTGXWAHF-IHRRRGAJSA-N
      0.000
      description
      1
    
    
      KAAPNMOKUUPKOE-SRVKXCTJSA-N
      Ser-Asn-Phe
      Chemical compound
      
      
      OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1
      KAAPNMOKUUPKOE-SRVKXCTJSA-N
      0.000
      description
      1
    
    
      MMAPOBOTRUVNKJ-ZLUOBGJFSA-N
      Ser-Asp-Ser
      Chemical compound
      
      
      C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O
      MMAPOBOTRUVNKJ-ZLUOBGJFSA-N
      0.000
      description
      1
    
    
      FMDHKPRACUXATF-ACZMJKKPSA-N
      Ser-Gln-Ser
      Chemical compound
      
      
      OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O
      FMDHKPRACUXATF-ACZMJKKPSA-N
      0.000
      description
      1
    
    
      LALNXSXEYFUUDD-GUBZILKMSA-N
      Ser-Glu-Leu
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O
      LALNXSXEYFUUDD-GUBZILKMSA-N
      0.000
      description
      1
    
    
      OHKFXGKHSJKKAL-NRPADANISA-N
      Ser-Glu-Val
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O
      OHKFXGKHSJKKAL-NRPADANISA-N
      0.000
      description
      1
    
    
      NMZXJDSKEGFDLJ-DCAQKATOSA-N
      Ser-Pro-Lys
      Chemical compound
      
      
      C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)O
      NMZXJDSKEGFDLJ-DCAQKATOSA-N
      0.000
      description
      1
    
    
      SOACHCFYJMCMHC-BWBBJGPYSA-N
      Ser-Thr-Cys
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)O
      SOACHCFYJMCMHC-BWBBJGPYSA-N
      0.000
      description
      1
    
    
      QYBRQMLZDDJBSW-AVGNSLFASA-N
      Ser-Tyr-Glu
      Chemical compound
      
      
      [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      QYBRQMLZDDJBSW-AVGNSLFASA-N
      0.000
      description
      1
    
    
      108010090804
      Streptavidin
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      ODSAPYVQSLDRSR-LKXGYXEUSA-N
      Thr-Cys-Asn
      Chemical compound
      
      
      [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O
      ODSAPYVQSLDRSR-LKXGYXEUSA-N
      0.000
      description
      1
    
    
      XPNSAQMEAVSQRD-FBCQKBJTSA-N
      Thr-Gly-Gly
      Chemical compound
      
      
      C[C@@H](O)[C@H](N)C(=O)NCC(=O)NCC(O)=O
      XPNSAQMEAVSQRD-FBCQKBJTSA-N
      0.000
      description
      1
    
    
      WBCCCPZIJIJTSD-TUBUOCAGSA-N
      Thr-His-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H]([C@@H](C)O)N
      WBCCCPZIJIJTSD-TUBUOCAGSA-N
      0.000
      description
      1
    
    
      WNQJTLATMXYSEL-OEAJRASXSA-N
      Thr-Phe-Leu
      Chemical compound
      
      
      [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O
      WNQJTLATMXYSEL-OEAJRASXSA-N
      0.000
      description
      1
    
    
      KPMIQCXJDVKWKO-IFFSRLJSSA-N
      Thr-Val-Glu
      Chemical compound
      
      
      [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      KPMIQCXJDVKWKO-IFFSRLJSSA-N
      0.000
      description
      1
    
    
      RWQNBRDOKXIBIV-UHFFFAOYSA-N
      Thymine
      Natural products
      
      
      CC1=CNC(=O)NC1=O
      RWQNBRDOKXIBIV-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      UEFHVUQBYNRNQC-SFJXLCSZSA-N
      Trp-Phe-Thr
      Chemical compound
      
      
      C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=CC=C1
      UEFHVUQBYNRNQC-SFJXLCSZSA-N
      0.000
      description
      1
    
    
      VCXWRWYFJLXITF-AUTRQRHGSA-N
      Tyr-Ala-Ala
      Chemical compound
      
      
      OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1
      VCXWRWYFJLXITF-AUTRQRHGSA-N
      0.000
      description
      1
    
    
      TVOGEPLDNYTAHD-CQDKDKBSSA-N
      Tyr-Ala-Leu
      Chemical compound
      
      
      CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1
      TVOGEPLDNYTAHD-CQDKDKBSSA-N
      0.000
      description
      1
    
    
      ADBDQGBDNUTRDB-ULQDDVLXSA-N
      Tyr-Arg-Leu
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O
      ADBDQGBDNUTRDB-ULQDDVLXSA-N
      0.000
      description
      1
    
    
      CKHQKYHIZCRTAP-SOUVJXGZSA-N
      Tyr-Gln-Pro
      Chemical compound
      
      
      C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O
      CKHQKYHIZCRTAP-SOUVJXGZSA-N
      0.000
      description
      1
    
    
      HDSKHCBAVVWPCQ-FHWLQOOXSA-N
      Tyr-Glu-Phe
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
      HDSKHCBAVVWPCQ-FHWLQOOXSA-N
      0.000
      description
      1
    
    
      KSCVLGXNQXKUAR-JYJNAYRXSA-N
      Tyr-Leu-Glu
      Chemical compound
      
      
      [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O
      KSCVLGXNQXKUAR-JYJNAYRXSA-N
      0.000
      description
      1
    
    
      VPEFOFYNHBWFNQ-UFYCRDLUSA-N
      Tyr-Pro-Tyr
      Chemical compound
      
      
      C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1
      VPEFOFYNHBWFNQ-UFYCRDLUSA-N
      0.000
      description
      1
    
    
      YFOCMOVJBQDBCE-NRPADANISA-N
      Val-Ala-Glu
      Chemical compound
      
      
      C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N
      YFOCMOVJBQDBCE-NRPADANISA-N
      0.000
      description
      1
    
    
      CGGVNFJRZJUVAE-BYULHYEWSA-N
      Val-Asp-Asn
      Chemical compound
      
      
      CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N
      CGGVNFJRZJUVAE-BYULHYEWSA-N
      0.000
      description
      1
    
    
      YODDULVCGFQRFZ-ZKWXMUAHSA-N
      Val-Asp-Ser
      Chemical compound
      
      
      CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O
      YODDULVCGFQRFZ-ZKWXMUAHSA-N
      0.000
      description
      1
    
    
      APEBUJBRGCMMHP-HJWJTTGWSA-N
      Val-Ile-Phe
      Chemical compound
      
      
      CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1
      APEBUJBRGCMMHP-HJWJTTGWSA-N
      0.000
      description
      1
    
    
      OVBMCNDKCWAXMZ-NAKRPEOUSA-N
      Val-Ile-Ser
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N
      OVBMCNDKCWAXMZ-NAKRPEOUSA-N
      0.000
      description
      1
    
    
      TVGWMCTYUFBXAP-QTKMDUPCSA-N
      Val-Thr-His
      Chemical compound
      
      
      C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N)O
      TVGWMCTYUFBXAP-QTKMDUPCSA-N
      0.000
      description
      1
    
    
      WUFHZIRMAZZWRS-OSUNSFLBSA-N
      Val-Thr-Ile
      Chemical compound
      
      
      CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N
      WUFHZIRMAZZWRS-OSUNSFLBSA-N
      0.000
      description
      1
    
    
      JLCPHMBAVCMARE-UHFFFAOYSA-N
      [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
      Polymers
      
      
      Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O
      JLCPHMBAVCMARE-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      PGAVKCOVUIYSFO-UHFFFAOYSA-N
      [[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
      Chemical compound
      
      
      OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1
      PGAVKCOVUIYSFO-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      DHKHKXVYLBGOIT-UHFFFAOYSA-N
      acetaldehyde Diethyl Acetal
      Natural products
      
      
      CCOC(C)OCC
      DHKHKXVYLBGOIT-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      230000002378
      acidificating effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      230000009471
      action
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      125000002252
      acyl group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      238000007259
      addition reaction
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      229960000643
      adenine
      Drugs
      
      
      
      
      0.000
      description
      1
    
    
      108010041407
      alanylaspartic acid
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      108010011559
      alanylphenylalanine
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      108010087924
      alanylproline
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      125000003342
      alkenyl group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      125000003545
      alkoxy group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      125000001118
      alkylidene group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      125000000304
      alkynyl group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      230000004075
      alteration
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      125000003368
      amide group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      150000001412
      amines
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      229940124277
      aminobutyric acid
      Drugs
      
      
      
      
      0.000
      description
      1
    
    
      125000002344
      aminooxy group
      Chemical group
      
      
      [H]N([H])O[*]
      
      0.000
      description
      1
    
    
      238000004458
      analytical method
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      239000012736
      aqueous medium
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      108010036533
      arginylvaline
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      125000003710
      aryl alkyl group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      125000003118
      aryl group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      125000004104
      aryloxy group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      108010040443
      aspartyl-aspartic acid
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      150000001540
      azides
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      230000009286
      beneficial effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      SRSXLGNVWSONIS-UHFFFAOYSA-N
      benzenesulfonic acid
      Chemical class
      
      
      OS(=O)(=O)C1=CC=CC=C1
      SRSXLGNVWSONIS-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      DRTQHJPVMGBUCF-PSQAKQOGSA-N
      beta-L-uridine
      Natural products
      
      
      O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1
      DRTQHJPVMGBUCF-PSQAKQOGSA-N
      0.000
      description
      1
    
    
      229960003237
      betaine
      Drugs
      
      
      
      
      0.000
      description
      1
    
    
      238000010170
      biological method
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      230000031018
      biological processes and functions
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      230000033228
      biological regulation
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      102000043871
      biotin binding protein
      Human genes
      
      
      
      
      0.000
      description
      1
    
    
      108700021042
      biotin binding protein
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      150000001642
      boronic acid derivatives
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      210000004899
      c-terminal region
      Anatomy
      
      
      
      
      0.000
      description
      1
    
    
      239000007978
      cacodylate buffer
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      238000004364
      calculation method
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      150000004657
      carbamic acid derivatives
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      239000004202
      carbamide
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      150000004649
      carbonic acid derivatives
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      238000006473
      carboxylation reaction
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      238000006555
      catalytic reaction
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      150000001768
      cations
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      230000003915
      cell function
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      210000000349
      chromosome
      Anatomy
      
      
      
      
      0.000
      description
      1
    
    
      230000000295
      complement effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      238000005094
      computer simulation
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      238000012937
      correction
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      125000004093
      cyano group
      Chemical group
      
      
      *C#N
      
      0.000
      description
      1
    
    
      OPTASPLRGRRNAP-UHFFFAOYSA-N
      cytosine
      Natural products
      
      
      NC=1C=CNC(=O)N=1
      OPTASPLRGRRNAP-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      229940104302
      cytosine
      Drugs
      
      
      
      
      0.000
      description
      1
    
    
      SUYVUBYJARFZHO-RRKCRQDMSA-N
      dATP
      Chemical compound
      
      
      C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1
      SUYVUBYJARFZHO-RRKCRQDMSA-N
      0.000
      description
      1
    
    
      238000013500
      data storage
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      YSMODUONRAFBET-UHFFFAOYSA-N
      delta-DL-hydroxylysine
      Natural products
      
      
      NCC(O)CCC(N)C(O)=O
      YSMODUONRAFBET-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      239000003398
      denaturant
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      238000013461
      design
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      238000000502
      dialysis
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      201000010099
      disease
      Diseases
      
      
      
      
      0.000
      description
      1
    
    
      208000037265
      diseases, disorders, signs and symptoms
      Diseases
      
      
      
      
      0.000
      description
      1
    
    
      238000004090
      dissolution
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      PMMYEEVYMWASQN-UHFFFAOYSA-N
      dl-hydroxyproline
      Natural products
      
      
      OC1C[NH2&#43;]C(C([O-])=O)C1
      PMMYEEVYMWASQN-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      238000009510
      drug design
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      239000003596
      drug target
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      239000012636
      effector
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      YSMODUONRAFBET-UHNVWZDZSA-N
      erythro-5-hydroxy-L-lysine
      Chemical compound
      
      
      NC[C@H](O)CC[C@H](N)C(O)=O
      YSMODUONRAFBET-UHNVWZDZSA-N
      0.000
      description
      1
    
    
      150000002148
      esters
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      RTZKZFJDLAIYFH-UHFFFAOYSA-N
      ether
      Substances
      
      
      CCOCC
      RTZKZFJDLAIYFH-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      150000002170
      ethers
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      DNJIEGIFACGWOD-UHFFFAOYSA-N
      ethyl mercaptane
      Natural products
      
      
      CCS
      DNJIEGIFACGWOD-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      238000002474
      experimental method
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      230000022244
      formylation
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      238000006170
      formylation reaction
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      BTCSSZJGUNDROE-UHFFFAOYSA-N
      gamma-aminobutyric acid
      Chemical compound
      
      
      NCCCC(O)=O
      BTCSSZJGUNDROE-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      108010063718
      gamma-glutamylaspartic acid
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      108010020688
      glycylhistidine
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      108010081551
      glycylphenylalanine
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      108010077515
      glycylproline
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      229960000789
      guanidine hydrochloride
      Drugs
      
      
      
      
      0.000
      description
      1
    
    
      PJJJBBJSCAKJQF-UHFFFAOYSA-N
      guanidinium chloride
      Chemical compound
      
      
      [Cl-].NC(N)=[NH2&#43;]
      PJJJBBJSCAKJQF-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      125000005843
      halogen group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      125000001072
      heteroaryl group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      125000005553
      heteroaryloxy group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      125000000623
      heterocyclic group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      238000013537
      high throughput screening
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      108010018006
      histidylserine
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      239000001257
      hydrogen
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      125000004435
      hydrogen atom
      Chemical group
      
      
      [H]*
      
      0.000
      description
      1
    
    
      230000002209
      hydrophobic effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      QJHBJHUKURJDLG-UHFFFAOYSA-N
      hydroxy-L-lysine
      Natural products
      
      
      NCCCCC(NO)C(O)=O
      QJHBJHUKURJDLG-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      150000002443
      hydroxylamines
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      238000007031
      hydroxymethylation reaction
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      229960002591
      hydroxyproline
      Drugs
      
      
      
      
      0.000
      description
      1
    
    
      230000002163
      immunogen
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      230000002779
      inactivation
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      239000003112
      inhibitor
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      230000003993
      interaction
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      230000002452
      interceptive effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      108010078274
      isoleucylvaline
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      238000002372
      labelling
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      108010012058
      leucyltyrosine
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      238000002898
      library design
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      230000007774
      longterm
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      239000006166
      lysate
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      239000012139
      lysis buffer
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      230000008531
      maintenance mechanism
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      239000003550
      marker
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      239000000463
      material
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      239000011159
      matrix material
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      230000001404
      mediated effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      238000012269
      metabolic engineering
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      108010056582
      methionylglutamic acid
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      125000002496
      methyl group
      Chemical group
      
      
      [H]C([H])([H])*
      
      0.000
      description
      1
    
    
      230000011987
      methylation
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      238000007069
      methylation reaction
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      244000005700
      microbiome
      Species
      
      
      
      
      0.000
      description
      1
    
    
      238000010369
      molecular cloning
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      231100000243
      mutagenic effect
      Toxicity
      
      
      
      
      0.000
      description
      1
    
    
      230000003505
      mutagenic effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      210000004897
      n-terminal region
      Anatomy
      
      
      
      
      0.000
      description
      1
    
    
      150000002823
      nitrates
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      150000002825
      nitriles
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      230000030648
      nucleus localization
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      238000005457
      optimization
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      229960003104
      ornithine
      Drugs
      
      
      
      
      0.000
      description
      1
    
    
      108010018625
      phenylalanylarginine
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      108010012581
      phenylalanylglutamate
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      235000021317
      phosphate
      Nutrition
      
      
      
      
      0.000
      description
      1
    
    
      239000008363
      phosphate buffer
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      150000008298
      phosphoramidates
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      150000008039
      phosphoramides
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      235000011007
      phosphoric acid
      Nutrition
      
      
      
      
      0.000
      description
      1
    
    
      150000003013
      phosphoric acid derivatives
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      150000003016
      phosphoric acids
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      230000037048
      polymerization activity
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      HJRIWDYVYNNCFY-UHFFFAOYSA-M
      potassium;dimethylarsinate
      Chemical compound
      
      
      [K&#43;].C[As](C)([O-])=O
      HJRIWDYVYNNCFY-UHFFFAOYSA-M
      0.000
      description
      1
    
    
      239000002244
      precipitate
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      230000002028
      premature
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      108010004914
      prolylarginine
      Proteins
      
      
      
      
      0.000
      description
      1
    
    
      238000002708
      random mutagenesis
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      239000000376
      reactant
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      239000011535
      reaction buffer
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      230000035484
      reaction time
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      230000010076
      replication
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      238000011160
      research
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      238000012163
      sequencing technique
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      238000007086
      side reaction
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      238000002741
      site-directed mutagenesis
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      238000002415
      sodium dodecyl sulfate polyacrylamide gel electrophoresis
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      238000010186
      staining
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      125000001424
      substituent group
      Chemical group
      
      
      
      
      0.000
      description
      1
    
    
      150000008163
      sugars
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      150000003457
      sulfones
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      150000003467
      sulfuric acid derivatives
      Chemical class
      
      
      
      
      0.000
      description
      1
    
    
      239000013595
      supernatant sample
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      238000010257
      thawing
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      230000001225
      therapeutic effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      YSMODUONRAFBET-WHFBIAKZSA-N
      threo-5-hydroxy-L-lysine
      Chemical compound
      
      
      NC[C@@H](O)CC[C@H](N)C(O)=O
      YSMODUONRAFBET-WHFBIAKZSA-N
      0.000
      description
      1
    
    
      229940113082
      thymine
      Drugs
      
      
      
      
      0.000
      description
      1
    
    
      231100000331
      toxic
      Toxicity
      
      
      
      
      0.000
      description
      1
    
    
      230000002588
      toxic effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      FGMPLJWBKKVCDB-UHFFFAOYSA-N
      trans-L-hydroxy-proline
      Natural products
      
      
      ON1CCCC1C(O)=O
      FGMPLJWBKKVCDB-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      238000012546
      transfer
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      230000009466
      transformation
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      230000001131
      transforming effect
      Effects
      
      
      
      
      0.000
      description
      1
    
    
      DRTQHJPVMGBUCF-UHFFFAOYSA-N
      uracil arabinoside
      Natural products
      
      
      OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1
      DRTQHJPVMGBUCF-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      229940045145
      uridine
      Drugs
      
      
      
      
      0.000
      description
      1
    
    
      238000010200
      validation analysis
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      238000012795
      verification
      Methods
      
      
      
      
      0.000
      description
      1
    
    
      239000011534
      wash buffer
      Substances
      
      
      
      
      0.000
      description
      1
    
    
      XLYOFNOQVPJJNP-UHFFFAOYSA-N
      water
      Substances
      
      
      O
      XLYOFNOQVPJJNP-UHFFFAOYSA-N
      0.000
      description
      1
    
    
      DGVVWUTYPXICAM-UHFFFAOYSA-N
      Î²âMercaptoethanol
      Chemical compound
      
      
      OCCS
      DGVVWUTYPXICAM-UHFFFAOYSA-N
      0.000
      description
      1
    
  

  

  
    ## Classifications
    
      
        
          
            C&mdash;CHEMISTRY; METALLURGY
            
          
          
            C12&mdash;BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
            
          
          
            C12P&mdash;FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
            
          
          
            C12P19/00&mdash;Preparation of compounds containing saccharide radicals
            
          
          
            C12P19/26&mdash;Preparation of nitrogen-containing carbohydrates
            
          
          
            C12P19/28&mdash;N-glycosides
            
          
          
            C12P19/30&mdash;Nucleotides
            
          
          
            C12P19/34&mdash;Polynucleotides, e.g. nucleic acids, oligoribonucleotides
            
          
        
      
      
        
          
            C&mdash;CHEMISTRY; METALLURGY
            
          
          
            C12&mdash;BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
            
          
          
            C12N&mdash;MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
            
          
          
            C12N15/00&mdash;Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
            
          
          
            C12N15/09&mdash;Recombinant DNA-technology
            
          
          
            C12N15/11&mdash;DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
            
          
          
            C12N15/52&mdash;Genes encoding for enzymes or proenzymes
            
          
        
      
      
        
          
            C&mdash;CHEMISTRY; METALLURGY
            
          
          
            C12&mdash;BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
            
          
          
            C12N&mdash;MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
            
          
          
            C12N15/00&mdash;Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
            
          
          
            C12N15/09&mdash;Recombinant DNA-technology
            
          
          
            C12N15/63&mdash;Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
            
          
          
            C12N15/70&mdash;Vectors or expression systems specially adapted for E. coli
            
          
        
      
      
        
          
            C&mdash;CHEMISTRY; METALLURGY
            
          
          
            C12&mdash;BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
            
          
          
            C12N&mdash;MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
            
          
          
            C12N9/00&mdash;Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
            
          
          
            C12N9/10&mdash;Transferases (2.)
            
          
          
            C12N9/12&mdash;Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
            
          
          
            C12N9/1241&mdash;Nucleotidyltransferases (2.7.7)
            
          
          
            C12N9/1264&mdash;DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
            
          
        
      
      
        
          
            C&mdash;CHEMISTRY; METALLURGY
            
          
          
            C12&mdash;BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
            
          
          
            C12Y&mdash;ENZYMES
            
          
          
            C12Y207/00&mdash;Transferases transferring phosphorus-containing groups (2.7)
            
          
          
            C12Y207/07&mdash;Nucleotidyltransferases (2.7.7)
            
          
          
            C12Y207/07031&mdash;DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal deoxynucleotidyl transferase
            
          
        
      
      
        
          
            C&mdash;CHEMISTRY; METALLURGY
            
          
          
            C07&mdash;ORGANIC CHEMISTRY
            
          
          
            C07K&mdash;PEPTIDES
            
          
          
            C07K2319/00&mdash;Fusion polypeptide
            
          
          
            C07K2319/20&mdash;Fusion polypeptide containing a tag with affinity for a non-protein ligand
            
          
        
      
    
  

  

  

  

  
    ## Landscapes
    
      
        Life Sciences &amp; Earth Sciences
        (AREA)
      
      
        Health &amp; Medical Sciences
        (AREA)
      
      
        Chemical &amp; Material Sciences
        (AREA)
      
      
        Organic Chemistry
        (AREA)
      
      
        Engineering &amp; Computer Science
        (AREA)
      
      
        Genetics &amp; Genomics
        (AREA)
      
      
        Zoology
        (AREA)
      
      
        Wood Science &amp; Technology
        (AREA)
      
      
        Bioinformatics &amp; Cheminformatics
        (AREA)
      
      
        General Engineering &amp; Computer Science
        (AREA)
      
      
        Molecular Biology
        (AREA)
      
      
        Biochemistry
        (AREA)
      
      
        General Health &amp; Medical Sciences
        (AREA)
      
      
        Biotechnology
        (AREA)
      
      
        Microbiology
        (AREA)
      
      
        Biomedical Technology
        (AREA)
      
      
        Medicinal Chemistry
        (AREA)
      
      
        Chemical Kinetics &amp; Catalysis
        (AREA)
      
      
        General Chemical &amp; Material Sciences
        (AREA)
      
      
        Physics &amp; Mathematics
        (AREA)
      
      
        Biophysics
        (AREA)
      
      
        Plant Pathology
        (AREA)
      
      
        Enzymes And Modification Thereof
        (AREA)
      
    
  


  
    ## Abstract
    
    
    The present invention discloses various terminal deoxynucleotidyl transferases (tdts) and variants thereof for de novo synthesis of polynucleotides having controlled sequences and efficient and controllable synthesis of nucleic acid molecules independent of templates, and finds that some amino acid residues of TdT catalytic domains may be specifically modified to enhance the ability of such modified tdts to synthesize polynucleotides.
    
  
  

  
    ## Description
    Translated from Chinese
    
    
       å¯æ§åæåé¾DNAçæ«ç«¯è½¬ç§»é¶åä½ååºç¨Terminal transferase variants for controllable synthesis of single-stranded DNA and their applications
    
    
      
         ææ¯é¢åTechnical Field
      
      
         æ¬åææ¶åæ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶åå¶åºç¨ï¼å°¤å¶æ¶åå¯æ§åæåé¾DNAçæ«ç«¯è½¬ç§»é¶åä½ååºç¨ï¼å±äºçç©ææ¯é¢åãThe present invention relates to terminal deoxynucleotidyl transferase and application thereof, in particular to a terminal transferase variant capable of controllably synthesizing single-stranded DNA and application thereof, belonging to the field of biotechnology.
      
    
    
      
         èæ¯ææ¯Background Art
      
      
         DNAæ¯çå½ä¿¡æ¯çè½½ä½ï¼è·å¾DNAæ¯ç ç©¶ãæ¹é ãååé çå½çé¦è¦æ­¥éª¤ãDNAåææ¯åæçç©å­¦çæ ¸å¿ä½¿è½ææ¯ä¹ä¸ï¼å¯å¯¹åºå ç»DNAè¿è¡å¤§è§æ¨¡åæï¼æå©äºæé«æä»¬å¯¹çå½ä½ççè§£ãé¢æµåè°æ§ï¼å¹¶èµäºæä»¬è®¾è®¡åæ¹é ç»èåè½çè³éæäººå·¥çå½çè½åãDNA is the carrier of life information, and obtaining DNA is the first step in studying, transforming, and creating life. DNA synthesis is one of the core enabling technologies of synthetic biology, which can synthesize genomic DNA on a large scale, helping to improve our understanding, prediction, and regulation of life, and giving us the ability to design and transform cell functions and even reconstruct artificial life.
      
      
         ä¸ä¸çºª50å¹´ä»£è³ä»ï¼æå¤§éç§ç å·¥ä½èå°è¯éè¿åå­¦åé¶ä¿çæ¹æ³åæDNAãé¦åè·å¾æåçæ¯åå­¦åæææ¯ãç»è¿å¤å¹´ä¼ååæ¹è¿ï¼DNAåå­¦åæç»åäºä»æ±å¼åæå°å¾®è¯çåæçåé©åå±ï¼å¹¶å¾å°äºå¹¿æ³å¸åºååºç¨ãä½æ¯åå­¦æ¹æ³ä¸æ¹é¢ï¼å¶èæçåå¯ååºä½¿å¯¡æ ¸è·é¸åæé¿åº¦å±éäº300ntä»¥åï¼é¾ä»¥å°è¾¾kbçº§çåºå é¿åº¦ãå æ­¤æ´é¿çæ®µåééè¿çç©ç»è£ææ¯æ¼æ¥å¯¡æ ¸è·é¸çæ®µï¼ç´è³è·å¾åºå ãæè²ä½æåºå ç»é¿åº¦çDNAãå¦ä¸æ¹é¢ï¼ååºæ­¥éª¤ç¹çãåä¸ªå¾ªç¯èæ¶è¾é¿(6-8åé)ãåå­¦è¯åæ¶èè¾å¤ä¸ææ¬è¾é«ï¼å¤§éä½¿ç¨ææ¯ãæççææºè¯åï¼æ±¡æè¾å¤§ãSince the 1950s, a large number of scientific researchers have tried to synthesize DNA through chemical and enzymatic methods. The first to succeed was chemical synthesis technology. After years of optimization and improvement, DNA chemical synthesis has undergone a transformation from column synthesis to microchip synthesis, and has been widely used in the market. However, on the one hand, the coupling efficiency and side reactions of chemical methods limit the length of oligonucleotide synthesis to less than 300nt, making it difficult to reach the gene length of kb. Therefore, longer fragments need to be spliced with oligonucleotide fragments through biological assembly technology until DNA of gene, chromosome or genome length is obtained. On the other hand, the reaction steps are cumbersome, a single cycle takes a long time (6-8 minutes), chemical reagents are consumed more and the cost is high, and a large amount of toxic and flammable organic reagents are used, which causes great pollution.
      
      
         å æ­¤ï¼çç©é¶åæDNAæä¸ºç ç©¶çç¦ç¹ãä½æ¯å¸¸è§çDNAèåé¶å·ææ¨¡æ¿ä¾èµæ§ï¼æ æ³ä»å¤´åæDNAãå¯»æ¾éæ¨¡æ¿ä¾èµæ§çDNAèåé¶æä¸ºé¶æ³åæçé¦è¦ä»»å¡ã1962å¹´Bollumé¦ååç°æ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶(TdT)ï¼å¹¶æåºTdTå¯ç¨äºåé¾å¯¡æ ¸è·é¸åæãç®åï¼é¶ä¿å¯¡æ ¸è·é¸åæéç¨3ä½å ä¿®é¥°åºå¢çæ ¸è·é¸ä¸ºåºç©ï¼è¯¥åºç©ä¸å¼ç©é¾ç5ä½ç£·é¸åºå¢ååºåï¼ç±äºè¯¥ä¿®é¥°åºå¢æ æ³ä¸ä¸ä¸ä¸ªæ ¸è·é¸5ä½çç£·é¸åºå¢ååºï¼é»æ­äºæ ¸è·é¸å¨å¯¡æ ¸è·é¸é¾çè¿ä¸æ­¥æºå¥ãæ¯æ¬¡é¶ä¿ååºåªè½å¬åä¸ä¸ªå¸¦ä¿®é¥°åºå¢çæ ¸è·é¸æºå¥ï¼éåéç¨åå­¦æçç©æ¹æ³é¤å»ä¿®é¥°åºå¢ï¼ä½¿3&#39;ç«¯éæ°æ¢å¤ä¸ºOHï¼ä»¥ä¾¿è¿è¡ä¸ä¸è½®åæå¾ªç¯ãä½è¯¥è¿ç¨éçåèç½çå¬åæçä½ï¼æ­£ç¡®çè¾¾ä¸å°ï¼å æ­¤å¯»æ¾ä¸ç§å·æé«æçå¬åæ´»æ§åç¸å¯¹ç¨³å®çé¶æ¯è¿«å¨çç«çéæ±ãTherefore, bioenzymatic DNA synthesis has become a research focus. However, conventional DNA polymerases are template-dependent and cannot synthesize DNA from scratch. Finding non-template-dependent DNA polymerases has become the primary task of enzymatic synthesis. In 1962, Bollum first discovered terminal deoxynucleotidyl transferase (TdT) and proposed that TdT can be used for single-stranded oligonucleotide synthesis. At present, enzymatic oligonucleotide synthesis uses nucleotides with modified groups at the 3rd position as substrates. After the substrate reacts with the 5th phosphate group of the primer chain, the modified group cannot react with the 5th phosphate group of the next nucleotide, blocking the further incorporation of the nucleotide into the oligonucleotide chain. Each enzymatic reaction can only catalyze the incorporation of a nucleotide with a modified group, and then chemical or biological methods are used to remove the modified group, so that the 3&#39; end is restored to OH for the next round of synthesis cycle. However, the catalytic efficiency of the wild-type protein in this process is low and the accuracy rate cannot be achieved. Therefore, it is an urgent need to find an enzyme with high catalytic activity and relative stability.
      
    
    
      
         åæåå®¹Summary of the invention
      
      
         ä¸ºè§£å³ä¸è¿°é®é¢ï¼æ¬ç³è¯·çåæäººéè¿ç ç©¶ç¨äºä»å¤´åæå·æåæ§çåºåçå¤æ ¸è·é¸å¹¶ä¸ä¸ä¾èµæ¨¡æ¿çæåµä¸é«æå¯æ§çåææ ¸é¸åå­çå¤ç§æ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶(TdT)åå¶åä½ï¼åç°TdTå¬åç»æåçä¸äºæ°¨åºé¸æ®åºå¯ä»¥è¢«ç¹å¼æ§ä¿®é¥°ä»¥æé«TdTåä½åæå¤æ ¸è·é¸çè½åãTo solve the above problems, the inventors of the present application studied a variety of terminal deoxynucleotidyl transferases (TdTs) and their variants for de novo synthesis of polynucleotides with controlled sequences and efficient and controllable synthesis of nucleic acid molecules without relying on templates, and found that some amino acid residues in the catalytic domain of TdT can be specifically modified to improve the ability of TdT variants to synthesize polynucleotides.
      
      
         æ¬åæéç¨ä»¥ä¸ææ¯æ¹æ¡ï¼The present invention adopts the following technical solutions:
      
      
         æ¬åææä¾å¤ç§æ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶çªåä½ï¼è¯¥çªåä½å·æå¬å3âç«¯å¸¦O-æ°¨åºä¿®é¥°åºå¢çè±æ°§æ ¸ç³æ ¸è·é¸çåè½ï¼æè¿°çªåä½åå«éèªY178ãF186ãI210ãI228ãV302ãD324ãR353ãD324ãT330ãG332ãF333ãR335ãK337ãI329ãI339ãG340ãH341ãI343ãR435ãG452ãW453ãT454ãG455ãS456ãR457ãN477ãH478ä¸­è³å°ä¸ä¸ªä½ç½®å¤çæ®åºæåè½ç­åçæ®åºçè³å°ä¸ä¸ªçªåï¼æç¤ºä½ç½®éè¿ä¸SEQ ID NO.1æ¯å¯¹ç¡®å®ãThe present invention provides a plurality of terminal deoxynucleotidyl transferase mutants, which have the function of catalyzing deoxyribonucleotides with an O-amino modification group at the 3&#39; end, and the mutants comprise at least one mutation of a residue at at least one position selected from Y178, F186, I210, I228, V302, D324, R353, D324, T330, G332, F333, R335, K337, I329, I339, G340, H341, I343, R435, G452, W453, T454, G455, S456, R457, N477, H478, or a functionally equivalent residue, wherein the positions are determined by comparison with SEQ ID NO.1.
      
      
         æ ¹æ®æ¬åæï¼âåè½ç­åæ®åºâãâåè½ç­åçæ®åºâææå¨ä¸SEQ ID NO.1åºååæºçTdTçåºåä¸­çå¹¶ä¸å·æç¸ååè½ä½ç¨çæ®åºãåè½ç­åæ®åºä½¿ç¨åºåæ¯å¯¹ï¼ä¾å¦ä½¿ç¨Mutalinå¨çº¿æ¯å¯¹è½¯ä»¶(http://multalin.toulouse.inra.fr/multalin/multalin.htmlï¼ 1988,Nucl.Acids Res.,16(22),10881â10890)æ¥é´å®ãæ­¤å¤ï¼å¯ä»¥éè¿èç½è´¨ä¸ç»´ç»ææ¯å¯¹ç¡®å®åè½ç­åæ®åºãæ¯å¯¹åï¼åè½ç­åæ®åºå¤äºæèèçä¸ååºåä¸çåæºä½ç½®å¤ãåºåæ¯å¯¹ååè½ç­åæ®åºçé´å®å¯ä»¥å¨ä»»ä½TdTä¸å¶å¤©ç¶åä½ï¼åæ¬ç§é´åä½ä¹é´è¿è¡ãAccording to the present invention, &#34;functionally equivalent residues&#34; and &#34;functionally equivalent residues&#34; mean residues in the sequence of TdT homologous to the sequence of SEQ ID NO.1 and having the same functional role. Functionally equivalent residues are identified using sequence alignment, for example, using Mutalin online alignment software ( http://multalin.toulouse.inra.fr/multalin/multalin.html; 1988 , Nucl.Acids Res., 16 (22), 10881-10890). In addition, functionally equivalent residues can be determined by protein three-dimensional structure alignment. After alignment, functionally equivalent residues are located at homologous positions on the different sequences under consideration. Sequence alignment and identification of functionally equivalent residues can be performed between any TdT and its natural variants, including interspecies variants.
      
      
         æ ¹æ®æ¬åæï¼æè¿°çªåä½çæ°¨åºé¸åºååå«éèªY178ãF186ãI210ãI228ãV302ãT330ãR335ãK337ãI339ãG340ãR435ãT454ãG455ãS456ãR457ãN477ãH478ä¸­è³å°ä¸ä¸ªä½ç½®å¤çæ®åºæåè½ç­åçæ®åºçè³å°ä¸ä¸ªçªåãAccording to the present invention, the amino acid sequence of the mutant comprises at least one mutation of a residue at at least one position selected from Y178, F186, I210, I228, V302, T330, R335, K337, I339, G340, R435, T454, G455, S456, R457, N477, H478, or a functionally equivalent residue.
      
      
         æ ¹æ®æ¬åæï¼æè¿°çªåä½çæ°¨åºé¸åºååå«éèªY178AãF186RãI210LãI228LãV302GãT330AãR335AãR335LãK337GãK337LãI339VãG340GãG340LãR435LãT454AãG455VãS456VãR457GãN477LãH478Gä¸­è³å°ä¸ä¸ªä½ç½®å¤çæ®åºæåè½ç­åçæ®åºçè³å°ä¸ä¸ªçªåãAccording to the present invention, the amino acid sequence of the mutant comprises at least one mutation of a residue at at least one position selected from Y178A, F186R, I210L, I228L, V302G, T330A, R335A, R335L, K337G, K337L, I339V, G340G, G340L, R435L, T454A, G455V, S456V, R457G, N477L, H478G, or a functionally equivalent residue.
      
      
         æ ¹æ®æ¬åæï¼æè¿°çªåä½çæ°¨åºé¸åºååå«Y178ãF186ãI210ãI228ãV302ãD324ãR353ãD324ãT330ãG332ãF333ãR335ãK337ãI329ãI339ãG340ãH341ãI343ãR435ãG452ãW453ãT454ãG455ãS456ãR457ãN477ãH478ä¸­ä»»æä¸¤ä¸ªä½ç¹çæ°¨åºé¸æ®åºççªåãAccording to the present invention, the amino acid sequence of the mutant comprises mutations of amino acid residues at any two positions among Y178, F186, I210, I228, V302, D324, R353, D324, T330, G332, F333, R335, K337, I329, I339, G340, H341, I343, R435, G452, W453, T454, G455, S456, R457, N477, and H478.
      
      
         æ ¹æ®æ¬åæï¼æè¿°çªåä½çæ°¨åºé¸åºååå«Y178ãF186ãI210ãI228ãV302ãT330ãR335ãK337ãI339ãG340ãR435ãT454ãG455ãS456ãR457ãN477ãH478ä¸­ä»»æä¸¤ä¸ªä½ç¹çæ°¨åºé¸æ®åºççªåãAccording to the present invention, the amino acid sequence of the mutant comprises mutations of amino acid residues at any two of Y178, F186, I210, I228, V302, T330, R335, K337, I339, G340, R435, T454, G455, S456, R457, N477, and H478.
      
      
         æ ¹æ®æ¬åæï¼æè¿°çªåä½çæ°¨åºé¸åºååå«Y178ãF186ãI210ãI228ãV302ãT330ãR335ãK337ãI339ãG340ãR435ãT454ãG455ãS456ãR457ãN477ãH478ä¸­ä¸¤ä¸ªä½ç¹çæ°¨åºé¸æ®åºççªåãAccording to the present invention, the amino acid sequence of the mutant comprises mutations of amino acid residues at two positions among Y178, F186, I210, I228, V302, T330, R335, K337, I339, G340, R435, T454, G455, S456, R457, N477, and H478.
      
      
         æ ¹æ®æ¬åæï¼æè¿°çªåä½çæ°¨åºé¸åºååå«å¦ä¸ä¸¤ä¸ªä½ç¹ççªåï¼Y178/F186ãI210/I228ãR335/K337ãI339/G340ãS456/R457ãAccording to the present invention, the amino acid sequence of the mutant comprises mutations at the following two sites: Y178/F186, I210/I228, R335/K337, I339/G340, and S456/R457.
      
      
         æ ¹æ®æ¬åæï¼æè¿°çªåä½çæ°¨åºé¸åºååå«å¦ä¸ä¸¤ä¸ªä½ç¹ççªåï¼Y178A/F186RãI210L/I228LãR335A/K337GãR335L/K337LãI339V/G340VãS456V/R457LãAccording to the present invention, the amino acid sequence of the mutant comprises mutations at the following two sites: Y178A/F186R, I210L/I228L, R335A/K337G, R335L/K337L, I339V/G340V, and S456V/R457L.
      
      
         æ ¹æ®æ¬åæï¼TdTçåä½å·æä»¥ä¸æè¿°çåä»£æåä»£çç»åï¼å¹¶ä¸ä¸SEQ ID NO.1æåè½ç­ååºåå·æè³å°80ï¼çåä¸æ§ï¼ä¼éå°ä¸SEQ ID NO.1æåè½ç­ååºåå·æè³å°85ï¼ã90ï¼ã95ï¼ã96ï¼ã97ï¼ã98ï¼æ99ï¼çåä¸æ§ãAccording to the present invention, the variant of TdT has the substitutions or combinations of substitutions described above and has at least 80% identity with SEQ ID NO.1 or a functionally equivalent sequence, preferably at least 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO.1 or a functionally equivalent sequence.
      
      
         æ ¹æ®æ¬åæï¼å¦ä»¥ä¸å¬å¼çTdTçææåä½é½è½å¤æ¢å¨æ²¡ææ¨¡æ¿çæåµä¸åææ ¸é¸çæ®µåè½å¤å°ä¿®é¥°çæ ¸è·é¸æºå¥å°æ ¸é¸çæ®µä¸­ãæå©å°ï¼æè¿°åä½ä¸SEQ ID NO.1çTdTç¸æ¯å·æå¢å çå°ä¿®é¥°çæ ¸è·é¸ï¼ä¼éå°3âO-ä¿®é¥°çæ ¸è·é¸æºå¥å°æ ¸é¸çæ®µä¸­çè½åãAccording to the present invention, all variants of TdT as disclosed above are capable of both synthesizing nucleic acid fragments in the absence of a template and incorporating modified nucleotides into nucleic acid fragments. Advantageously, the variants have an increased ability to incorporate modified nucleotides, preferably 3&#39;O-modified nucleotides, into nucleic acid fragments compared to the TdT of SEQ ID NO.1.
      
      
         å¨ä»¥ä¸æè¿°çä¸äºå®æ½æ¹æ¡ä¸­ï¼åä½TdTå¨æºå¥3âO-ä¿®é¥°çæ ¸è·ä¸ç£·é¸æ¹é¢çæçæ¯åºåSEQ ID NO.1çéçåTdTçæççè³å°110ï¼ï¼å¨å¶ä»å®æ½æ¹æ¡ä¸­ï¼åä½TdTå¨æºå¥3âO-ä¿®é¥°çæ ¸è·ä¸ç£·é¸æ¹é¢çæçæ¯åºåSEQ ID NO.1çéçåTdTçæççè³å°150ï¼ï¼å¨å¶ä»å®æ½æ¹æ¡ä¸­ï¼åä½TdTå¨æºå¥3âO-ä¿®é¥°çæ ¸è·ä¸ç£·é¸æ¹é¢çæçæ¯åºåSEQIDNO.1çéçåTdTçæççè³å°200ï¼ãå¨ä¸ä¸ªå·ä½å®æ½æ¹æ¡ä¸­ï¼åä½è¿åå«å¨åºå330ä½å°343ä½X1X2X3X4RX5GX6NX7X8X9DX10çè³å°åä¿å®åºåä¸­çæ®åºçè³å°ä¸ä¸ªçªåï¼å¶ä¸­ï¼In some embodiments described above, the efficiency of the variant TdT in incorporating 3&#39;O-modified nucleoside triphosphates is at least 110% of the efficiency of the wild-type TdT of sequence SEQ ID NO.1; in other embodiments, the efficiency of the variant TdT in incorporating 3&#39;O-modified nucleoside triphosphates is at least 150% of the efficiency of the wild-type TdT of sequence SEQ ID NO.1; in other embodiments, the efficiency of the variant TdT incorporating 3&#39;O-modified nucleoside triphosphates is at least 200% of the efficiency of the wild-type TdT of sequence SEQ ID NO.1. In a specific embodiment, the variant further comprises at least one mutation of a residue in at least a semi-conserved region of sequence positions 330 to 343 X1X2X3X4RX5GX6NX7X8X9DX10, wherein,
      
      
         X1è¡¨ç¤ºéèªAãIãLãVãPãQãTãKãEçæ®åºï¼X1 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      
      
         X2è¡¨ç¤ºéèªGãLãVãFãYãCãHãRãDçæ®åºï¼X2 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      
      
         X3è¡¨ç¤ºéèªAãIãLãVãPãQãTãKãEçæ®åºï¼X3 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      
      
         X4è¡¨ç¤ºéèªGãLãVãFãYãCãHãRãDçæ®åºï¼X4 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      
      
         X5è¡¨ç¤ºéèªAãIãLãVãPãQãTãKãEçæ®åºï¼X5 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      
      
         X6è¡¨ç¤ºéèªGãLãVãFãYãCãHãRãDçæ®åºï¼X6 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      
      
         X7è¡¨ç¤ºéèªAãIãLãVãPãQãTãKãEçæ®åºï¼X7 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      
      
         X8è¡¨ç¤ºéèªGãLãVãFãYãCãHãRãDçæ®åºï¼X8 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      
      
         X9è¡¨ç¤ºéèªAãIãLãVãPãQãTãKãEçæ®åºï¼X9 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      
      
         X10è¡¨ç¤ºéèªGãLãVãFãYãCãHãRãDçæ®åºãX10 represents a residue selected from G, L, V, F, Y, C, H, R, and D.
      
      
         å¨å¦ä¸ä¸ªå·ä½å®æ½æ¹æ¡ä¸­ï¼è¿åå«å¨åºå449ä½å°460ä½ALLX1X2X3X4X5X6QFGçè³å°åä¿å®åºåä¸­çæ®åºçè³å°ä¸ä¸ªçªåï¼å¶ä¸­ï¼In another specific embodiment, it further comprises at least one mutation of a residue in at least a semi-conserved region of sequence positions 449 to 460 ALLX1X2X3X4X5X6QFG, wherein
      
      
         X1è¡¨ç¤ºéèªAãIãLãVãPãQãTãKãEçæ®åºï¼X1 represents a residue selected from A, I, L, V, P, Q, T, K, E;
      
      
         X2è¡¨ç¤ºéèªGãLãVãFãYãCãHãRãDçæ®åºï¼X2 represents a residue selected from G, L, V, F, Y, C, H, R, D;
      
      
         X3è¡¨ç¤ºéèªAãIãLãVãPãQãTãKãEçæ®åºï¼X3 represents a residue selected from A, I, L, V, P, Q, T, K, E;
      
      
         X4è¡¨ç¤ºéèªGãLãVãFãYãCãHãRãDçæ®åºï¼X4 represents a residue selected from G, L, V, F, Y, C, H, R, D;
      
      
         X5è¡¨ç¤ºéèªAãIãLãVãPãQãTãKãEçæ®åºï¼X5 represents a residue selected from A, I, L, V, P, Q, T, K, E;
      
      
         X6è¡¨ç¤ºéèªGãLãVãFãYãCãHãRãDçæ®åºãX6 represents a residue selected from G, L, V, F, Y, C, H, R, and D.
      
      
         æ ¹æ®æ¬åæï¼æè¿°åä½åæ¬å¨SEQ ID NO.1åºç¡ä¸å¢å æå é¤é¨åæ°¨åºé¸ï¼ä¾æ§æå©ç¨3âO-ä¿®é¥°çæ ¸è·é¸åææ ¸é¸çåè½çåä½ãä¼éï¼æè¿°åä½çåºåä¸ºSEQ ID NO.2ãAccording to the present invention, the variant includes a variant that adds or deletes some amino acids based on SEQ ID NO.1 and still has the function of synthesizing nucleic acid using 3&#39;O-modified nucleotides. Preferably, the sequence of the variant is SEQ ID NO.2.
      
      
         æ ¹æ®æ¬åæï¼æè¿°TdTçåä½ï¼åæ¬ä¸ä¼å½±åèç½æ´»æ§çååï¼å¦å¨ä¸è¿°åä½æåè½ç­ååºåçNæ«ç«¯å/æCæ«ç«¯å¤åå«æ ç­¾åºåï¼è¯¸å¦MBPæ ç­¾ãHISæ ç­¾ãGSTç­æ ç­¾ãä¼éï¼æè¿°åä½çåºåä¸ºSEQ ID NO.3æSEQ ID NO.4ãAccording to the present invention, the variant of TdT includes changes that do not affect protein activity, such as including a tag sequence at the N-terminus and/or C-terminus of the above variant or functionally equivalent sequence, such as MBP tag, HIS tag, GST tag, etc. Preferably, the sequence of the variant is SEQ ID NO.3 or SEQ ID NO.4.
      
      
         æ ¹æ®æ¬åæï¼TdTçåä½è½å¤æºå¥ä¿®é¥°çæ ¸è·é¸ï¼ä¼éå°æºå¥ä¿®é¥°ç3âO-æ ¸è·é¸ï¼å¹¶ä¸æ´ä¼éå°æºå¥3âO-å°é­çæ ¸è·é¸ãAccording to the present invention, variants of TdT are capable of incorporating modified nucleotides, preferably modified 3&#39;O-nucleotides, and more preferably 3&#39;O-blocked nucleotides.
      
      
         å¨æ¬åæçä¸ä¸æä¸­ï¼è¡¨è¿°âä¿®é¥°çæ ¸è·é¸âæ¯æå«æä¸ä¸ä¸ªç£·é¸åºå¢ç»åçæ ¸è·(å³éæ¥å°è±æ°§æ ¸ç³ææ ¸ç³ç³åå­ä¸çç¢±åº)çåå­ï¼æè¿°æ ¸è·å¨å¶ä¸ä¸ªæ«ç«¯(2âã3âã5âæç¢±åº)ä¸å·æè³å°ä¸ä¸ªå¦å¤çåºå¢ãæè¿°å¦å¤çåºå¢éè¿é»æ­¢ä»»ä½ç£·é¸äºé¯é®(3âO-ä¿®é¥°ã2âæ2âO-ä¿®é¥°)çå½¢æï¼æéè¿ç©ºé´ä¸é»æ­¢èåé¶éæ¥å°å¨å¶3âæ«ç«¯åå«è¿æ ·çä¿®é¥°çæ ¸è·é¸(5âæç¢±åºä¿®é¥°)çä»»ä½æ ¸é¸çæ®µæ¥é»æ­æ ¸è·é¸çè¿ä¸æ­¥æ·»å ãæ­¤å¤ï¼æè¿°å¦å¤çåºå¢æå©å°å·æå¯éæ§è´¨ï¼åè®¸è¯¥åºå¢éè¿ç¹å®çè£è§£ååºè¢«å»é¤ãIn the context of the present invention, the expression &#34;modified nucleotide&#34; refers to a molecule containing a nucleoside (i.e. a base attached to a deoxyribose or ribose sugar molecule) bound to three phosphate groups, which has at least one additional group at one of its ends (2&#39;, 3&#39;, 5&#39; or base). The additional group blocks the further addition of nucleotides by preventing the formation of any phosphodiester bond (3&#39;O-modification, 2&#39; or 2&#39;O-modification), or by sterically preventing the polymerase from attaching to any nucleic acid fragment containing such a modified nucleotide (5&#39; or base modification) at its 3&#39; end. In addition, the additional group advantageously has a reversible property, allowing the group to be removed by a specific cleavage reaction.
      
      
         æ ¹æ®æ¬åæï¼æè¿°åä½åå«éèªè¡¨1ä¸­å¬å¼çåä»£çç»åçè³å°ä¸ç§åä»£çç»åæåè½ç­åæ®åºãAccording to the invention, the variant comprises at least one combination of substitutions selected from the combinations of substitutions disclosed in Table 1 or functionally equivalent residues.
      
      
         æ¬åæçå¦ä¸ä¸ªç®çæ¯æä¾å¤ç§å·æå¬åéå¤©ç¶3â-OHä¿®é¥°çæ ¸è·é¸çæ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶åä½ãæè¿°æ«ç«¯è½¬ç§»é¶åä½æ èªç¶è§£æçæ¶ä½ç»æï¼ä¸ç»´ç»æä¸ºéè¿Alphafold2è¿è¡åæºå»ºæ¨¡è·å¾ãAnother object of the present invention is to provide a variety of terminal deoxynucleotidyl transferase variants that catalyze non-natural 3&#39;-OH modified nucleotides. The terminal transferase variants have no naturally resolved crystal structure, and the three-dimensional structure is obtained by homology modeling using Alphafold2.
      
      
         æ¬åæè¿æä¾ç¼ç å¦ä¸æå®ä¹çTdTçåä½çæ ¸é¸åå­ãThe invention also provides nucleic acid molecules encoding variants of TdT as defined above.
      
      
         æ¬åæè¿æä¾ä¸ç§è¡¨è¾¾è½½ä½ï¼å¶åå«æ¬åææè¿°çæ ¸é¸åå­ãThe present invention also provides an expression vector comprising the nucleic acid molecule of the present invention.
      
      
         æ¬åæè¿æä¾ä¸ç§å®¿ä¸»ç»èï¼å¶ç¹å¾å¨äºï¼æè¿°å®¿ä¸»ç»èåå«æ¬åææè¿°çæ ¸é¸åå­æèæè¿°è¡¨è¾¾è½½ä½ãThe present invention also provides a host cell, characterized in that the host cell contains the nucleic acid molecule or the expression vector described in the present invention.
      
      
         æ¬åæè¿ä¸æ­¥æä¾ç¨äºäº§çTdTçåä½çæ¹æ³ï¼å¶ä¸­ï¼å¦ä¸æå®ä¹çå®¿ä¸»ç»èå¨åè®¸ç¼ç æè¿°åä½çæ ¸é¸è¡¨è¾¾çå¹å»æ¡ä»¶ä¸è¢«å¹å»ï¼å¹¶ä¸å¶ä¸­åä½ä»»éå°è¢«åæ¶ãThe present invention further provides a method for producing a variant of TdT, wherein a host cell as defined above is cultivated under culture conditions allowing expression of a nucleic acid encoding said variant, and wherein the variant is optionally recovered.
      
      
         æ¬åæè¿æ¶åTdTçåä½ç¨äºå¨æ²¡ææ¨¡æ¿çæåµä¸ç¨ä¸ç§ææ´å¤ç§3âO-ä¿®é¥°çæ ¸è·é¸åææ ¸é¸åå­çç¨éãThe present invention also relates to the use of variants of TdT for the synthesis of nucleic acid molecules with one or more 3&#39;O-modified nucleotides in the absence of a template.
      
      
         å¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼è¿æ ·çæ¹æ³åæ¬ä»¥ä¸æ­¥éª¤ï¼(a)æä¾åå«å·ææ¸¸ç¦»3â-ç¾åºçå¯¡æ ¸è·é¸çèµ·å§çæ®µï¼(b)å¨é¶ä¿å»¶ä¼¸æ¡ä»¶ä¸ï¼å¨3â-O-å¯éå°é­çæ ¸è·çå­å¨ä¸ï¼ä½¿æ¬åæçTdTåä½ä¸èµ·å§çæ®µæå»¶ä¼¸çèµ·å§çæ®µååºãIn some embodiments, such a method comprises the following steps: (a) providing a starting fragment comprising an oligonucleotide having a free 3&#39;-hydroxyl group; (b) reacting a TdT variant of the invention with the starting fragment or the extended starting fragment under enzymatic extension conditions in the presence of a 3&#39;-O-reversibly blocked nucleoside.
      
      
         å¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼è¿æ ·çæ¹æ³è¿åæ¬æ­¥éª¤(c)ä½¿å»¶ä¼¸çèµ·å§çæ®µå»å°é­ä»¥å½¢æå·ææ¸¸ç¦»3â-ç¾åºçå»¶ä¼¸çèµ·å§çæ®µï¼å(d)éå¤æ­¥éª¤(b)å(c)ï¼ç´å°åæé¢å®åºåçæ ¸é¸åå­ãIn some embodiments, such a method further comprises the step of (c) deblocking the extended starting fragment to form an extended starting fragment having a free 3&#39;-hydroxyl group, and (d) repeating steps (b) and (c) until a nucleic acid molecule of a predetermined sequence is synthesized.
      
      
         æ¬åæçåä¸ä¸ªç®çæ¯æä¾ä¸ç§ä¸éè¦æ¨¡æ¿çåææ ¸é¸åå­çæ¹æ³ï¼è¯¥æ¹æ³åæ¬ä½¿æ ¸é¸å¼ç©ä¸è³å°ä¸ç§æ ¸è·é¸ï¼ä¼éå°è³å°ä¸ç§3â-O-ä¿®é¥°çæ ¸è·é¸åæ ¹æ®æ¬åæçTdTçåä½æ¥è§¦çæ­¥éª¤ãAnother object of the present invention is to provide a method for synthesizing a nucleic acid molecule without the need for a template, the method comprising the step of contacting a nucleic acid primer with at least one nucleotide, preferably at least one 3&#39;-O-modified nucleotide and a variant of TdT according to the present invention.
      
      
         æ¬åæè¿æä¾äºä¸ç§ç¨äºè¿è¡æ ¸è·é¸æºå¥ååºçè¯åçãé¶ææ ¸è·é¸ç»åç©ï¼å¶ç¹å¾å¨äºï¼åå«æ¬åæçTdTçåä½ãThe present invention also provides a kit, enzyme or nucleotide composition for carrying out a nucleotide incorporation reaction, characterized in that it comprises a variant of the TdT of the present invention.
      
      
         æ ¹æ®æ¬åæï¼æè¿°è¯åçãé¶ææ ¸è·é¸ç»åç©è¿åæ¬ï¼ä¸ç§æå¤ç§æ ¸è·é¸(ä¼éå°ä¸ç§æå¤ç§3âO-ä¿®é¥°çæ ¸è·é¸)ï¼ææ ¸è·åå­ãAccording to the present invention, the kit, enzyme or nucleotide composition further comprises: one or more nucleotides (preferably one or more 3&#39;O-modified nucleotides), or nucleoside molecules.
      
      
         æ ¹æ®æ¬åæï¼æè¿°ä¿®é¥°çæ ¸è·é¸è¢«è§åæ è®°ä»¥åè®¸å¶æ£æµãAccording to the present invention, the modified nucleotides are fluorescently labeled to allow their detection.
      
      
         è¿ä¸æ­¥å°ï¼æ¬åææè¿°è¯åçãé¶ææ ¸è·é¸ç»åç©è¿åæ¬ï¼ä»»éå°è³å°ä¸ç§DNAæ¨¡æ¿åå­ææ ¸é¸å¼ç©ãFurthermore, the kit, enzyme or nucleotide composition of the present invention further comprises: optionally at least one DNA template molecule or nucleic acid primer.
      
      
         ä¼éå°ï¼æè¿°è¿è¡æ ¸è·é¸æºå¥ååºçè¯åçãé¶ææ ¸è·é¸ç»åç©ï¼åå«ï¼1)æ ¹æ®æ¬åææä¾çTdTçåä½ï¼2)ä¸ç§æå¤ç§æ ¸è·é¸(ä¼éå°ä¸ç§æå¤ç§3âO-ä¿®é¥°çæ ¸è·é¸)ï¼3)ä»»éå°è³å°ä¸ç§æ ¸é¸å¼ç©ãPreferably, the kit, enzyme or nucleotide composition for performing a nucleotide incorporation reaction comprises: 1) a variant of TdT provided according to the present invention; 2) one or more nucleotides (preferably one or more 3&#39;O-modified nucleotides); 3) optionally at least one nucleic acid primer.
      
      
         æççææï¼Beneficial effects:
      
      
         1)æ¬åææä¾äºå¤ç§æ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶çªåä½ï¼å¯ä»¥å¨ä¸ä¾èµæ¨¡æ¿çæåµä¸é«æå¯æ§çåææ ¸é¸åå­ï¼å¹¶æè®¶çåç°å¤ç§çªåä½çæçæ¾èé«äºæªæ¹é åçéçåæ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶ã1) The present invention provides a variety of terminal deoxynucleotidyl transferase mutants that can efficiently and controllably synthesize nucleic acid molecules without relying on a template, and surprisingly found that the efficiency of the various mutants is significantly higher than that of the wild-type terminal deoxynucleotidyl transferase before modification.
      
      
         2)æ¬åææä¾çå¤ç§æ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶çªåä½ï¼å¯ä»¥åºç¨äºåé¾DNAçå¯æ§ç²¾ååæã2) The various terminal deoxynucleotidyl transferase mutants provided by the present invention can be applied to the controllable and precise synthesis of single-stranded DNA.
      
    
    
      
         éå¾è¯´æBRIEF DESCRIPTION OF THE DRAWINGS
      
      
         å¾1ä¸ºTdTååä½å¬åååºç¤ºæå¾ãFIG1 is a schematic diagram of the catalytic reaction of TdT and its variants.
      
      
         å¾2ä¸ºé¨åTdTåä½å¬å3ç«¯å¸¦å¯éç»æ­¢ä¿®é¥°åºå¢çç¸å¯¹æ´»æ§ãFIG2 shows the relative catalytic activities of some TdT variants with a reversible termination modification group at the 3&#39; end.
      
      
         å¾3ä¸ºåºç¨TdTåä½å®æ10ä¸ªæ ¸è·é¸åæå¾ªç¯çåæ§PAGEç»æãFIG3 shows the denaturing PAGE results of completing 10 nucleotide synthesis cycles using TdT variants.
      
      
        
           åææè¿°Description of the invention
        
      
      
         DNAèåé¶å®¶ææ ¹æ®å¶åºååæºæ§åæ¶ä½ç»æè¢«åä¸º7ä¸ªå®¶æãå¶ä¸­ï¼PolXå®¶æçèåé¶ä»£è¡¨äºä»å¤å¶èåé¶å°æ«ç«¯è½¬ç§»é¶çå®½èå´çèåé¶ãæ¥èªPolXå®¶æçèåé¶å­å¨äºéå¸¸å®½èå´ççæ ¸çç©ä½ä¸­ãæ¥èªPolXå®¶æçèåé¶åä¸ä¼å¤ç§çç©è¿ç¨ï¼å¹¶ä¸ç¹å«æ¯DNAæä¼¤ä¿®å¤æºå¶æéè¯¯çº æ­£æºå¶ãPolXå®¶æååç»ä¸ºèåé¶Î²(PolÎ²)ãÎ¼(PolÎ¼)ãÎ»(PolÎ»)ãæ¥èªéµæ¯çIV(Pol IV)åæ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶(TdT)ãTdTå¤©ç¶åä¸DNAä¿®å¤åç»´ææºå¶ãç¹å«å°ï¼å³ä½¿å¨ä¸å­å¨æ¨¡æ¿é¾çæåµä¸ï¼TdTä¹å·æä¿å­æ ¸è·é¸èåæ´»æ§çç¬ç¹è½åãå¨ç¹å®æ¡ä»¶ä¸å¹¶ä¸ä½¿ç¨å¤©ç¶æ ¸è·é¸ï¼å¨ä¸å­å¨ä»»ä½äºè¡¥é¾çæåµä¸ï¼TdTè½å¤ä½¿DNAçæ®µå»¶ä¼¸å ç¾ä¸ªæ ¸è·é¸ãç¶èï¼éçåTdTå®å¨ä¸è½æææºå¥ç³ä¿®é¥°çæ ¸è·é¸ãThe DNA polymerase family is divided into 7 families according to its sequence homology and crystal structure. Among them, the polymerase of the PolX family represents a wide range of polymerases from replication polymerases to terminal transferases. Polymerases from the PolX family are present in a very wide range of eukaryotic organisms. Polymerases from the PolX family participate in many biological processes, and in particular DNA damage repair mechanisms or error correction mechanisms. The PolX family is further grouped into polymerase Î² (PolÎ²), Î¼ (PolÎ¼), Î» (PolÎ»), IV (Pol IV) from yeast, and terminal deoxynucleotidyl transferase (TdT). TdT naturally participates in DNA repair and maintenance mechanisms. In particular, TdT has the unique ability to preserve nucleotide polymerization activity even in the absence of a template chain. Under specific conditions and using natural nucleotides, in the absence of any complementary chain, TdT can extend DNA fragments by hundreds of nucleotides. However, wild-type TdT cannot effectively incorporate sugar-modified nucleotides at all.
      
      
         å æ­¤ï¼æ¬åæçç®çæ¯æä¾å·æè¢«é¶åççªåçTdTçåä½ï¼è¯¥è¢«é¶åççªååè®¸TdTçåä½å¨æ ¸è·é¸çæ®µçåææé´å°ä¿®é¥°çæ ¸è·é¸æºå¥å°æè¿°æ ¸é¸çæ®µä¸­ãæ´ç¹å«å°ï¼æ¬åæäººå·²é´å®äºå¯ä»¥åç¬æç»åå°è¢«æå©å°åä»£çç¹å®çæ°¨åºé¸æ®åºï¼ä»¥æé«é¶åæä¸åé¿åº¦ä¸å·æé¢å®åºåçæ ¸é¸çæ®µçè½åï¼åæ¬éè¿ä½¿ç¨ä¿®é¥°çæ ¸è·é¸åæä¸åé¿åº¦ä¸å·æé¢å®åºåçæ ¸é¸çæ®µçè½åãTherefore, it is an object of the present invention to provide variants of TdT having targeted mutations that allow the variants of TdT to incorporate modified nucleotides into nucleic acid fragments during the synthesis of the nucleotide fragments. More particularly, the inventors have identified specific amino acid residues that can be advantageously substituted, alone or in combination, to improve the ability of the enzyme to synthesize nucleic acid fragments of varying lengths and having a predetermined sequence, including the ability to synthesize nucleic acid fragments of varying lengths and having a predetermined sequence by using modified nucleotides.
      
      
        
           å®ä¹definition
        
      
      
         å¦å¶ä¸­ä½¿ç¨çï¼æ¯è¯­âçªåä½âåâåä½âå¯ä»¥äºæ¢ä½¿ç¨ï¼ä»¥ææ¥æºäºSEQ ID NO.1å¹¶ä¸å¨ä¸ä¸ªææ´å¤ä¸ª(ä¾å¦å ä¸ª)ä½ç½®å¤åå«ä¿®é¥°ææ¹åï¼å³åä»£ãæå¥å/æç¼ºå¤±å¹¶ä¸æ¢å·æå¨æ²¡ææ¨¡æ¿çæåµä¸çèåé¶æ´»æ§åå·ææºå¥ä¸ä¸ªææ´å¤ä¸ªä¿®é¥°çç»æ­¢åæ ¸è·é¸çè½åçå¤è½ãåä½å¯ä»¥éè¿æ¬é¢åçç¥çå¤ç§ææ¯è·å¾ãç¹å«å°ï¼ç¨äºæ¹åç¼ç éçåèç½çDNAåºåçææ¯çå®ä¾åæ¬ä½ä¸éäºå®ç¹è¯±åãéæºè¯±åååæå¯¡æ ¸è·é¸æå»ºãè¯±åæ´»æ§åæ¬å¯¹èç½æèå¨æ¬åæçæåµä¸å¯¹èåé¶çåºåä¸­çä¸ä¸ªæå ä¸ªæ°¨åºé¸çç¼ºå¤±ãæå¥æåä»£ãè¢«é¶åçæ°¨åºé¸å¯ä»¥ä¼´éæåå¸å¨èåé¶çæ´ä¸ªåºåä¸ãä¾å¦ï¼ç¹å®çåºåºæç»æç¹å¾å¯ä»¥è¢«é¶åãAs used therein, the terms &#34;mutant&#34; and &#34;variant&#34; can be used interchangeably to refer to a polypeptide derived from SEQ ID NO.1 and comprising a modification or change, i.e., a substitution, insertion and/or deletion, at one or more (e.g., several) positions and having both polymerase activity in the absence of a template and the ability to incorporate one or more modified terminator nucleotides. Variants can be obtained by a variety of techniques well known in the art. In particular, examples of techniques for altering the DNA sequence encoding the wild-type protein include, but are not limited to, site-directed mutagenesis, random mutagenesis, and synthetic oligonucleotide construction. Mutagenic activity includes deletions, insertions, or substitutions of one or more amino acids in the sequence of a protein or, in the case of the present invention, a polymerase. Targeted amino acids can be accompanied by or distributed over the entire sequence of the polymerase. For example, specific motifs or structural features can be targeted.
      
      
         å¦æ¬æå³äºæ°¨åºé¸çä½ç½®ä½¿ç¨çæ¯è¯­âä¿®é¥°âæâæ¹åâææï¼ç¹å®ä½ç½®ä¸­çæ°¨åºé¸ä¸éçåèç½çæ°¨åºé¸ç¸æ¯è¢«ä¿®é¥°ãThe term &#34;modification&#34; or &#34;alteration&#34; as used herein with respect to the position of an amino acid means that the amino acid in the specific position is modified compared to the amino acid of the wild-type protein.
      
      
         âåä»£âææä¸ä¸ªæ°¨åºé¸æ®åºè¢«å¦ä¸ä¸ªæ°¨åºé¸æ®åºæ¿ä»£ãä¼éå°ï¼æ¯è¯­âåä»£âæ¯æä¸ä¸ªæ°¨åºé¸æ®åºè¢«éèªä»¥ä¸çå¦ä¸ä¸ªæ°¨åºé¸æ®åºæ¿ä»£ï¼20ç§æ åçå¤©ç¶å­å¨çæ°¨åºé¸æ®åºãç½è§çå¤©ç¶å­å¨çæ°¨åºé¸æ®åº(ä¾å¦ï¼ç¾è¯æ°¨é¸ãç¾èµæ°¨é¸ãå«ç¾åºèµæ°¨é¸ã6-N-ç²åºèµæ°¨é¸ãN-ä¹åºçæ°¨é¸ãN-ç²åºçæ°¨é¸ãN-ä¹åºå¤©å¬é°èºãå«-å¼äº®æ°¨é¸ãN-ç²åºå¼äº®æ°¨é¸ãN-ç²åºç¼¬æ°¨é¸ãç¦è°·æ°¨é°èºãæ°¨åºä¸é¸ãé¸æ°¨é¸ãæ­£äº®æ°¨é¸ãæ­£ç¼¬æ°¨é¸)åéå¸¸ç»åæäº§ççéå¤©ç¶å­å¨çæ°¨åºé¸æ®åº(ä¾å¦ï¼ç¯å·±åºä¸æ°¨é¸)ãä¼éå°ï¼æ¯è¯­âåä»£âæ¯æä¸ä¸ªæ°¨åºé¸æ®åºè¢«éèª20ç§æ åçå¤©ç¶å­å¨çæ°¨åºé¸æ®åºçå¦ä¸ä¸ªæ°¨åºé¸æ®åºæ¿ä»£ãç¬¦å·â+âæç¤ºåä»£çç»åã&#34;Substitution&#34; means that one amino acid residue is replaced by another amino acid residue. Preferably, the term &#34;substitution&#34; refers to the replacement of one amino acid residue by another amino acid residue selected from the 20 standard naturally occurring amino acid residues, rare naturally occurring amino acid residues (e.g., hydroxyproline, hydroxylysine, allohydroxylysine, 6-N-methyllysine, N-ethylglycine, N-methylglycine, N-ethylasparagine, allo-isoleucine, N-methylisoleucine, N-methylvaline, pyroglutamine, aminobutyric acid, ornithine, norleucine, norvaline) and non-naturally occurring amino acid residues that are usually produced synthetically (e.g., cyclohexylalanine). Preferably, the term &#34;substitution&#34; refers to the replacement of one amino acid residue by another amino acid residue selected from the 20 standard naturally occurring amino acid residues. The symbol &#34;+&#34; indicates a combination of substitutions.
      
      
         å¨æ¬æä¸­ï¼æ°¨åºé¸ç±æ ¹æ®ä»¥ä¸å½åæ³çå¶åå­æ¯æä¸å­æ¯ä»£ç ä»£è¡¨ï¼Aï¼ä¸æ°¨é¸(Ala)ï¼Cï¼åè±æ°¨é¸(Cys)ï¼Dï¼å¤©å¬æ°¨é¸(Asp)ï¼Eï¼è°·æ°¨é¸(Glu)ï¼Fï¼è¯ä¸æ°¨é¸(Phe)ï¼Gï¼çæ°¨é¸(Gly)ï¼Hï¼ç»æ°¨é¸(His)ï¼Iï¼å¼äº®æ°¨é¸(Ile)ï¼Kï¼èµæ°¨é¸(Lys)ï¼Lï¼äº®æ°¨é¸(Leu)ï¼Mï¼ç²ç¡«æ°¨é¸(Met)ï¼Nï¼å¤©å¬é°èº(Asn)ï¼Pï¼è¯æ°¨é¸(Pro)ï¼Qï¼è°·æ°¨é°èº(Gln)ï¼Rï¼ç²¾æ°¨é¸(Arg)ï¼Sï¼ä¸æ°¨é¸(Ser)ï¼Tï¼èæ°¨é¸(Thr)ï¼Vï¼ç¼¬æ°¨é¸(Val)ï¼Wï¼è²æ°¨é¸(Trp)åYï¼éªæ°¨é¸(Tyr)ãIn this document, amino acids are represented by their single-letter or three-letter codes according to the following nomenclature: A: alanine (Ala); C: cysteine (Cys); D: aspartic acid (Asp); E: glutamic acid (Glu); F: phenylalanine (Phe); G: glycine (Gly); H: histidine (His); I: isoleucine (Ile); K: lysine (Lys); L: leucine (Leu); M: methionine (Met); N: asparagine (Asn); P: proline (Pro); Q: glutamine (Gln); R: arginine (Arg); S: serine (Ser); T: threonine (Thr); V: valine (Val); W: tryptophan (Trp) and Y: tyrosine (Tyr).
      
      
         å¨æ¬æä»¶ä¸­ï¼ä½¿ç¨ä»¥ä¸æ¯è¯­æç¤ºåä»£ï¼L238Aè¡¨ç¤ºäº²æ¬åºåçä½ç½®238å¤çæ°¨åºé¸æ®åº(äº®æ°¨é¸ï¼L)è¢«æ¹åä¸ºä¸æ°¨é¸(A)ãA132V/I/Mè¡¨ç¤ºäº²æ¬åºåçä½ç½®132å¤çæ°¨åºé¸æ®åº(ä¸æ°¨é¸ï¼A)è¢«ä»¥ä¸æ°¨åºé¸ä¹ä¸åä»£ï¼ç¼¬æ°¨é¸(V)ãå¼äº®æ°¨é¸(I)æç²ç¡«æ°¨é¸(M)ãåä»£å¯ä»¥æ¯ä¿å®åä»£æéä¿å®åä»£ãä¿å®åä»£çå®ä¾å¨ç¢±æ§æ°¨åºé¸(ç²¾æ°¨é¸ãèµæ°¨é¸åç»æ°¨é¸)ãé¸æ§æ°¨åºé¸(è°·æ°¨é¸åå¤©å¬æ°¨é¸)ãææ§æ°¨åºé¸(è°·æ°¨é°èºãå¤©å¬é°èºåèæ°¨é¸)ãçæ°´æ§æ°¨åºé¸(ç²ç¡«æ°¨é¸ãäº®æ°¨é¸ãå¼äº®æ°¨é¸ãåè±æ°¨é¸åç¼¬æ°¨é¸)ãè³é¦ææ°¨åºé¸(è¯ä¸æ°¨é¸ãè²æ°¨é¸åéªæ°¨é¸)åå°æ°¨åºé¸(çæ°¨é¸ãä¸æ°¨é¸ãåä¸æ°¨é¸)çç»åãIn this document, the following terms are used to indicate substitutions: L238A means that the amino acid residue (leucine, L) at position 238 of the parent sequence is changed to alanine (A). A132V/I/M means that the amino acid residue (alanine, A) at position 132 of the parent sequence is replaced by one of the following amino acids: valine (V), isoleucine (I) or methionine (M). Substitutions can be conservative substitutions or non-conservative substitutions. Examples of conservative substitutions are in the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine, asparagine and threonine), hydrophobic amino acids (methionine, leucine, isoleucine, cysteine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine) and small amino acids (glycine, alanine and serine).
      
      
         å¦æ¬æä½¿ç¨çï¼æ¯è¯­âåºååä¸æ§âæâåä¸æ§âæ¯æä¸¤ä¸ªå¤è½åºåä¹é´å¹é(ç¸åæ°¨åºé¸æ®åº)çæ°ç®(æä»¥ç¾åæ¯ï¼è¡¨ç¤ºçåæ°)ãåºååä¸æ§éè¿å¨å¯¹é½ä»¥ä¾¿ä½¿éå ååä¸æ§æå¤§ååæ¶ä½¿åºåç©ºä½æå°åæ¶æ¯è¾åºåæ¥ç¡®å®ãç¹å«å°ï¼åºååä¸æ§å¯ä»¥æ ¹æ®ä¸¤ä¸ªåºåçé¿åº¦ä½¿ç¨å¤ç§æ°å­¦å¨å±æå±é¨æ¯å¯¹ç®æ³ä¸­çä»»ä½ä¸ç§æ¥ç¡®å®ãç¸ä¼¼é¿åº¦çåºåä¼éå°ä½¿ç¨å¨å±æ¯å¯¹ç®æ³(ä¾å¦ï¼NeedlemanåWunschç®æ³ï¼NeedlemanåWunsch,1970)è¿è¡æ¯å¯¹ï¼è¯¥å¨å±æ¯å¯¹ç®æ³å¨æ´ä¸ªé¿åº¦ä¸æä½³å°å¯¹é½åºåï¼èå®è´¨ä¸ä¸åé¿åº¦çåºåä¼éå°ä½¿ç¨å±é¨æ¯å¯¹ç®æ³(ä¾å¦ï¼SmithåWatermanç®æ³(SmithåWatermanï¼1981)æAltschulç®æ³(Altschulç­äººï¼1997ï¼Altschulç­äººï¼2005å¹´)è¿è¡æ¯å¯¹ãåºäºç¡®å®æ°¨åºé¸åºååä¸æ§ç¾åæ¯çç®ççæ¯å¯¹å¯ä»¥ä»¥æ¬é¢åææ¯èå´åçå¤ç§æ¹å¼å®ç°ï¼ä¾å¦ï¼ä½¿ç¨äºèç½ç½ç«è¯¸å¦http://blast.ncbi.nlm.nih.gov/æhttp://www.ebi.ac.uk/Tools/emboss/ä¸å¯å¾çå¬ä¼å¯å¾çè®¡ç®æºè½¯ä»¶ãæ¬é¢åææ¯äººåå¯ä»¥ç¡®å®ç¨äºæµéæ¯å¯¹çéå½åæ°ï¼åæ¬å¨ææ¯è¾çåºåçå¨é¿ä¸å®ç°æå¤§æ¯å¯¹æéçä»»ä½ç®æ³ãåºäºæ¬æçç®çï¼æ°¨åºé¸åºååä¸æ§ï¼å¼æ¯æä½¿ç¨æå¯¹åºåæ¯å¯¹ç¨åºEMBOSS Needleçæçå¼ï¼è¯¥ç¨åºä½¿ç¨Needleman-Wunschç®æ³åå»ºä¸¤ä¸ªåºåçæä½³å¨å±æ¯å¯¹ï¼å¶ä¸­æææç´¢åæ°è¢«è®¾ç½®ä¸ºé»è®¤å¼ï¼å³è¯åç©éµï¼BLOSUM62ï¼ç©ºä½å¼æ¾ï¼10ï¼ç©ºä½å»¶ä¼¸ï¼0.5ï¼æ«ç«¯ç©ºä½ç½åï¼åï¼æ«ç«¯ç©ºä½å¼æ¾ï¼10ï¼ä¸æ«ç«¯ç©ºä½å»¶ä¼¸ï¼0.5ãAs used herein, the term &#34;sequence identity&#34; or &#34;identity&#34; refers to the number (or fraction expressed as a percentage %) of matches (identical amino acid residues) between two polypeptide sequences. Sequence identity is determined by comparing the sequences while aligning them so as to maximize overlap and identity while minimizing sequence gaps. In particular, sequence identity can be determined using any of a variety of mathematical global or local alignment algorithms depending on the length of the two sequences. Sequences of similar length are preferably aligned using a global alignment algorithm (e.g., the Needleman and Wunsch algorithm; Needleman and Wunsch, 1970), which optimally aligns sequences over their entire length, while sequences of substantially different lengths are preferably aligned using a local alignment algorithm (e.g., the Smith and Waterman algorithm (Smith and Waterman, 1981) or the Altschul algorithm (Altschul et al., 1997; Altschul et al., 2005). Alignment for the purpose of determining percent amino acid sequence identity can be achieved in a variety of ways that are within the skill in the art, for example, using publicly available computer software available on Internet websites such as http://blast.ncbi.nlm.nih.gov/ or http://www.ebi.ac.uk/Tools/emboss/. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, % amino acid sequence identity values refer to the alignment of sequences using the pairwise sequence alignment program EMBOSS The values generated by Needle, which uses the Needleman-Wunsch algorithm to create an optimal global alignment of two sequences, where all search parameters are set to the default values, i.e., scoring matrix=BLOSUM62, gap opening=10, gap extension=0.5, terminal gap penalty=false, terminal gap opening=10, and terminal gap extension=0.5.
      
      
         æ¬æä¸­ï¼æ¯è¯­âè½âãâå¤è½âãâèç½âãâé¶âæ¯æéè¿è½é®è¿æ¥çæ°¨åºé¸é¾ï¼èä¸å½¢ææè¿°é¾çæ°¨åºé¸çæ°ç®æ å³ãAs used herein, the terms &#34;peptide&#34;, &#34;polypeptide&#34;, &#34;protein&#34; and &#34;enzyme&#34; refer to a chain of amino acids linked by peptide bonds, regardless of the number of amino acids forming the chain.
      
      
         é¤éå¦æè¯´æï¼æ¬ç³è¯·ä¸­å¬å¼çä½ç½®åèSEQ ID NO.1ä¸­ååºçæ°¨åºé¸åºåç¼å·ãUnless otherwise indicated, positions disclosed in this application refer to the amino acid sequence numbering listed in SEQ ID NO.1.
      
      
        
           TdTçåä½Variants of TdT
        
      
      
         æ¬åææä¾äºTdTé¶çåä½ï¼å¶å¯ç¨äºå¨ä¸ä½¿ç¨æ¨¡æ¿é¾çæåµä¸åæé¢å®åºåçå¤æ ¸è·é¸ï¼è¯¸å¦DNAæRNAãæ¬åæçTdTåä½åè®¸å¨é¶ä»å¯¼çå¤æ ¸è·é¸åææ¹æ³ä¸­ä½¿ç¨ä¿®é¥°çæ ¸è·é¸ï¼å¹¶ä¸ç¹å«æ¯ä½¿ç¨3âO-ä¿®é¥°çæ ¸è·é¸ãThe present invention provides variants of TdT enzymes, which can be used to synthesize polynucleotides of predetermined sequence, such as DNA or RNA, without using a template strand. The TdT variants of the present invention allow the use of modified nucleotides, and in particular the use of 3&#39;O-modified nucleotides, in enzyme-mediated polynucleotide synthesis methods.
      
      
         å¨æ¬åæçä¸ä¸æä¸­ï¼âä¿®é¥°çæ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶âãâä¿®é¥°çTdTâãâæ«ç«¯è±æ°§æ ¸è·é¸è½¬ç§»é¶çåä½âåâTdTçåä½âæ¯æä¸TdTçæ°¨åºé¸åºåå±æè³å°25ï¼çåä¸æ§ãä¼éå°ï¼TdTçåä½ä¸SEQ ID NO.1å±æè³å°40ï¼çåä¸æ§ãIn the context of the present invention, &#34;modified terminal deoxynucleotidyl transferase&#34;, &#34;modified TdT&#34;, &#34;variant of terminal deoxynucleotidyl transferase&#34; and &#34;variant of TdT&#34; refer to an amino acid sequence that shares at least 25% identity with TdT. Preferably, the variant of TdT shares at least 40% identity with SEQ ID NO.1.
      
      
         å·²ç¥TdTç±ä»Næ«ç«¯è³Cæ«ç«¯çä¸åç»æåææï¼åå«å¯¹åºäºæ ¸å®ä½ç»æå(NLS)ãBRCTæ ·ç»æååå¬åç»æå(C-TdT)ãIt is known that TdT is composed of different domains from the N-terminus to the C-terminus, which correspond to the nuclear localization domain (NLS), the BRCT-like domain and the catalytic domain (C-TdT), respectively.
      
      
         æ¬åæçåä½æ ¹æ®å¶å¨ç¹å®æ®åºä¸ççªåæ¥æè¿°ï¼å¶ä½ç½®éè¿ä¸é¶åºåSEQ IDNO.1æ¯å¯¹æåèé¶åºåSEQ ID NO.1æ¥ç¡®å®ãç¶èï¼å¨æ¬åæçä¸ä¸æä¸­ï¼å·æä¸SEQ IDNO.1åè½ç­ååºåçä»»ä½åä½ä¹æ¯æ¬åæçä¸é¨åãä»¥ç¸åæ¹å¼ï¼å¨åè½ç­åæ®åºä¸æºå¸¦ç¸åçªåçä»»ä½åä½ä¹æ¯æ¬åæçä¸é¨åãThe variants of the present invention are described according to their mutations at specific residues, the positions of which are determined by comparison with or reference to the enzyme sequence SEQ ID NO.1. However, in the context of the present invention, any variant having a functionally equivalent sequence to SEQ ID NO.1 is also part of the present invention. In the same way, any variant carrying the same mutation at a functionally equivalent residue is also part of the present invention.
      
      
         å¨æ¬åæçä¸ä¸æä¸­ï¼âåè½ç­ååºåâæ¯æä¸SEQ ID NO.1åæºçTdTçåºåãâåè½ç­åæ®åºâææå¨ä¸SEQ ID NO.1åºååæºçTdTçåºåä¸­çå¹¶ä¸å·æç¸ååè½ä½ç¨çæ®åºãåè½ç­åæ®åºä½¿ç¨åºåæ¯å¯¹ï¼ä¾å¦ä½¿ç¨Mutalinå¨çº¿æ¯å¯¹è½¯ä»¶(http://multalin.toulouse.inra.fr/multalin/multalin.htmlï¼1988,Nucl.Acids Res.,16(22),10881â10890)æ¥é´å®ãæ¯å¯¹åï¼åè½ç­åæ®åºå¤äºæèèçä¸ååºåä¸çåæºä½ç½®å¤ãåºåæ¯å¯¹ååè½ç­åæ®åºçé´å®å¯ä»¥å¨ä»»ä½TdTä¸å¶å¤©ç¶åä½ï¼åæ¬ç§é´åä½ä¹é´è¿è¡ãIn the context of the present invention, &#34;functionally equivalent sequence&#34; refers to a sequence of TdT homologous to SEQ ID NO.1. &#34;Functionally equivalent residues&#34; means residues in a sequence of TdT homologous to SEQ ID NO.1 and having the same functional role. Functionally equivalent residues are identified using sequence alignment, for example using Mutalin online alignment software (http://multalin.toulouse.inra.fr/multalin/multalin.html; 1988, Nucl. Acids Res., 16 (22), 10881-10890). After alignment, the functionally equivalent residues are at homologous positions on the different sequences under consideration. Sequence alignment and identification of functionally equivalent residues can be performed between any TdT and its natural variants, including interspecies variants.
      
      
         TdTå¯ä»¥åç°äºè®¸å¤å¶ä»çç©ä½æå¾®çç©ä¸­ãææè¿äºTdTé½æ¯ç¨äºè¿è¡æ¬åæçè¯å¥½åéèãç¹å«å°ï¼æ¹åç¹å®TdTåºåä»¥èµäºæè¿°èåé¶å¢å çæºå¥ä¿®é¥°çæ ¸è·é¸çè½åçä¿®é¥°ï¼å¯ä»¥é¶åä»»ä½å¶ä»TdTåºåãå æ­¤ï¼æ¬æåèSEQ ID NO.1ï¼å¹¶ä¸æ´ç¹å«å°ï¼åèå¯¹åºäºSEQ ID N0.1çæ°¨åºé¸æ®åº330è³343ã449è³460ççªåæç»åï¼å¯ä»¥è½¬åº§è³ä»»ä½å¶ä»çTdTåºåãTdT can be found in many other organisms or microorganisms. All of these TdTs are good candidates for carrying out the present invention. In particular, modifications that change a specific TdT sequence to confer an increased ability of the polymerase to incorporate modified nucleotides can target any other TdT sequence. Therefore, this article is with reference to SEQ ID NO.1, and more particularly, with reference to mutations or combinations corresponding to amino acid residues 330 to 343, 449 to 460 of SEQ ID NO.1, which can be transposed to any other TdT sequence.
      
      
         æ¬åææ´ç¹å«å°æä¾äºå¦è¡¨1ä¸­ååºçè³å°ä¸ä¸ªåä»£æåä»£çç»åçTdTçåä½ãæ¬åæçåä½è³å°åå«å·¦æ ä¸­ååºçä¸ç§°ä¸ºâå¯åçªåâçæ°¨åºé¸åä»£æåè½ç­åæ®åºï¼ä»¥åä»»éå°å³æ ä¸­ååºçä¸ç§°ä¸ºâä»»éçæå®çªåâçä¸ç§æä¸¤ç§åä»£çç»åæåè½ç­ååºåãThe present invention more particularly provides variants of TdT with at least one substitution or combination of substitutions as listed in Table 1. The variants of the present invention comprise at least the amino acid substitutions or functionally equivalent residues listed in the left column and referred to as &#34;variable mutations&#34;, and optionally one or two substitution combinations or functionally equivalent sequences listed in the right column and referred to as &#34;optional constant mutations&#34;.
      
      
         æ ¹æ®æ¬åæï¼TdTçåä½å·æä»¥ä¸æè¿°çåä»£æåä»£çç»åï¼å¹¶ä¸ä¸SEQ ID NO.1æåè½ç­ååºåå·æè³å°80ï¼çåä¸æ§ï¼ä¼éå°ä¸SEQ ID NO.1æåè½ç­ååºåå·æè³å°85ï¼ã90ï¼ã95ï¼ã96ï¼ã97ï¼ã98ï¼æ99ï¼çåä¸æ§ãAccording to the present invention, the variant of TdT has the substitutions or combinations of substitutions described above and has at least 80% identity with SEQ ID NO.1 or a functionally equivalent sequence, preferably at least 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO.1 or a functionally equivalent sequence.
      
      
         æ ¹æ®æ¬åæï¼å¦ä»¥ä¸å¬å¼çTdTçææåä½é½è½å¤æ¢å¨æ²¡ææ¨¡æ¿çæåµä¸åææ ¸é¸çæ®µåè½å¤å°ä¿®é¥°çæ ¸è·é¸æºå¥å°æ ¸é¸çæ®µä¸­ãæå©å°ï¼æè¿°åä½ä¸SEQ ID NO.1çTdTç¸æ¯å·æå¢å çå°ä¿®é¥°çæ ¸è·é¸ï¼ä¼éå°3âO-ä¿®é¥°çæ ¸è·é¸æºå¥å°æ ¸é¸çæ®µä¸­çè½åãAccording to the present invention, all variants of TdT as disclosed above are capable of both synthesizing nucleic acid fragments in the absence of a template and incorporating modified nucleotides into nucleic acid fragments. Advantageously, the variants have an increased ability to incorporate modified nucleotides, preferably 3&#39;O-modified nucleotides, into nucleic acid fragments compared to the TdT of SEQ ID NO.1.
      
      
         å¨ä»¥ä¸æè¿°çä¸äºå®æ½æ¹æ¡ä¸­ï¼åä½TdTå¨æºå¥3âO-ä¿®é¥°çæ ¸è·ä¸ç£·é¸æ¹é¢çæçæ¯åºåSEQ ID NO.1çéçåTdTçæççè³å°110ï¼ï¼å¨å¶ä»å®æ½æ¹æ¡ä¸­ï¼åä½TdTå¨æºå¥3âO-ä¿®é¥°çæ ¸è·ä¸ç£·é¸æ¹é¢çæçæ¯åºåSEQ ID NO.1çéçåTdTçæççè³å°150ï¼ï¼å¨å¶ä»å®æ½æ¹æ¡ä¸­ï¼åä½TdTå¨æºå¥3âO-ä¿®é¥°çæ ¸è·ä¸ç£·é¸æ¹é¢çæçæ¯åºåSEQIDNO.1çéçåTdTçæççè³å°200ï¼ãIn some embodiments described above, the efficiency of the variant TdT incorporating 3âO-modified nucleoside triphosphates is at least 110% of the efficiency of the wild-type TdT of sequence SEQ ID NO.1; in other embodiments, the efficiency of the variant TdT incorporating 3âO-modified nucleoside triphosphates is at least 150% of the efficiency of the wild-type TdT of sequence SEQ ID NO.1; in other embodiments, the efficiency of the variant TdT incorporating 3âO-modified nucleoside triphosphates is at least 200% of the efficiency of the wild-type TdT of sequence SEQIDNO.1.
      
      
        
           å¦å¤çä¿®é¥°Additional Modifications
        
      
      
         å¨å®æ½æ¹æ¡ä¸­ï¼TdTçåä½è¿åæ¬å¨å¶Næ«ç«¯ãCæ«ç«¯æä¸¤ä¸ªæ«ç«¯ä¸­çä»»ä½ç±»åçæ ç­¾è½(tagging peptide)ï¼è¯¸å¦His-æ ç­¾åºåãæè¿°æ ç­¾è½å¯ä»¥ç¨äºçº¯åãé´å®ãå¢å è¡¨è¾¾ãåæ³æ§(secretability)æå¢å å¬åæ´»æ§ãå°çè§£ï¼è¿æ ·çä¸åçæ ç­¾å¨æç®ä¸­è¢«å¹¿æ³æè¿°ï¼å¹¶ä¸å æ­¤æ¬åææ¶µçäºææ¯äººåå·²ç¥çæææ ç­¾ãIn an embodiment, the variant of TdT further comprises any type of tagging peptide, such as a His-tag sequence, in its N-terminus, C-terminus or both ends. The tag peptide can be used for purification, identification, increased expression, secretability or increased catalytic activity. It will be understood that such different tags are widely described in the literature, and therefore the present invention encompasses all tags known to the skilled person.
      
      
         æ¬åæçåä½è¿å¯ä»¥å¨èç½çNæ«ç«¯åºåå/æCæ«ç«¯åºååå«ä¸ä¸ªææ´å¤ä¸ªå¤æºæå¼æºç¹å¾ï¼ç¨äºä¾å¦éç»èåé¶ççº¯åãThe variants of the invention may also comprise one or more foreign or heterologous features in the N-terminal region and/or C-terminal region of the protein, useful, for example, in the purification of the recombinant polymerase.
      
      
         æ¬åæçåä½è¿å¯ä»¥åå«ä½ç½®330è³343ã449è³460ä¹é´çæ®åºæåè½ç­åæ®åº(å¶ä¸­ä½ç½®éè¿åèSEQ ID NO.1ä¸­ååºçæ°¨åºé¸åºåç¼å·)çåä»£ãå¨å¦ä¸ç§ç¹å®å®æ½æ¹æ¡ä¸­ï¼TdTçåä½è³å°åå«æ°¨åºé¸åºåSEQ ID NO.1æåè½ç­ååºåçåä»£ãThe variants of the present invention may also comprise substitutions of residues between positions 330 to 343, 449 to 460 or functionally equivalent residues (wherein the positions are numbered by reference to the amino acid sequence listed in SEQ ID NO. 1). In another specific embodiment, the variant of TdT comprises at least substitutions of the amino acid sequence SEQ ID NO. 1 or a functionally equivalent sequence.
      
      
        
           ä¿®é¥°çæ ¸è·é¸Modified nucleotides
        
      
      
         æ ¹æ®æ¬åæï¼TdTçåä½è½å¤æºå¥ä¿®é¥°çæ ¸è·é¸ï¼ä¼éå°æºå¥ä¿®é¥°ç3âO-æ ¸è·é¸ï¼å¹¶ä¸æ´ä¼éå°æºå¥3âO-å°é­çæ ¸è·é¸ãAccording to the present invention, variants of TdT are capable of incorporating modified nucleotides, preferably modified 3&#39;O-nucleotides, and more preferably 3&#39;O-blocked nucleotides.
      
      
         å¨æ¬åæçä¸ä¸æä¸­ï¼è¡¨è¿°âä¿®é¥°çæ ¸è·é¸âæ¯æå«æä¸ä¸ä¸ªç£·é¸åºå¢ç»åçæ ¸è·(å³éæ¥å°è±æ°§æ ¸ç³ææ ¸ç³ç³åå­ä¸çç¢±åº)çåå­ï¼æè¿°æ ¸è·å¨å¶ä¸ä¸ªæ«ç«¯(2âã3âã5âæç¢±åº)ä¸å·æè³å°ä¸ä¸ªå¦å¤çåºå¢ãæè¿°å¦å¤çåºå¢éè¿é»æ­¢ä»»ä½ç£·é¸äºé¯é®(3âO-ä¿®é¥°ã2âæ2âO-ä¿®é¥°)çå½¢æï¼æéè¿ç©ºé´ä¸é»æ­¢èåé¶éæ¥å°å¨å¶3âæ«ç«¯åå«è¿æ ·çä¿®é¥°çæ ¸è·é¸(5âæç¢±åºä¿®é¥°)çä»»ä½æ ¸é¸çæ®µæ¥é»æ­æ ¸è·é¸çè¿ä¸æ­¥æ·»å ãæ­¤å¤ï¼æè¿°å¦å¤çåºå¢æå©å°å·æå¯éæ§è´¨ï¼åè®¸è¯¥åºå¢éè¿ç¹å®çè£è§£ååºè¢«å»é¤ãIn the context of the present invention, the expression &#34;modified nucleotide&#34; refers to a molecule containing a nucleoside (i.e. a base attached to a deoxyribose or ribose sugar molecule) bound to three phosphate groups, which has at least one additional group at one of its ends (2&#39;, 3&#39;, 5&#39; or base). The additional group blocks the further addition of nucleotides by preventing the formation of any phosphodiester bond (3&#39;O-modification, 2&#39; or 2&#39;O-modification), or by sterically preventing the polymerase from attaching to any nucleic acid fragment containing such a modified nucleotide (5&#39; or base modification) at its 3&#39; end. In addition, the additional group advantageously has a reversible property, allowing the group to be removed by a specific cleavage reaction.
      
      
         æ ¸è·é¸ææ ¸è·ä¸ç£·é¸åæ¬è±æ°§èºè·ä¸ç£·é¸(dTAP)ãè±æ°§é¸è·ä¸ç£·é¸(dGTP)ãè±æ°§èè·ä¸ç£·é¸(dCTP)æè±æ°§è¸è·ä¸ç£·é¸(dTTP)ï¼ä½ä¸ºå«æè±æ°§æ ¸ç³çæ ¸è·é¸çå®ä¾ãèºè·ä¸ç£·é¸(ATP)ãé¸è·ä¸ç£·é¸(GTP)ãèè·ä¸ç£·é¸(CTP)æå°¿è·ä¸ç£·é¸(UTP)æ¯å«ææ ¸ç³çæ ¸è·ä¸ç£·é¸çå¦å¤çå®ä¾ãå¶ä»ç±»åçæ ¸è·ï¼è¯¸å¦å¤©ç¶å­å¨çä¿®é¥°çæ ¸è·åäººå·¥æ ¸è·å¯ä»¥ä¸ä¸ä¸ªç£·é¸ç»åå½¢ææ ¸è·ä¸ç£·é¸ãå¨ç¹å®å®æ½æ¹æ¡ä¸­ï¼ä¿®é¥°çæ ¸è·é¸æ¯3âO-å°é­çæ ¸è·é¸ï¼å¶åå«å¯éå°éæ¥å°æ ¸è·ä¸ç£·é¸ç3âæ«ç«¯çåºå¢ï¼ä»¥é»æ­¢è¿ä¸æ­¥çæ ¸è·é¸æ·»å ãæè¿°åºå¢å¯ä»¥å·æä¸åçåå­¦æ§è´¨ï¼è¯¸å¦å æ°®åºç²åºãæ°¨åºæ°§åºåç¯ä¸åºãNucleotide or nucleoside triphosphate include deoxyadenosine triphosphate (dTAP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP) or deoxythymidine triphosphate (dTTP), as examples of nucleotides containing deoxyribose. Adenosine triphosphate (ATP), guanosine triphosphate (GTP), cytidine triphosphate (CTP) or uridine triphosphate (UTP) are other examples of nucleoside triphosphates containing ribose. Other types of nucleosides, such as naturally occurring modified nucleosides and artificial nucleosides can be combined with three phosphoric acids to form nucleoside triphosphates. In a specific embodiment, the modified nucleotide is a nucleotide closed by 3&#39;O-, which includes a group reversibly attached to the 3&#39; end of nucleoside triphosphates, to prevent further nucleotides from adding. The group can have different chemical properties, such as azidomethyl, aminooxy and allyl.
      
      
         å¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼ä¿®é¥°çæ ¸è·é¸åæ¬åå«åå¤ç¢±åºæå§å¶ç¢±åºåä»¥ä¸æ ¸ç³æè±æ°§æ ¸ç³ç³é¨åçä¿®é¥°çæ ¸è·é¸ææ ¸è·åå­ï¼æè¿°æ ¸ç³æè±æ°§æ ¸ç³ç³é¨åå·æä¸å¶å±ä»·å°éæ¥çå¯å»é¤ç3â-OHå°é­åºå¢ï¼ä½¿å¾3âç¢³åå­å·²éæ¥å¯éç»æ(-O-Z)çåºå¢ï¼In some embodiments, the modified nucleotides include modified nucleotides or nucleoside molecules comprising a purine base or a pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3&#39;-OH blocking group covalently attached thereto such that the 3&#39; carbon atom has attached a group of a reversible structure (-O-Z),
      
      
         å¶ä¸­-Zæ¯-C(R&#39;)2-O-R&#34;ã-C(R&#39;)2-N(R&#34;)2ã-C(R&#39;)2-N(H)R&#34;ã-C(R&#39;)2-S-Râå-C(R&#39;)2-Fçä»»ä½ä¸ç§ï¼å¶ä¸­æ¯ä¸ªR&#34;æ¯å¯å»é¤çä¿æ¤åºå¢ææ¯å¯å»é¤çä¿æ¤åºå¢çä¸é¨åï¼æ¯ä¸ªR&#39;ç¬ç«å°æ¯æ°¢åå­ãç·åºãåä»£çç·åºãè³åºç·åºãç¯åºãçåºãè³åºãæè³åºãæç¯ãé°åºãæ°°åºãç·æ°§åºãè³åºæ°§åºãæè³åºæ°§åºæé°èºåºå¢ï¼æéè¿è¿æ¥åºå¢éæ¥çå¯æ£æµæ è®°ç©ï¼æ¡ä»¶æ¯å¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼è¿æ ·çåä»£åºå·æè³å¤10ä¸ªç¢³åå­å/æè³å¤5ä¸ªæ°§ææ°®æåå­ï¼æ(R&#39;)2ä»£è¡¨å¼ï¼C(R&#34;&#39;)2çæ¬¡ç·åºåºå¢(alkylidene)ï¼å¶ä¸­æ¯ä¸ªR&#34;&#39;å¯ä»¥æ¯ç¸åçæä¸åçï¼å¹¶ä¸éèªåå«æ°¢åå¤ç´ åå­ä»¥åç·åºåºå¢çç»ï¼æ¡ä»¶æ¯å¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼æ¯ä¸ªR&#34;&#39;çç·åºå·æ1è³3ä¸ªç¢³åå­ï¼å¹¶ä¸å¶ä¸­åå­å¯ä»¥ååºä»¥äº§çä¸­é´ä½ï¼æè¿°ä¸­é´ä½ä¸­æ¯ä¸ªR&#34;è¢«äº¤æ¢ä¸ºHï¼æå¶ä¸­Zæ¯-(R&#39;)2-Fï¼Fè¢«äº¤æ¢ä¸ºOHãSHæNH2ï¼ä¼éå°äº¤æ¢ä¸ºOHï¼æè¿°ä¸­é´ä½å¨æ°´æ§æ¡ä»¶ä¸è§£ç¦»ä»¥æä¾å·ææ¸¸ç¦»3&#39;-OHçåå­ï¼æ¡ä»¶æ¯å½Zæ¯-C(R&#39;)2-S-R&#34;æ¶ï¼ä¸¤ä¸ªR&#39;åºå¢åä¸æ¯Hãå¨æäºå®æ½æ¹æ¡ä¸­ï¼ä¿®é¥°çæ ¸è·é¸ææ ¸è·çR&#39;æ¯ç·åºæåä»£çç·åºï¼æ¡ä»¶æ¯è¿æ ·çç·åºæåä»£çç·åºå·æ1è³10ä¸ªç¢³åå­å0è³4ä¸ªæ°§ææ°®æåå­ãå¨æäºå®æ½æ¹æ¡ä¸­ï¼ä¿®é¥°çæ ¸è·é¸ææ ¸è·ç-Zæ¯å¼-C(Râ)2-N3ãå¨æäºå®æ½æ¹æ¡ä¸­ï¼Zæ¯å æ°®åºç²åºãwherein -Z is any of -C(R&#39;)2-OR&#34;, -C(R&#39;)2-N(R&#34;)2, -C(R&#39;)2-N(H)R&#34;, -C(R&#39;)2-SR&#34;, and -C(R&#39;)2-F, wherein each R&#34; is a removable protecting group or is part of a removable protecting group; each R&#39; is independently a hydrogen atom, an alkyl group, a substituted alkyl group, an arylalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, a heterocycle, an acyl group, a cyano group, an alkoxy group, an aryloxy group, a heteroaryloxy group, or an amide group, or a detectable label attached via a linker; provided that in some embodiments In some embodiments, such substituents have up to 10 carbon atoms and/or up to 5 oxygen or nitrogen heteroatoms; or (R&#39;)2 represents an alkylidene group of formula =C(R&#34;&#39;)2, wherein each R&#34;&#39; may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups, provided that in some embodiments, the alkyl group of each R&#34;&#39; has 1 to 3 carbon atoms; and wherein the molecule can be reacted to produce an intermediate in which each R&#34; is exchanged for H, or wherein Z is -(R&#39;)2-F, F is exchanged for OH, SH or NH2 , preferably for OH, which intermediate dissociates under aqueous conditions to provide a molecule with a free 3&#39;-OH; provided that when Z is -C(R&#39;)2-SR&#34;, both R&#39; groups are not H. In certain embodiments, R&#39; of the modified nucleotide or nucleoside is an alkyl or substituted alkyl, provided that such alkyl or substituted alkyl has 1 to 10 carbon atoms and 0 to 4 oxygen or nitrogen heteroatoms. In certain embodiments, the -Z of the modified nucleotide or nucleoside is of the formula -C(R&#39;)2-N3. In certain embodiments, Z is azidomethyl.
      
      
         å¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼Zæ¯å·ææä¸å·ææåå­çåå­éä¸º200ææ´å°çå¯è£è§£ææºé¨åãå¨å¶ä»å®æ½æ¹æ¡ä¸­ï¼Zæ¯å·ææä¸å·ææåå­çåå­éä¸º100ææ´å°çå¯è£è§£ææºé¨åãå¨å¶ä»å®æ½æ¹æ¡ä¸­ï¼Zæ¯å·ææä¸å·ææåå­çåå­éä¸º50ææ´å°çå¯è£è§£ææºé¨åãIn some embodiments, Z is a cleavable organic moiety with a molecular weight of 200 or less with or without heteroatoms. In other embodiments, Z is a cleavable organic moiety with a molecular weight of 100 or less with or without heteroatoms. In other embodiments, Z is a cleavable organic moiety with a molecular weight of 50 or less with or without heteroatoms.
      
      
         å¨å¦å¤çç¹å®å®æ½æ¹æ¡ä¸­ï¼â3âOä¿®é¥°çæ ¸è·é¸âæ¯æå¨3âæ«ç«¯å¤æºå¸¦3â-O-ç²åºã3â-å æ°®åºã3â-O-å æ°®åºç²åºã3â-O-æ°¨åºã3â-æ°¨åºæ°§åºæ3â-O-ç¯ä¸åºåºå¢çæ ¸è·ä¸ç£·é¸ãå¨å¦å¤çå®æ½æ¹æ¡ä¸­ï¼3â-å°é­çæ ¸è·ä¸ç£·é¸è¢«3â-O-å æ°®åºç²åºã3â-æ°¨åºæ°§åºæ3â-O-ç¯ä¸åºåºå¢å°é­ãå¨å¶ä»å®æ½æ¹æ¡ä¸­ï¼â3âOä¿®é¥°çæ ¸è·é¸âæ¯æå¨3âæ«ç«¯å¤æºå¸¦é¯ãéãèãç£·é¸é¯(phosphates)ãç¢³é¸é¯(carbonate)ãæ°¨åºç²é¸é¯ãç¾èºãç¡¼é¸é¯(borate)ãç¡é¸é¯(nitrate)ãç³ãç£·é°èºãç£·é°èºé¸é¯ãè¯ç£ºé¸é¯ãç¡«é¸é¯ãç ç±»ææ°¨åºé¸çæ ¸è·ä¸ç£·é¸ãå¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼åè¿°3â-O-å°ç«¯åºå¢å·æ100ææ´å°çåå­éãIn other specific embodiments, &#34;3&#39;O modified nucleotides&#34; refer to nucleoside triphosphates carrying 3&#39;-O-methyl, 3&#39;-azido, 3&#39;-O-azidomethyl, 3&#39;-O-amino, 3&#39;-aminooxy or 3&#39;-O-allyl groups at the 3&#39; end. In other embodiments, 3&#39;-blocked nucleoside triphosphates are blocked by 3&#39;-O-azidomethyl, 3&#39;-aminooxy or 3&#39;-O-allyl groups. In other embodiments, &#34;3&#39;O modified nucleotides&#34; refer to nucleoside triphosphates carrying esters, ethers, nitrile, phosphates, carbonates, carbamates, hydroxylamines, borates, nitrates, sugars, phosphoramides, phosphoramidates, benzenesulfonates, sulfates, sulfones or amino acids at the 3&#39; end. In some embodiments, the aforementioned 3&#39;-O-blocking group has a molecular weight of 100 or less.
      
      
         å¨å¶ä»å®æ½æ¹æ¡ä¸­ï¼æ¬åæç3â-O-å°ç«¯åºå¢åæ¬ç²åºã3â-O-(2-ç¡åºèåº)ãç¯ä¸åºãèºãå æ°®åºç²åºãåä¸æ°§åºä¹æ°§åºæçä¸åºãIn other embodiments, the 3&#39;-O-capping group of the present invention includes methyl, 3&#39;-O-(2-nitrobenzyl), allyl, amine, azidomethyl, tert-butoxyethoxy, or propargyl.
      
      
         å¨å¦å¤çç¹å®å®æ½æ¹æ¡ä¸­ï¼â3âOä¿®é¥°çæ ¸è·é¸âæ¯æå·æç»æ­¢åæåºç©ä¿®é¥°åºå¢çæ ¸è·ä¸ç£·é¸ï¼è¯¸å¦å¨WO2016034807ä¸­æè¿°çé£äºãIn another specific embodiment, &#34;3&#39;O modified nucleotide&#34; refers to a nucleoside triphosphate with a terminator effector modification group, such as those described in WO2016034807.
      
      
         æè¶£çæ¯ï¼æ¬åæçåä½ä¸éçåTdTç¸æ¯è¡¨ç°åºå¯¹ä¿®é¥°çæ ¸è·é¸çå¢å çäº²ååï¼å¹¶ä¸ä»èè¡¨ç°åºå¢å çå¨æ ¸é¸åææé´å°è¿æ ·çä¿®é¥°çæ ¸è·é¸æºå¥æ ¸é¸åºåçè½åãæ´ç¹å«å°ï¼æ¬åæçåä½è½å¤ä½¿ç¨ä¿®é¥°ç3âO-æ ¸è·é¸(å¹¶ä¸æ´ç¹å«å°ï¼3âO-å°é­æ ¸è·é¸)å¹¶é«æå°å°å¶æºå¥å°æ ¸é¸åºåä¸­ï¼è¿å¨éçåå°é¼ TdTçæåµä¸­æ¯ä¸å¯è½ç(åè§Knappç­äººChem.Eur.J.,2011,17:2903)ãInterestingly, the variants of the present invention exhibit increased affinity for modified nucleotides compared to wild-type TdT, and thereby exhibit increased ability to incorporate such modified nucleotides into nucleic acid sequences during nucleic acid synthesis. More particularly, the variants of the present invention are able to use modified 3&#39;O-nucleotides (and more particularly, 3&#39;O-blocked nucleotides) and efficiently incorporate them into nucleic acid sequences, which is not possible in the case of wild-type mouse TdT (see Knapp et al. Chem. Eur. J., 2011, 17: 2903).
      
      
         æ ¹æ®ç¹å®æ¹é¢ï¼æ¬åææ¶åè½å¤å¨æ ¸é¸é¶ä¿åææ¹æ³ä¸­ä¸ä¿®é¥°çæ ¸è·é¸ï¼ç¹å«å°ä¸3âO-ä¿®é¥°çæ ¸è·é¸(ä¾å¦ï¼3âO-å°é­çæ ¸è·é¸)ä¸èµ·å·¥ä½ï¼å¹¶ä¸å·æäº§çé¿é¿åº¦æ ¸é¸åå­ææ ¸é¸åå­è¡çç©çè½åçTdTçåä½ãAccording to a specific aspect, the present invention relates to variants of TdT that are capable of working with modified nucleotides, particularly with 3&#39;O-modified nucleotides (e.g., 3&#39;O-blocked nucleotides), in nucleic acid enzymatic synthesis methods and have the ability to produce long-length nucleic acid molecules or nucleic acid molecule derivatives.
      
      
        
           æ ¸é¸çé¶ä¿åæEnzymatic synthesis of nucleic acids
        
      
      
         æ¬åæçç®çæ¯æä¾å¯ä»¥ç¨äºæ ¸é¸åæçTdTçåä½ï¼è¯¸å¦å¨Ybertç­äººWO2015/159023ï¼Jensenç­äººï¼Biochemistry,57:1821-1832(2018)ï¼Hiattç­äººï¼ç¾å½ä¸å©ç¬¬5808045å·ä¸­æè¿°çãæ´ç¹å«å°ï¼æ¬åæçç®çæ¯æä¾éäºåèµ·å§æ ¸é¸é¾æ·»å ä¿®é¥°çæ ¸è·é¸çTdTçåä½ãç¶åå¯ä»¥é¤å»å°é­åºå¢ï¼ä»¥åè®¸æ·»å æ°çä¿®é¥°çæ ¸è·é¸ãThe object of the present invention is to provide variants of TdT that can be used for nucleic acid synthesis, such as described in Ybert et al. WO2015/159023; Jensen et al., Biochemistry, 57:1821-1832 (2018); Hiatt et al., U.S. Patent No. 5,808,045. More particularly, the object of the present invention is to provide variants of TdT that are suitable for adding modified nucleotides to the starting nucleic acid chain. The blocking group can then be removed to allow the addition of new modified nucleotides.
      
      
         æ ¹æ®æ¬åæï¼éè¿ä½¿ç¨æ¬åæçåä½ï¼å®æ½åæ¬æ·»å åå»ä¿æ¤çè¿ç»­å¾ªç¯æ¯å¯è½çãå æ­¤ï¼è¯¥æ¹æ³å°åè®¸éè¿æ·»å å¯éä¿®é¥°çæ ¸è·é¸åè¿ä¸æ­¥å»é¤å°é­åºå¢çå¤ä¸ªå¾ªç¯ï¼ä»¥åè®¸èµ·å§æ ¸é¸é¾åæ§å¶å°å»¶ä¼¸ä¸ºéå®çåºåãAccording to the present invention, by using the variant of the present invention, it is possible to implement continuous cycles including addition and deprotection. Therefore, the method will allow multiple cycles of adding reversibly modified nucleotides and further removing the blocking group to allow the initial nucleic acid chain to be controlled to extend to a defined sequence.
      
      
         æ¬åæé¢æäºå¨ä»»ä½é¶ä¿æ ¸é¸åææ¹æ³ä¸­ä½¿ç¨æ ¹æ®æ¬åæçä¿®é¥°çTdTãThe present invention contemplates the use of a modified TdT according to the present invention in any enzymatic nucleic acid synthesis method.
      
      
         æ¬åæçåä¸ä¸ªç®çæ¯æä¾ä¸ç§ç¨äºå¨æ²¡ææ¨¡æ¿çæåµä¸åææ ¸é¸åå­çæ¹æ³ï¼è¯¥æ¹æ³åæ¬ä½¿æ ¸é¸å¼ç©ä¸è³å°ä¸ç§æ ¸è·é¸ï¼ä¼éå°è³å°ä¸ç§3âO-ä¿®é¥°çæ ¸è·é¸åæ¬åæçåä½äºèæ¥è§¦çæ­¥éª¤ãAnother object of the present invention is to provide a method for synthesizing a nucleic acid molecule in the absence of a template, the method comprising the step of contacting a nucleic acid primer with both at least one nucleotide, preferably at least one 3&#39;O-modified nucleotide and a variant of the present invention.
      
      
         æ¬åæé¢æäºé¶ä¿æ ¸é¸åææ¹æ³çæ¦å¿µãå¨è¿æ ·çæ¹æ³ä¸­ï¼æ ¸é¸åå­å¨ä¸å­å¨ä»»ä½æ¨¡æ¿é¾çæåµä¸ä»å¤´åæãå æ­¤ï¼æ ¸è·é¸çæåºåºåä¸èµ·å§æ ¸é¸çæ®µåå©äºæ¬åæçåä½å¶èãå°çè§£ï¼æ¯ä¸ªæ ¸è·é¸ä¸çé¿çæ ¸é¸é¾çå®éå¶èåæ´æ®éçé«å¶èæçæ¯éå¸¸éè¦çãè¿å°çè§£ï¼éç»æ­¢åæ ¸è·é¸ï¼è¯¸å¦å¤©ç¶æ ¸è·é¸ææ°¸ä¹æ è®°çæ ¸è·é¸å°ä¸åè®¸å¯¹åæçåºåè¿è¡ä»»ä½æ§å¶ï¼å¹¶ä¸å°å¯¼è´ä¾å¦ä¸åæ§å¶çä¸ä¸ææçå¤èæ·»å (poly-addition)ãThe present invention contemplates the concept of enzymatic nucleic acid synthesis methods. In such methods, nucleic acid molecules are synthesized from scratch in the absence of any template strands. Therefore, the ordered sequence of nucleotides is coupled to the starting nucleic acid fragment by means of variants of the present invention. It will be understood that the quantitative coupling of each nucleotide to the growing nucleic acid chain and the more general high coupling efficiency are very important. It will also be understood that non-terminator nucleotides, such as natural nucleotides or permanently labeled nucleotides will not allow any control of the synthesized sequence, and will result in, for example, uncontrolled and undesirable poly-addition.
      
      
         æ ¹æ®ç¹å®å®æ½æ¹æ¡ï¼é¶ä¿æ ¸é¸åææ¹æ³åæ¬ï¼According to certain embodiments, the enzymatic nucleic acid synthesis method comprises:
      
      
         a.æä¾ä¸åºä½æ¯æç©è¿æ¥çæ ¸é¸åå­ï¼a. providing a nucleic acid molecule attached to a solid support;
      
      
         b.ä½¿ååçæ ¸é¸åå­ä¸å¯éç»æ­¢åä¿®é¥°çæ ¸è·é¸åæ ¹æ®æ¬åæçTdTçåä½ååºï¼b. reacting the previous nucleic acid molecule with a reversible terminator-modified nucleotide and a variant of TdT according to the present invention;
      
      
         æ ¹æ®å¦ä¸ä¸ªç¹å®å®æ½æ¹æ¡ï¼é¶ä¿æ ¸é¸æ¹æ³åæ¬ï¼According to another specific embodiment, the enzymatic nucleic acid method comprises:
      
      
         a.æä¾ä¸åºä½æ¯æç©è¿æ¥çæ ¸é¸åå­ï¼a. providing a nucleic acid molecule attached to a solid support;
      
      
         b.æ·»å å¯éä¿®é¥°çæ ¸è·é¸åæ ¹æ®æ¬åæçTdTçåä½ï¼b. adding reversibly modified nucleotides and variants of TdT according to the present invention;
      
      
         c.é¦åä»åºä½æ¯æç©ä¸­å»é¤ä¸ç§æå ç§è¯åï¼c. first removing one or more reagents from the solid support;
      
      
         d.ä½¿å¯éä¿®é¥°çæ ¸è·é¸çå¯éé¨åååºï¼ä»¥ä½¿å¯éä¿®é¥°çæ ¸è·é¸å»ä¿æ¤ï¼ç¨äºè¿ä¸æ­¥çåç»­å»¶ä¼¸ï¼d. reacting the reversible portion of the reversibly modified nucleotide to deprotect the reversibly modified nucleotide for further subsequent extension;
      
      
         e.å¶æ¬¡ä»åºä½æ¯æç©ä¸­å»é¤ä¸ç§æå ç§è¯åï¼e. secondly removing one or more reagents from the solid support;
      
      
         f.ä»»éå°å¹¶æç»ä»åºä½æ¯æç©ä¸è£è§£æ ¸é¸åå­ãf. Optionally and finally cleaving the nucleic acid molecule from the solid support.
      
      
         æ ¹æ®å¦ä¸ä¸ªç¹å®å®æ½æ¹æ¡ï¼é¶ä¿æ ¸é¸æ¹æ³åæ¬ä»¥ä»¥ä¸æ¹å¼ç»åçå¾ªç¯ï¼According to another specific embodiment, the enzymatic nucleic acid method comprises cycles subdivided in the following manner:
      
      
         a.ç§°ä¸ºç¬¬ä¸é¶æ®µçä½¿Xiä¸ªæ ¸è·é¸å»¶ä¼¸å°æè¿°çæ®µä¸ä¸ªæ«ç«¯çé¶æ®µï¼Xå¨1ä¸5ä¹é´ï¼ä¼éå°å¨1ä¸3ä¹é´æ¯å¯è½çï¼iæ¯å¾ªç¯æ°ï¼ä½¿å¾è·å¾åå«n+Xiä¸ªæ ¸è·é¸ççæ®µæä¸ºå¯è½ï¼å¹¶ä¸åæ¬ä»¥ä¸é¶æ®µï¼a. a stage called the first stage in which Xi nucleotides are extended to one end of the fragment, x being between 1 and 5, preferably between 1 and 3, i being the number of cycles, making it possible to obtain a fragment containing n+Xi nucleotides, and comprising the following stages:
      
      
         -å°åæ¬nä¸ªæ ¸è·é¸çåå§æ ¸é¸çæ®µæå»¶ä¼¸è¿ç¨ä¸­çæ ¸é¸çæ®µçç¬¬ä¸æ«ç«¯éæ¥å°ç¬¬ä¸æ¯æç©ä¸çç¬¬ä¸éæ¥é¶æ®µï¼- a first attachment stage of attaching the first end of an initial nucleic acid fragment comprising n nucleotides or a nucleic acid fragment in the process of extension to a first support,
      
      
         -æ·»å TdTçåä½æéçè¯åçé¶æ®µï¼- stage of adding the reagents required for the variants of TdT,
      
      
         -TdTçåä½åæè¿°æ ¸é¸çæ®µçç¬¬äºæ«ç«¯æ·»å Xiä¸ªæ ¸è·é¸çé¶æ®µï¼Xå¨1ä¸5ä¹é´ï¼ä¼éå°1ä¸3ä¹é´ï¼iæ¯å¾ªç¯æ°ï¼- a phase in which a variant of TdT adds Xi nucleotides to the second end of the nucleic acid fragment, x is between 1 and 5, preferably between 1 and 3, i is the cycle number,
      
      
         -ä»ååºä»è´¨ä¸­å»é¤ä¸ææçè¯åçä»»éçé¶æ®µï¼- an optional stage for removing undesirable reagents from the reaction medium,
      
      
         -ä½¿åå«n+Xiä¸ªæ ¸è·é¸çæè¿°çæ®µä»æè¿°ç¬¬ä¸æ¯æç©ä¸è±ç¦»çé¶æ®µï¼- a stage of detaching said fragment comprising n+Xi nucleotides from said first support,
      
      
         -è½¬ç§»åå«n+Xiä¸ªæ ¸è·é¸çæè¿°çæ®µçç¬¬ä¸è½¬ç§»é¶æ®µï¼- a first transfer phase of transferring said fragment comprising n+Xi nucleotides,
      
      
         b.ç§°ä¸ºç¬¬äºé¶æ®µççº¯åå·æåå«n+Xiä¸ªæ ¸è·é¸çæ­£ç¡®åºåççæ®µçé¶æ®µï¼åæ¬ä»¥ä¸è¿ç»­é¶æ®µï¼b. The stage of purifying the fragments having the correct sequence containing n+Xi nucleotides, called the second stage, comprises the following consecutive stages:
      
      
         -å°åå«n+Xiä¸ªæ ¸è·é¸çæè¿°çæ®µéæ¥å°ç¬¬äºæ¯æç©ä¸çç¬¬äºéæ¥é¶æ®µï¼æè¿°éæ¥éè¿æºå¸¦å¨ç¬¬ä¸é¶æ®µæé´æ·»å çXiä¸ªæ ¸è·é¸çæ«ç«¯è¿è¡ï¼- a second attachment phase of attaching said fragment comprising n+Xi nucleotides to a second support via the end carrying the Xi nucleotides added during the first phase,
      
      
         -å»é¤æ²¡æè¢«éæ¥å°ç¬¬äºæ¯æç©ä¸ççæ®µçé¶æ®µï¼- a stage of removing the fragments not attached to the second support,
      
      
         -ä½¿åå«n+Xiä¸ªæ ¸è·é¸çæè¿°çæ®µä»æè¿°ç¬¬äºæ¯æç©ä¸åç¦»çé¶æ®µï¼- a stage of detaching said fragment comprising n+Xi nucleotides from said second support,
      
      
         -ä»ååºä»è´¨ä¸­å»é¤ä¸ææçæ®çè¯åçä»»éçé¶æ®µï¼- an optional stage for removing undesirable residual reagents from the reaction medium;
      
      
         c.ç§°ä¸ºç¬¬ä¸é¶æ®µçä»»éçå¯¹å·æåå«n+Xiä¸ªæ ¸è·é¸çæ­£ç¡®åºåççæ®µè¿è¡æ©å¢ï¼ä¼éå°é¶ä¿æ©å¢ï¼è¯¸å¦éè¿PCRæ©å¢çé¶æ®µï¼åæ¬ä»¥ä¸è¿ç»­é¶æ®µï¼c. The optional amplification of the fragment with the correct sequence comprising n+Xi nucleotides, preferably enzymatically, such as by PCR, called the third phase, comprises the following successive phases:
      
      
         -æ·»å æ©å¢æéçè¯åçé¶æ®µï¼- the stage of adding the reagents required for amplification,
      
      
         -åå«n+Xiä¸ªæ ¸è·é¸ççæ®µä»¥åå¢å å­Yiåå¢çé¶æ®µ(ä»»éå°ç±ä½¿è¯¥è¿ç¨æä¸ºå¯è½çå­é¶æ®µç»æ)ï¼iæ¯å¾ªç¯æ°ï¼Yå¨1ä¸4Ã1010ä¹é´ï¼ä¼éå°å¨1ä¸1Ã109ä¹é´æ¯å¯è½çï¼- a stage (optionally consisting of sub-stages that make this process possible) in which the fragment containing n+Xi nucleotides is multiplied with a multiplication factor Yi, i being the cycle number, Y being between 1 and 4Ã10 10 , preferably between 1 and 1Ã10 9 possible,
      
      
         -è½¬ç§»åå«n+Xiä¸ªæ ¸è·é¸ççæ®µçé¶æ®µï¼- a stage of transferring a fragment containing n+Xi nucleotides,
      
      
         æ¯ä¸ªå¾ªç¯é½å¨ä¸é¶ä¿æ·»å åé¶ä¿æ©å¢ç¸å®¹çååºä»è´¨ï¼è¯¸å¦æ°´æ§ä»è´¨ä¸­è¿è¡ï¼åææ¹æ³è¿åæ¬å¨ææiä¸ªå»¶ä¼¸å¾ªç¯ç»ææ¶ä»¥åå¢å å­Yfè¿è¡æç»æ©å¢çé¶æ®µãEach cycle is carried out in a reaction medium compatible with enzymatic addition and enzymatic amplification, such as an aqueous medium, and the synthesis method also includes a stage of final amplification with a multiplication factor Yf at the end of all i extension cycles.
      
      
         å¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼åæå¤æ ¸è·é¸çæ¹æ³åæ¬ä»¥ä¸æ­¥éª¤ï¼(a)æä¾å·ææ¸¸ç¦»3â-ç¾åºçèµ·å§çæ®µï¼(b)å¨å»¶ä¼¸æ¡ä»¶ä¸ï¼å¨3â-O-å°é­çæ ¸è·ä¸ç£·é¸å­å¨ä¸ï¼ä½¿èµ·å§çæ®µæå·ææ¸¸ç¦»3â-ç¾åºçå»¶ä¼¸ä¸­é´ä½ä¸æ¬åæçåä½TdTååºï¼ä»¥äº§ç3â-O-å°é­çå»¶ä¼¸ä¸­é´ä½ï¼(c)ä½¿å»¶ä¼¸ä¸­é´ä½å»å°é­ä»¥äº§çå·ææ¸¸ç¦»3â-ç¾åºçå»¶ä¼¸ä¸­é´ä½ï¼å(d)éå¤æ­¥éª¤(b)å(c)ï¼ç´å°åæå¤æ ¸è·é¸ãIn some embodiments, the method of synthesizing a polynucleotide includes the following steps: (a) providing a starting fragment having a free 3&#39;-hydroxyl group; (b) reacting the starting fragment or an extension intermediate having a free 3&#39;-hydroxyl group with a variant TdT of the present invention in the presence of a 3&#39;-O-blocked nucleoside triphosphate under extension conditions to produce a 3&#39;-O-blocked extension intermediate; (c) deblocking the extension intermediate to produce an extension intermediate having a free 3&#39;-hydroxyl group; and (d) repeating steps (b) and (c) until a polynucleotide is synthesized.
      
      
         å¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼åæå¤æ ¸è·é¸çæ¹æ³åæ¬ä»¥ä¸æ­¥éª¤ï¼(a)æä¾éæ¥å°åºä½æ¯æç©çèµ·å§çæ®µï¼å¼ååæ¯å·ææ¸¸ç¦»3â-ç¾åºçå¯¡æ ¸è·é¸ï¼(b)å¨å»¶ä¼¸æ¡ä»¶ä¸ï¼å¨3â-O-å°é­çæ ¸è·ä¸ç£·é¸å­å¨ä¸ï¼ä½¿èµ·å§çæ®µæå·ææ¸¸ç¦»3â-ç¾åºçå»¶ä¼¸ä¸­é´ä½ä¸æ¬åæçåä½TdTååºï¼ä»¥äº§ç3â-O-å°é­çå»¶ä¼¸ä¸­é´ä½ï¼(c)æ´æ¶¤åºä½æ¯æç©ä»¥å»é¤æªæºå¥ç3â-O-å°é­çæ ¸è·ä¸ç£·é¸ï¼(d)éè¿å°åºä½æ¯æç©æ´é²äºå»å°é­åä½¿å»¶ä¼¸ä¸­é´ä½å»å°é­ï¼ä»¥äº§çå·ææ¸¸ç¦»3â-ç¾åºçå»¶ä¼¸ä¸­é´ä½ï¼å(e)éå¤æ­¥éª¤(b)å(d)ï¼ç´å°åæå¤æ ¸è·é¸ãè¯¥æ¹æ³å¯ä»¥åæ¬ä»åºä½æ¯æç©ä¸è£è§£å®æçå¤æ ¸è·é¸çå¦å¤çæ­¥éª¤ãIn some embodiments, the method of synthesizing a polynucleotide comprises the following steps: (a) providing a starting fragment attached to a solid support, the initiator being an oligonucleotide having a free 3&#39;-hydroxyl group; (b) reacting the starting fragment or an extension intermediate having a free 3&#39;-hydroxyl group with a variant TdT of the present invention in the presence of a 3&#39;-O-blocked nucleoside triphosphate under extension conditions to produce a 3&#39;-O-blocked extension intermediate; (c) washing the solid support to remove unincorporated 3&#39;-O-blocked nucleoside triphosphate; (d) deblocking the extension intermediate by exposing the solid support to a deblocking agent to produce an extension intermediate having a free 3&#39;-hydroxyl group; and (e) repeating steps (b) and (d) until a polynucleotide is synthesized. The method may include an additional step of cleaving the completed polynucleotide from the solid support.
      
      
         å¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼å¯¹äºæ­¥éª¤(b)ï¼TdTå¬åçæ·»å ååºï¼é¶ä¿æ¡ä»¶å¯ä»¥å«æçº¦0.20Î¼Mè³çº¦200Î¼Mçå·æä¿æ¤3â-ç¾åºçå¯å»é¤çå°é­é¨åçæ ¸è·é¸åçº¦0.20Î¼Mè³200Î¼Mçæ¥æºäºèµ·å§åºç©çæ¸¸ç¦»åæªä¿®é¥°ç3â-ç¾åºãå¨ä¸äºå®æ½æ¹æ¡ä¸­ï¼ååºç¼å²æ¶²å«æçº¦10mMè³çº¦500mMçäºç²èé¸é¾(potassium cacodylate)ç¼å²æ¶²(pHå¨6.5ä¸7.5ä¹é´)åçº¦0.01mMè³çº¦10mMçäºä»·é³ç¦»å­(ä¾å¦ï¼CoC12æMnC12)ãå¶ä»ç¼å²æ¶²ç»åç©åç»åå¯ä»¥éäºæ¬åæçç¹å®ææçå®æ½æ¹æ¡ãIn some embodiments, for step (b), the TdT-catalyzed addition reaction, the enzymatic conditions may contain about 0.20 Î¼M to about 200 Î¼M of a nucleotide having a removable blocking portion protecting the 3&#39;-hydroxyl and about 0.20 Î¼M to 200 Î¼M of a free and unmodified 3&#39;-hydroxyl derived from the starting substrate. In some embodiments, the reaction buffer contains about 10 mM to about 500 mM potassium cacodylate buffer (pH between 6.5 and 7.5) and about 0.01 mM to about 10 mM of a divalent cation (e.g., CoCl 2 or MnCl 2 ). Other buffer compositions and components may be suitable for specific desired embodiments of the present invention.
      
      
         å¨æ¬åæçä¸ä¸æä¸­ï¼è¡¨è¿°âè£è§£ååºâæ¯æè½å¤è£è§£ååæè¿°çå¯éä¿®é¥°çæ ¸è·é¸ä¸çéå åºå¢çç©è´¨æç©çæ¡ä»¶çä»»ä½ä½ç¨ãæ¬é¢åææ¯äººåè½å¤ç¡®å®ä»»ä½ååååºçåºå¢çè£è§£ååºãIn the context of the present invention, the expression &#34;cleavage reaction&#34; refers to any action of substances or physical conditions capable of cleaving additional groups on the previously described reversibly modified nucleotides. A person skilled in the art is able to determine the cleavage reaction of any of the previously listed groups.
      
      
         å¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼è£è§£åæ¯åå­¦è£è§£åãå¨æ¿ä»£å®æ½æ¹æ¡ä¸­ï¼è£è§£åæ¯é¶ä¿è£è§£åãIn one embodiment, the cleavage agent is a chemical cleavage agent. In an alternative embodiment, the cleavage agent is an enzymatic cleavage agent.
      
      
         æ¬é¢åææ¯äººåå°çè§£ï¼è£è§£åçéæ©åå³äºæä½¿ç¨ç3â-æ ¸è·é¸å°é­åºå¢çç±»åãä¾å¦ï¼ä¸(2-ç¾§ä¹åº)è¦(TCEP)å¯ä»¥ç¨äºè£è§£3âO-å æ°®åºç²åºåºå¢ï¼é¯ç»åç©å¯ä»¥ç¨äºè£è§£3âO-ç¯ä¸åºåºå¢ï¼æèäºç¡é¸é å¯ä»¥ç¨äºè£è§£3âO-æ°¨åºåºå¢ãå¨ç¹å®å®æ½æ¹æ¡ä¸­ï¼è£è§£ååºåæ¬ï¼TCEPãé¯ç»åç©æäºç¡é¸é ãThose skilled in the art will appreciate that the selection of cleavage agent depends on the type of employed 3&#39;-nucleotide blocking group.For example, tris (2-carboxyethyl) phosphine (TCEP) can be used for cracking 3&#39;O-azidomethyl group, palladium complex can be used for cracking 3&#39;O-allyl group, or sodium nitrite can be used for cracking 3&#39;O-amino group.In specific embodiments, cleavage reaction comprises: TCEP, palladium complex or sodium nitrite.
      
      
         å¨ç¹å®å®æ½æ¹æ¡ä¸­ï¼è£è§£ååºå¨éå ç»åè¯¸å¦åæ§å(ä¾å¦å°¿ç´ ãçé¸èãç²é°èºæçèç¢±)çå­å¨ä¸è¿è¡ãå¨å¦å¤çå®æ½æ¹æ¡ä¸­ï¼è£è§£ååºç¨ä¸ç§ææ´å¤ç§ç¼å²æ¶²è¿è¡ãæ¬é¢åææ¯äººåå°çè§£ï¼ç¼å²æ¶²çéæ©åå³äºç¡®åçååºæºçãIn certain embodiments, the cleavage reaction is carried out in the presence of an additional component such as a denaturant (e.g., urea, guanidine hydrochloride, formamide, or betaine). In other embodiments, the cleavage reaction is carried out with one or more buffers. It will be appreciated by those skilled in the art that the selection of buffer depends on the exact reaction mechanism.
      
      
         æ¬åææ¶åå·æä»¥å®éæ¹å¼æºå¥ä¿®é¥°çæ ¸è·é¸çè½åçTdTçåä½ãâå®éæ¹å¼âæâå®éååºâææä¸ç§è¿è¡å®å¨çååºï¼å³å¶ä¸­ååºç©å®å¨è½¬åä¸ºäº§ç©çååºãä»¥å®éæ¹å¼æºå¥å¯éä¿®é¥°çæ ¸è·é¸çèåé¶æ¯è½å¤ç¨ææå¯ç¨çæ ¸è·é¸å»¶ä¼¸æ¯ä¸ªæ ¸é¸çæ®µï¼å¯¼è´é¿åº¦ä¸ºnçææèµ·å§çæ®µè½¬åä¸ºé¿åº¦ä¸ºn+1ççæ®µçèåé¶ãThe present invention relates to variants of TdT that have the ability to incorporate modified nucleotides in a quantitative manner. &#34;Quantitative manner&#34; or &#34;quantitative reaction&#34; means a reaction that proceeds to completion, i.e., a reaction in which the reactants are completely converted to products. A polymerase that incorporates reversibly modified nucleotides in a quantitative manner is a polymerase that is able to extend each nucleic acid fragment with all available nucleotides, resulting in the conversion of all starting fragments of length n into fragments of length n+1.
      
      
         å¦æ¬æä½¿ç¨çï¼âèµ·å§çæ®µâæ¯æå·ææ¸¸ç¦»3âæ«ç«¯çå¯ä»¥è¢«è¿ä¸æ­¥å»¶ä¼¸çç­å¯¡æ ¸è·é¸åºåãå¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼èµ·å§çæ®µæ¯DNAèµ·å§çæ®µãå¨æ¿ä»£å®æ½æ¹æ¡ä¸­ï¼èµ·å§çæ®µæ¯RNAèµ·å§çæ®µãAs used herein, &#34;starting fragment&#34; refers to a short oligonucleotide sequence with a free 3&#39; end that can be further extended. In one embodiment, the starting fragment is a DNA starting fragment. In an alternative embodiment, the starting fragment is an RNA starting fragment.
      
      
         å¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼èµ·å§çæ®µå·æ3ä¸100ä¸ªä¹é´çæ ¸è·é¸ï¼ç¹å«æ¯3ä¸20ä¸ªä¹é´çæ ¸è·é¸ãIn one embodiment, the starting fragment has between 3 and 100 nucleotides, in particular between 3 and 20 nucleotides.
      
      
         å¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼èµ·å§çæ®µæ¯åé¾çãå¨æ¿ä»£å®æ½æ¹æ¡ä¸­ï¼èµ·å§çæ®µæ¯åé¾çãIn one embodiment, the starting fragment is single-stranded. In an alternative embodiment, the starting fragment is double-stranded.
      
      
         å¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼èµ·å§çæ®µè¢«åºå®å¨åºä½æ¯æç©ä¸ãèµ·å§çæ®µå¯ä»¥éè¿å¤ç§æ¹æ³è¢«éæ¥å°åºä½æ¯æç©ä¸ï¼äº§çå¨çæ®µå°ç»åçå¤ç§é¶ä¿æåæååºæ¡ä»¶ä¸ç¨³å®çãIn one embodiment, the starting fragment is immobilized on a solid support.The starting fragment can be attached to a solid support by a variety of methods, resulting in a fragment that is stable under the various enzymatic or synthetic reaction conditions to which the fragment will be subjected.
      
      
         å¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼èµ·å§çæ®µéè¿å¯éç¸äºä½ç¨é¨åè¢«åºå®å¨åºä½æ¯æç©ä¸ï¼æè¿°å¯éç¸äºä½ç¨é¨åè¯¸å¦åå­¦å¯è£è§£æ¥å¤´ãæä½/åç«åæ§è¡¨ä½ãçç©ç´ /çç©ç´ ç»åèç½æè°·è±çè½-GSTæ ç­¾ãå¨å¦å¤çå®æ½æ¹æ¡ä¸­ï¼èµ·å§çæ®µéè¿åå­¦å¯è£è§£æ¥å¤´è¢«åºå®å¨åºä½æ¯æç©ä¸ï¼æè¿°åå­¦å¯è£è§£æ¥å¤´è¯¸å¦äºç¡«åç©ãç¯ä¸åºæå æ°®åç©æ©è½çåèºç¼©éé(hemiaminal ether)æ¥å¤´ãIn one embodiment, the starting fragment is immobilized on a solid support via a reversible interaction portion such as a chemically cleavable linker, an antibody/immunogenic epitope, biotin/biotin binding protein, or a glutathione-GST tag. In other embodiments, the starting fragment is immobilized on a solid support via a chemically cleavable linker such as a hemiamine acetal ether linker masked by a disulfide, allyl, or azide.
      
      
         å¨èµ·å§çæ®µä¸­ï¼è¢«åºå®çé¨åå«æè³å°ä¸ä¸ªéå¶æ§ä½ç¹ãæç®ä¸­æè¿°äºä½¿ç¨éå¶æ§é¶åéå¶æ§ä½ç¹å¨ç¹å®ä½ç¹å¤éæ©æ§æ°´è§£æ ¸é¸é¾ãä»»ä½ææ¯äººåé½è½å¤éæ©ä¸èµ·å§çæ®µè£è§£ä½ç¹åºåå¹éçéå½çéå¶æ§é¶ãIn the starting fragment, the fixed part contains at least one restriction site. The use of restriction enzymes and restriction sites to selectively hydrolyze nucleic acid chains at specific sites has been described in the literature. Any technician can select a suitable restriction enzyme that matches the starting fragment cleavage site sequence.
      
      
         å¨æ¿ä»£å®æ½æ¹æ¡ä¸­ï¼èµ·å§çæ®µå«æè³å°ä¸ä¸ªå°¿è·ãç¨å°¿å§å¶-DNAç³åºåé¶(UDG)å¤çäº§çæ ç¢±åºä½ç¹ãç¨æ åå¤/æ å§å¶(AP)ä½ç¹ååæ ¸é¸é¶å¯¹éå½çåºç©çå¤çå°æåæ ¸é¸é¾ãIn an alternative embodiment, the starting fragment contains at least one uridine. Treatment with uracil-DNA glycosylase (UDG) generates an abasic site. Treatment of an appropriate substrate with an apurinic/apyrimidinic (AP) site endonuclease will extract the nucleic acid strand.
      
      
        
           æ ¸é¸åå­Nucleic acid molecules
        
      
      
         æ¬åæçåä¸ä¸ªç®çæ¯æä¾ç¼ç æ¬åæçåä½çæ ¸é¸åå­ãå¦æ¬æä½¿ç¨çï¼âæ ¸é¸åå­âæ¯ææ ¸è·çèåç©ãå¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼æ ¸é¸æ¯DNAãå¨æ¿ä»£å®æ½æ¹æ¡ä¸­ï¼æ ¸é¸æ¯RNAãå¨æ¿ä»£å®æ½æ¹æ¡ä¸­ï¼æ ¸é¸æ¯XNAãIt is a further object of the present invention to provide nucleic acid molecules encoding variants of the present invention. As used herein, &#34;nucleic acid molecule&#34; refers to a polymer of nucleosides. In one embodiment, the nucleic acid is DNA. In an alternative embodiment, the nucleic acid is RNA. In an alternative embodiment, the nucleic acid is XNA.
      
      
         æ¬é¢åææ¯äººåå°çè§£ï¼ååååºçæ¯ä¸ªæ ¸é¸åå­å¯ä»¥å¨ææèååå­çæ ¸è·é¸çç¢±åºä¸æºå¸¦ä¿®é¥°ãè¿æ ·çä¿®é¥°å¯ä»¥æ¯å¤©ç¶ä¿®é¥°ï¼è¯¸å¦è¡¨è§éä¼ ä¿®é¥°ï¼æéå¤©ç¶ä¿®é¥°ï¼è¯¸å¦æ è®°ç©ãThose skilled in the art will appreciate that each of the nucleic acid molecules listed above may carry modifications at the bases of the nucleotides constituting the polymeric molecule. Such modifications may be natural modifications, such as epigenetic modifications, or non-natural modifications, such as markers.
      
      
         å¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼æ ¸é¸åå­æ¯æºå¸¦å¤©ç¶å­å¨çè¡¨è§éä¼ ä¿®é¥°è¯¸å¦ç²åºåãç¾ç²åºåãç²é°åæ5-ç¾§åºåçDNAãRNAæXNAãIn one embodiment, the nucleic acid molecule is a DNA, RNA or XNA that carries a naturally occurring epigenetic modification such as methylation, hydroxymethylation, formylation or 5-carboxylation.
      
      
         å¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼æ ¸é¸åå­æ¯æºå¸¦éå¤©ç¶å­å¨çä¿®é¥°è¯¸å¦è§åæ ç­¾ãè§åæ è®°ç©ãç¸äºä½ç¨åºå¢çDNAãRNAæXNAãIn one embodiment, the nucleic acid molecule is a DNA, RNA or XNA carrying a non-naturally occurring modification such as a fluorescent tag, fluorescent marker, interactive group.
      
      
         å¨ä¸ç§å®æ½æ¹æ¡ä¸­ï¼æ ¸é¸åå­æ¯å·æå¤äº50ä¸ªã100ä¸ªã200ä¸ªã300ä¸ªã400ä¸ªã500ä¸ªã600ä¸ªã700ä¸ªã800ä¸ªã900ä¸ªã1 000ä¸ªã2 000ä¸ªã3 000ä¸ªã4 000ä¸ªã5 000ä¸ªã6 000ä¸ªã7000ä¸ªã8 000ä¸ªã9 000ä¸ªã10 000ä¸ªã15 000ä¸ªã20 000ä¸ªã30 000ä¸ªã40 000ä¸ªã50 000ä¸ªæä¸ª100 000ä¸ªæ ¸è·é¸çé¿åº¦çèåç©åå­ãIn one embodiment, the nucleic acid molecule is a polymer molecule having a length of more than 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 15,000, 20,000, 30,000, 40,000, 50,000 or 100,000 nucleotides.
      
      
        
           åºç¨application
        
      
      
         æ¬ææè¿°äºTdTçåä½ç¨äºæ ¸é¸åæãå¯¡æ ¸è·é¸åæãæ¢éåæãå æ ç­¾ãæ ¸é¸æ©å¢ãééä½ãæ²»çæ§æ ¸é¸åå­ãè¯ç©é¶åç°åéªè¯ãç¾çè¯æ­ãä»£è°¢å·¥ç¨ãæ°æ®å­å¨ãä½ç©æ¹è¯ãæåºè®¾è®¡ãæµåºæ± ãæ ¸é¸æ è®°æéæ¥ææ¶åæ ¸é¸åå­çä»»ä½å¶ä»åºç¨çç¨éãDescribed herein are uses of variants of TdT for nucleic acid synthesis, oligonucleotide synthesis, probe synthesis, tagging, nucleic acid amplification, aptamers, therapeutic nucleic acid molecules, drug target discovery and validation, disease diagnostics, metabolic engineering, data storage, crop improvement, library design, sequencing pools, nucleic acid labeling or attachment, or any other application involving nucleic acid molecules.
      
      
        
           åä½TdTçäº§çGeneration of variant TdT
        
      
      
         æ¬åæçåä½å¯ä»¥éè¿å¯¹å·²ç¥çåèæéçåTdTçç¼ç å¤æ ¸è·é¸è¿è¡çªåï¼ç¶åä½¿ç¨å¸¸è§åå­çç©å­¦ææ¯ä½¿å¶è¡¨è¾¾æ¥äº§çãä¾å¦ï¼å°é¼ TdTåºå (SEQ ID NO.1)å¯ä»¥ä½¿ç¨å¸¸è§åå­çç©å­¦ææ¯ï¼ä¾å¦ä½¿ç¨ç±Stemmerç­äººï¼Gene,164:49-53(1995)ï¼Kodumalç­äººï¼Proc.Natl.Acad.Sci.,101:15573-15578(2004)ç­æè¿°çæ¹æ¡ç±åæçæ®µç»è£ï¼æèå¶å¯ä»¥ä½¿ç¨Bouleç­äººï¼Biotech NO.logy,10:199-208(1998)ï¼æBentolilaç­äººï¼EMBO J.,14:4221-4229(1995)ç­æè¿°çæ¹æ¡ä»å°é¼ ç»èç´æ¥åéãVariants of the present invention can be produced by mutating a known reference or wild-type TdT encoding polynucleotide and then expressing it using conventional molecular biology techniques. For example, the mouse TdT gene (SEQ ID NO.1) can be assembled from synthetic fragments using conventional molecular biology techniques, such as by the protocols described by Stemmer et al., Gene, 164:49-53 (1995); Kodumal et al., Proc. Natl. Acad. Sci., 101:15573-15578 (2004); or it can be directly cloned from mouse cells using the protocols described by Boule et al., Biotech NO.logy, 10:199-208 (1998), or Bentolila et al., EMBO J., 14:4221-4229 (1995).
      
      
         ä¾å¦ï¼å¯ä»¥å°åç¦»çTdTåºå æå¥è¡¨è¾¾è½½ä½ï¼è¯¸å¦pET32(NO.vagen)ä¸­ï¼å¾å°è½½ä½pCTdTï¼ç¶åè¯¥è½½ä½pCTdTå¯ä»¥è¢«ç¨äºä½¿ç¨å¸¸è§æ¹æ¡å¶å¤åè¡¨è¾¾åä½TdTèç½ãå·ææ­£ç¡®åºåçè½½ä½å¯ä»¥å¨å¤§è æè(E.coli)çäº§èæ ªä¸­è½¬åãFor example, the isolated TdT gene can be inserted into an expression vector, such as pET32 (NO.vagen), resulting in the vector pCTdT, which can then be used to prepare and express variant TdT proteins using conventional protocols. The vector with the correct sequence can be transformed in an E. coli production strain.
      
      
         ä½¿ç¨å¸¸è§ææ¯å°è½¬åçèæ ªå¹å»æå¢å(pellets)ï¼ä»å¶ä¸­æåTdTèç½ãä¾å¦ï¼å°ååå¶å¤çå¢åå¨30âè³37âæ°´æµ´ä¸­è§£å»ãå®å¨è§£å»åï¼å°å¢åéæ¬äºè£è§£ç¼å²æ¶²ä¸­ï¼è¯¥ç¼å²æ¶²ç±50mM Tris-HCl(Sigma)pH 7.5ã150mM NaCl(Sigma)ã0.5mMå·¯åºä¹é(Sigma)ã5ï¼çæ²¹(Sigma)ã20mMåªå(Sigma)å1ç100mLèç½é¶æ··åç©æå¶å(Thermofisher)ç»æãä»ç»è¿è¡éæ¬ï¼ä»¥é¿åèéä½è¿æ©æº¶è§£åæ®çãéè¿å ä¸ªå¾ªç¯çå¼æ°åç¢å¨(French press)è£è§£éæ¬çç»èï¼ç´å°è·å¾å®å¨çé¢è²åååº¦ãéå¸¸ä½¿ç¨çååæ¯14,000psiãç¶åå°è£è§£ç©ä»¥10,000rpmç¦»å¿1hè³1h 30minãä½¿ç¦»å¿æ¶²(centrifugate)éè¿0.2Î¼mè¿æ»¤å¨ï¼ä»¥å»é¤ä»»ä½ç¢çï¼ç¶åæ±çº¯åãThe transformed strains are cultured into pellets using conventional techniques, from which TdT protein is extracted. For example, the previously prepared pellets are thawed in a 30Â°C to 37Â°C water bath. After complete thawing, the pellets are resuspended in a lysis buffer consisting of 50mM Tris-HCl (Sigma) pH 7.5, 150mM NaCl (Sigma), 0.5mM mercaptoethanol (Sigma), 5% glycerol (Sigma), 20mM imidazole (Sigma) and 1 100mL protease mixture inhibitor (Thermofisher). Resuspend carefully to avoid premature dissolution and residue of aggregates. The resuspended cells are lysed by several cycles of French press until complete color uniformity is obtained. The pressure commonly used is 14,000psi. The lysate is then centrifuged at 10,000rpm for 1h to 1h 30min. The centrifuge is passed through a 0.2Î¼m filter to remove any debris, and then column purified.
      
      
         å¯ä»¥ä»¥ä¸æ­¥äº²åç¨åºä»ç¦»å¿æ¶²ä¸­çº¯åTdTèç½ãä¾å¦ï¼ä½¿ç¨Ni-NTAäº²åæ±(GEHealthcare)ç»åèåé¶ãæåï¼æ±å·²è¢«æ´æ¶¤ï¼å¹¶ç¨15ä¸ªæ±ä½ç§¯ç50mM Tris-HCl(Sigma)pH7.5ã150mM NaCl(Sigma)å20mMåªå(Sigma)å¹³è¡¡ãå¹³è¡¡åï¼ä½¿èåé¶ä¸æ±ç»åãç¶åï¼å°ç±50mM Tris-HCl(Sigma)pH 7.5ã500mM NaCl(Sigma)å20mMåªå(Sigma)ç»æçæ´æ¶¤ç¼å²æ¶²æ½å å°æ±ä¸ï¼æç»­15ä¸ªæ±ä½ç§¯ãæ´æ¶¤åï¼å°èåé¶ç¨50mM Tris-HCl(Sigma)pH 7.5ã500mMNaCl(Sigma)å0.5Måªå(Sigma)æ´è±ãå¯¹åºäºæé«æµåº¦çæå´è¶£çèåé¶ççº§åè¢«æ¶éå¹¶åå¹¶å¨åä¸æ ·åä¸­ãå°åå¹¶ççº§åç¸å¯¹äºéæç¼å²æ¶²(20mM Tris-HCl pH 6.8ã200mMNaClã50mM MgOAcã100mM[NH4]2SO4)éæãéååå©æµç¼©è¿æ»¤å¨(Amicon Ultra-30,MerkMillipore)æµç¼©éææ¶²ãå°æµç¼©çé¶åéå¨å°ç­åè¯æ ·ä¸­ï¼æç»æ·»å 50ï¼ççæ²¹ï¼å¹¶ä¸ç¶åå°è¿äºç­åè¯æ ·å·å»å¨-20âå¹¶é¿æå¨å­ãå¨SDS-PAGEåè¶ä¸­åæ5Î¼Lççº¯åçé¶çä¸åçº§åãTdT protein can be purified from the centrifuge with a one-step affinity procedure. For example, a Ni-NTA affinity column (GE Healthcare) is used to bind polymerase. Initially, the column has been washed and balanced with 50mM Tris-HCl (Sigma) pH 7.5, 150mM NaCl (Sigma) and 20mM imidazoles (Sigma) for 15 column volumes. After balance, polymerase is combined with the column. Then, a wash buffer consisting of 50mM Tris-HCl (Sigma) pH 7.5, 500mM NaCl (Sigma) and 20mM imidazoles (Sigma) is applied to the column for 15 column volumes. After washing, polymerase is eluted with 50mM Tris-HCl (Sigma) pH 7.5, 500mM NaCl (Sigma) and 0.5M imidazoles (Sigma). The fractions corresponding to the polymerase of interest at the highest concentration are collected and merged in a single sample. The combined fractions were dialyzed against dialysis buffer (20 mM Tris-HCl pH 6.8, 200 mM NaCl, 50 mM MgOAc, 100 mM [NH 4 ] 2 SO 4 ). The dialysate was subsequently concentrated with the aid of a concentration filter (Amicon Ultra-30, Merk Millipore). The concentrated enzyme was distributed in small aliquots, 50% glycerol was finally added, and these aliquots were then frozen at -20Â°C and stored for a long term. 5 Î¼L of the different fractions of the purified enzyme were analyzed in SDS-PAGE gels.
      
      
        
           è¯åçãé¶åæ ¸è·é¸ç»åç©Kits, enzymes and nucleotide compositions
        
      
      
         æ¬åæçç¹å®æ¹é¢æ¶ååå«æ ¹æ®æ¬åæææ¬åæçä»»ä½ç¹å®æ¹é¢çTdTçåä½ä»¥åä»»éå°å·æéèªä»¥ä¸çä¸ç§ææ´å¤ç§ç»åçä»»ä½ç»åçç»åç©åè¯åççç¨éï¼èµ·å§çæ®µãä¸ç§ææ´å¤ç§å¯éç»æ­¢åæ ¸è·é¸ãå¦å¤çé¶åè£è§£ååºä¸­ä½¿ç¨çè¯åãæè¿°è¯åçå¯ä»¥ç¨äºå¨é¶ä¿æ ¸é¸åæçæ¹æ³ä¸­ä½¿ç¨ãParticular aspects of the invention relate to the use of compositions and kits comprising a variant of TdT according to the invention or any particular aspect of the invention and optionally with any combination of one or more components selected from the group consisting of a starting fragment, one or more reversible terminator nucleotides, additional enzymes and reagents used in the cleavage reaction. The kits may be for use in a method of enzymatic nucleic acid synthesis.
      
      
         æ¬åææ¶µçåå«æ ¹æ®æ¬åæææ¬åæä»»ä½ç¹å®æ¹é¢çTdTåä½çç©è´¨ç»åç©ï¼å¶ä¸­å¯éä¿®é¥°çæ ¸è·é¸ä¸éå½çç¼å²æ¶²åæ¯ä¾æµåº¦æ··åãThe invention encompasses a composition of matter comprising a TdT variant according to the invention or any specific aspect of the invention, wherein the reversibly modified nucleotides are mixed with an appropriate buffer and proportional concentration.
      
    
    
      
         å·ä½å®æ½æ¹å¼DETAILED DESCRIPTION
      
      
         ä¸è¿°å®æ½ä¾ä¸­æä½¿ç¨çå®éªæ¹æ³å¦æ ç¹æ®è¯´æï¼åä¸ºå¸¸è§æ¹æ³ãUnless otherwise specified, the experimental methods used in the following examples are conventional methods.
      
      
         ä¸è¿°å®æ½ä¾ä¸­æç¨çææãè¯åç­ï¼å¦æ ç¹æ®è¯´æï¼åå¯ä»åä¸éå¾å¾å°ãUnless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
      
      
         å¨ä¸é¢çå®æ½ä¾ä¸­è¿ä¸æ­¥è¯´ææ¬åæï¼ä½å¹¶ä¸éå¶æ¬åæçèå´ãé¨ååå­åéæ¹æ³ç»èä¾æ®è¯åãé¶æè¯åçæä¾åå®¶ä¸åèææå·®å«ï¼åºå½æç§äº§åè¯´æè¿è¡æä½ï¼å¨å®æ½ä¾ä¸­ä¸åè¯¦ç»æè¿°ãå®æ½ä¾ä¸­æè¿°åç§è¯¦ç»çè¡¨è¾¾æ¡ä»¶ãå¹å»æ¡ä»¶ãååºæ¡ä»¶ãæ£æµæ¡ä»¶ä»ä¸ºç¤ºä¾ï¼æ¬åæä¸ä»éäºæ­¤ï¼ææå¯ä»¥å®ç°ç¸åºææçæ¡ä»¶ååæ¬ãThe present invention is further illustrated in the following examples, but the scope of the present invention is not limited thereto. The details of some molecular cloning methods vary depending on the reagents, enzymes or kits provided by different vendors, and should be performed according to the product instructions, and will not be described in detail in the examples. The various detailed expression conditions, culture conditions, reaction conditions, and detection conditions described in the examples are only examples, and the present invention is not limited thereto, and all conditions that can achieve the corresponding effects are included.
      
      
         å®æ½ä¾1ãTdTèç½çç©ç§æ¥æºExample 1: Species origin of TdT protein
      
      
         æ¬åæéç¨çç©ç§æ¥æºåæ°¨åºé¸åºåï¼SEQ ID NO.1(ç½åéï¼ZaTdT)ãThe species source and amino acid sequence used in the present invention are: SEQ ID NO.1 (white-throated sparrow, ZaTdT).
      
      
         æ¬å®æ½ä¾éç¨çé¶ï¼åºå åç±éå¯æºåæï¼åæå»ºè³pET-28aè½½ä½ï¼ä½äºé¶åä½ç¹NdeIåXhoIä¹é´ï¼å¹¶å¨å¤§è æèä¸­è¡¨è¾¾çº¯åèç½ãZaTdTèç½çæå»ºåè¡¨è¾¾çº¯åè½½ä½ä»¥PET-28aè½½ä½ä¸ºä¾ï¼å®¿ä¸»èä»¥å¤§è æèï¼æ¬åæåå«ä½å¹¶ä¸ä»éäºæ­¤ï¼ææå¯ä»¥æåè¡¨è¾¾çº¯åZaTdTèç½çè½½ä½åå®¿ä¸»èååºåå«ãThe enzymes used in this example were synthesized by Jin Weizhi, and were constructed into the pET-28a vector, located between the restriction sites NdeI and XhoI, and the purified protein was expressed in Escherichia coli. The construction and expression and purification vector of ZaTdT protein was taken as an example of PET-28a vector, and the host bacteria was Escherichia coli. The present invention includes but is not limited to this, and all vectors and host bacteria that can successfully express and purify ZaTdT protein should be included.
      
      
         æ¬åæè¿éç¨å°SEQ ID NO.1åNç«¯æªç­é¨åæ°¨åºé¸ï¼åºåå¦SEQ ID NO:2(ZaTdT-JD)æç¤ºï¼æ¬åæè¿éç¨å°SEQ ID NO.1æSEQ ID NO:2çNç«¯æ·»å é¨åæ°¨åºé¸ï¼åºåå¦SEQID NO:3(MBP-ZaTdT)æSEQ ID NO:4(MBP-ZaTdT-JD)æç¤ºãThe present invention also adopts the method of truncating some amino acids at the N-terminus of SEQ ID NO.1, and the sequence is shown in SEQ ID NO:2 (ZaTdT-JD); the present invention also adopts the method of adding some amino acids to the N-terminus of SEQ ID NO.1 or SEQ ID NO:2, and the sequence is shown in SEQID NO:3 (MBP-ZaTdT) or SEQ ID NO:4 (MBP-ZaTdT-JD).
      
      
         å®æ½ä¾2ãé«æ´»æ§åä½çè·å¾Example 2: Obtaining highly active variants
      
      
         æ¬åæå¯¹æ¥èªç½åéçZaTdTè¿è¡åæºå»ºæ¨¡è·å¾å¶ä¸ç»´èç½ç»æï¼åºäºåæäººå·²æç»éªï¼éè¿è®¡ç®æºæ¨¡æçæ§è®¾è®¡ãåç¹æå¤ç¹é¥±åçªåï¼ç»åé«ééç­éç­ææ®µï¼è·å¾å·æé«å¬åæçååºç©ç¹å¼æ§çåä½ï¼æ¬åææåå«çåä½å¦ä¸è¡¨æç¤ºãThe present invention performs homology modeling on ZaTdT from white-throated sparrow to obtain its three-dimensional protein structure. Based on the inventor&#39;s prior experience, variants with high catalytic efficiency and substrate specificity are obtained through computer simulation rational design, single-point or multi-point saturation mutation, combined with high-throughput screening and other means. The variants included in the present invention are shown in the following table.
      
      
         è¡¨1æ¬åææåå«ççªåä½Table 1 Mutants included in the present invention
      
      
        
          
            
          
          
        
      
      
        
          
            
          
          
        
      
      
        
          
            
          
          
        
      
      
        
          
            
          
          
        
      
      
        
          
            
          
          
        
      
      
        
          
            
          
          
        
      
      
        
          
            
          
          
        
      
      
        
          
            
          
          
        
      
      
        
          
            
          
          
        
      
      
         å®æ½ä¾3ãZaTdTåä½èç½çè·å¾Example 3. Obtaining ZaTdT variant protein
      
      
         ä¸ºäºä½å¤æ£æµZaTdTåä½é¶æ´»æ§ï¼å¨å¤§è æèä¸­å¯¹è¯¥é¶è¿è¡å¤æºè¡¨è¾¾åçº¯åãå®æ½ä¾ä¸­æè¿°çå®¿ä¸»èä¸ºE.coli BL21(DE3)ï¼ä½æ¯å®¿ä¸»èå¹¶ä¸ä»éäºæ­¤ï¼ææå¯ä»¥ç¨äºè¡¨è¾¾èç½çå®¿ä¸»ååæ¬ãèç½è¡¨è¾¾ãçº¯åçæ¹æ³åç§ä¸å©ï¼201911034444.6ãIn order to detect the activity of ZaTdT variant enzyme in vitro, the enzyme was exogenously expressed and purified in E. coli. The host bacteria described in the embodiment is E. coli BL21 (DE3), but the host bacteria are not limited to this, and all hosts that can be used to express proteins are included. The protein expression and purification methods refer to patent: 201911034444.6.
      
      
         å®æ½ä¾4ãåè½éªè¯Example 4: Functional Verification
      
      
         æ¬åæå®æ½ä¾æè¿°éç¨åºç©åä»¥è±æ°§æ ¸ç³æ ¸è·é¸(dNTPs)ä¸ºåºç¡ï¼3&#39;-OHç«¯åæ´ä¸ºå¯éç»æ­¢åºå¢ï¼åæ¬èºåå¤è±æ°§æ ¸ç³æ ¸è·é¸ãé¸åå¤è±æ°§æ ¸ç³æ ¸è·é¸ãèå§å¶è±æ°§æ ¸ç³æ ¸è·é¸ãè¸èºå§å¶è±æ°§æ ¸ç³æ ¸è·é¸ãä¼éå°ï¼3&#39;ç«¯çä¿®é¥°åºå¢ä¸ºæ°§æ°¨åºãThe substrates used in the embodiments of the present invention are all based on deoxyribonucleotides (dNTPs), and the 3&#39;-OH end is changed to a reversible termination group, including adenine deoxyribonucleotide, guanine deoxyribonucleotide, cytosine deoxyribonucleotide, and thymine deoxyribonucleotide. Preferably, the modification group at the 3&#39; end is an oxyamino group.
      
      
         1ãç¤ºæå¾1. Schematic diagram
      
      
         å¨èµ·å§åºåå­å¨çæåµä¸ï¼ZaTdTå¬å3âç«¯å¸¦O-æ°¨åºä¿®é¥°åºå¢çè±æ°§æ ¸ç³æ ¸è·é¸å å¥èµ·å§åºå3ç«¯çå¬åååºï¼å¦å¾1æç¤ºãIn the presence of the starting sequence, ZaTdT catalyzes the addition of a deoxyribonucleotide with an O-amino modification group at the 3&#39; end to the 3&#39; end of the starting sequence, as shown in Figure 1.
      
      
         2ãä½å¤çº¯é¶ååº2. In vitro pure enzyme reaction
      
      
         ååºä½ç³»ï¼100mM NaClï¼0.25mM CoCl2ï¼50mM KAcï¼10mM Mg(Ac)2ï¼pH 6.8ãåºç©ï¼1Î¼Mèµ·å§é¾(16ntï¼ACTAGGACGACTCGAATT)ï¼100Î¼M 3âç«¯å¸¦O-æ°¨åºä¿®é¥°åºå¢çè±æ°§æ ¸ç³æ ¸è·é¸ãé¶ï¼50Î¼M TdTèç½åçªåä½ãReaction system: 100mM NaCl, 0.25mM CoCl 2 , 50mM KAc, 10mM Mg(Ac) 2 , pH 6.8. Substrate: 1Î¼M starting chain (16nt: ACTAGGACGACTCGAATT), 100Î¼M deoxyribonucleotide with O-amino modification group at 3&#39; end. Enzyme: 50Î¼M TdT protein and mutant.
      
      
         ååºæ¡ä»¶ï¼å å¥é¶åå¼å§ååºï¼30âååº5ä¸åæ¶é´ï¼éå95âç­æ´»èç½ï¼ç¦»å¿å»æ²æ·ãç¦»å¿åä¸æ¸æ¶²æ ·åéç¨20ï¼å°¿ç´ -èä¸ç¯é°èºåè¶(åæ§PAGE)æ£æµåæï¼300Vçµåè·3hãåè¶ç»1*SYBR Goldæè²20minï¼è¿ä¸æ­¥ç¨Tanonçè§ååè¶æåä»ªåæå¾çåä¸ªDNAæ¡å¸¦çååå¯åº¦ãç¨æºå¥æ ¸è·é¸ä¹åçDNAæ¡å¸¦çååå¯åº¦(17ntå¯¹åºçååå¯åº¦)é¤ä»¥æ»ä½DNAæ¡å¸¦çååå¯åº¦(16ntå17ntå¯¹åºçååå¯åº¦)ï¼è·å¾æ ¸è·é¸æºå¥æçãæºå¥æçä¹ä»¥åºç©æµåº¦é¤ä»¥ååºæ¶é´è·å¾åä½é¶ååºçå¬åæçãReaction conditions: After adding the enzyme, the reaction started, and the reaction was carried out at 30Â°C for 5 different times, followed by inactivation of the protein at 95Â°C and centrifugation to remove the precipitate. After centrifugation, the supernatant sample was detected and analyzed using 20% urea-polyacrylamide gel (denaturing PAGE) and run at 300V for 3h. The gel was stained with 1*SYBR Gold for 20min, and the net optical density of each DNA band in the image was further analyzed using Tanon&#39;s fluorescent gel imager. The net optical density of the DNA band after the incorporation of nucleotides (the net optical density corresponding to 17nt) was divided by the net optical density of the overall DNA band (the net optical density corresponding to 16nt and 17nt) to obtain the nucleotide incorporation efficiency. The incorporation efficiency multiplied by the substrate concentration divided by the reaction time obtained the catalytic efficiency of the variant enzyme reaction.
      
      
         ZaTdTçNç«¯æ°¨åºé¸ç¼ºå¤±ææ·»å çåæ§PAGEåæç»æå¦è¡¨2æç¤ºï¼ç»ææ¾ç¤ºï¼ZaTdTãZaTdTçNç«¯æ°¨åºé¸ç¼ºå¤±ææ·»å çåä½åè½å¤ååºç©ç»åï¼å¹¶ä¸ç»è®¡ç®ï¼Nç«¯ç¼ºå¤±ææ·»å é¨åæ°¨åºé¸ä¸å½±åZaTdTçå¬åæçãThe results of denaturing PAGE analysis of the N-terminal amino acid deletion or addition of ZaTdT are shown in Table 2. The results show that ZaTdT and variants of ZaTdT with N-terminal amino acid deletion or addition can bind to the substrate, and according to calculations, the N-terminal deletion or addition of some amino acids does not affect the catalytic efficiency of ZaTdT.
      
      
         ZaTdTåé¨ååç¹æå¤ç¹åä½çå¬åæçå¦è¡¨3æç¤ºãZaTdTåé¨ååç¹æå¤ç¹åä½çå¬åæçé¤ä»¥éçåTdTçå¬åæçè·å¾TdTçªåä½çç¸å¯¹æ´»æ§ï¼é¨ååä½çç¸å¯¹æ´»æ§å¦å¾2æç¤ºãThe catalytic efficiencies of ZaTdT and some single-site or multi-site variants are shown in Table 3. The catalytic efficiencies of ZaTdT and some single-site or multi-site variants were divided by the catalytic efficiency of wild-type TdT to obtain the relative activities of TdT mutants. The relative activities of some variants are shown in FIG2 .
      
      
         ç»ææ¾ç¤ºï¼ä¸éçåç¸æ¯ï¼å¤ç§åä½çå¬åæçå¾å°äºæ¾èçæåï¼æé«æé«åæ°çº¦60åãThe results showed that compared with the wild type, the catalytic efficiency of multiple variants was significantly improved, with the highest increase being about 60 times.
      
      
         è¡¨2 ZaTdT Nç«¯ç¼ºå¤±ææ·»å æ°¨åºé¸åçå¬åæçTable 2 Catalytic efficiency of ZaTdT after N-terminal deletion or addition of amino acids
      
      
        
          
            
               
               
              
                
                  
                     é¶Enzymes
                  
                  
                     å¬åæçnM/minCatalytic efficiency nM/min
                  
                
                
                  
                     ZaTdTT8h
                  
                  
                     4.40Â±0.234.40Â±0.23
                  
                
                
                  
                     ZaTdT-JDJbXj
                  
                  
                     4.35Â±0.184.35Â±0.18
                  
                
                
                  
                     MBP-ZaTdTMBP-ZaTdT
                  
                  
                     4.65Â±0.314.65Â±0.31
                  
                
                
                  
                     MBP-ZaTdT-JDMBP-ZaTdT-JD
                  
                  
                     4.52Â±0.274.52Â±0.27
                  
                
              
            
          
        
      
      
         è¡¨3 ZaTdTåé¨åçªåä½çå¬åæçTable 3 Catalytic efficiency of ZaTdT and some mutants
      
      
        
          
            
               
               
              
                
                  
                     é¶Enzymes
                  
                  
                     å¬åæçnM/minCatalytic efficiency nM/min
                  
                
                
                  
                     WTWT
                  
                  
                     4.404.40
                  
                
                
                  
                     S1S1
                  
                  
                     24.8224.82
                  
                
                
                  
                     S16S16
                  
                  
                     20.6820.68
                  
                
                
                  
                     S19S19
                  
                  
                     48.8848.88
                  
                
                
                  
                     S23S23
                  
                  
                     31.6831.68
                  
                
                
                  
                     S32S32
                  
                  
                     20.2420.24
                  
                
                
                  
                     S40S40
                  
                  
                     42.3742.37
                  
                
                
                  
                     S43S43
                  
                  
                     6.786.78
                  
                
                
                  
                     S64S64
                  
                  
                     15.5215.52
                  
                
                
                  
                     S76S76
                  
                  
                     88.2288.22
                  
                
                
                  
                     S78S78
                  
                  
                     124.65124.65
                  
                
                
                  
                     S98S98
                  
                  
                     189.95189.95
                  
                
                
                  
                     S100S100
                  
                  
                     260.61260.61
                  
                
                
                  
                     S101S101
                  
                  
                     175.47175.47
                  
                
                
                  
                     S102S102
                  
                  
                     167.95167.95
                  
                
                
                  
                     S169S169
                  
                  
                     188.85188.85
                  
                
                
                  
                     S170S170
                  
                  
                     164.03164.03
                  
                
                
                  
                     S194S194
                  
                  
                     26.9326.93
                  
                
                
                  
                     S209S209
                  
                  
                     39.4239.42
                  
                
                
                  
                     S227S227
                  
                  
                     23.3223.32
                  
                
                
                  
                     S237S237
                  
                  
                     28.7828.78
                  
                
                
                  
                     S251S251
                  
                  
                     41.5441.54
                  
                
                
                  
                     S254S254
                  
                  
                     21.6521.65
                  
                
                
                  
                     S259S259
                  
                  
                     88.6688.66
                  
                
                
                  
                     S265S265
                  
                  
                     156.68156.68
                  
                
              
            
          
        
      
      
         å®æ½ä¾5ãTdTåä½å¨åé¾æ ¸è·é¸åæä¸­çåºç¨Example 5: Application of TdT variants in single-stranded nucleotide synthesis
      
      
         (1)åºå®ï¼å¸¦æçç©ç´ æ è®°çèµ·å§é¾ä¸é¾éäº²åç´ ç£ç ç»åï¼30â20minï¼(1) Fixation: the biotin-labeled starting strand is bound to streptavidin magnetic beads at 30Â°C for 20 min;
      
      
         (2)ååºï¼å°ç»åæèµ·å§é¾çç£ç ç½®äºå¦ä¸ååºä½ç³»ï¼50mM PBSï¼0.25mM CoCl2ï¼0.25mM 3â-OHè¢«O-æ°¨åºä¿®é¥°çæ ¸è·é¸ï¼1.5mg/mL TdTåä½(S100)ã30âååº10minã(2) Reaction: The magnetic beads bound with the initiator chain were placed in the following reaction system: 50 mM PBS, 0.25 mM CoCl 2 , 0.25 mM nucleotides whose 3&#39;-OH was modified with O-amino group, and 1.5 mg/mL TdT variant (S100). The reaction was carried out at 30Â°C for 10 min.
      
      
         (3)è±ä¿æ¤ï¼ç¨0.7Mäºç¡é¸æº¶æ¶²è±ä¿æ¤ï¼åç¨ç£·é¸çBufferæ´ä¸¤éã(3) Deprotection: deprotect with 0.7 M nitrous acid solution; then wash twice with phosphate buffer.
      
      
         (4)éå¤(2)(3)æ­¥éª¤ï¼å¾ªç¯9æ¬¡ã(4) Repeat steps (2) and (3) for 9 times.
      
      
         (5)æ¯ä¸ªå¾ªç¯æ ·åè¿è¡20ï¼å°¿ç´ -èä¸ç¯é°èºåè¶(åæ§PAGE)æ£æµï¼ç»1*SYBRGoldæè²åç»æå¦å¾3æç¤ºã(5) Each cycle sample was subjected to 20% urea-polyacrylamide gel (denaturing PAGE) detection, and the results after 1*SYBR Gold staining are shown in FIG3 .
      
      
         ç»ææ¾ç¤ºï¼TdTåä½S100å¯ä»¥å®æ10ä¸ªæ ¸è·é¸çåæï¼å¯ä»¥åºç¨å°åé¾æ ¸è·é¸åæä¸­ãç±æ­¤å¯ç¥ï¼è¡¨1æè¡¨3ä¸­åå«çä¸S100åä½ç¸åçå·æå¨åé¾å¯¡æ ¸è·é¸æ«ç«¯æºå¥ä¿®é¥°æ ¸è·é¸åè½çåä½ï¼åå¯ä»¥åºç¨å°åé¾DNAåæä¸­ãThe results show that the TdT variant S100 can complete the synthesis of 10 nucleotides and can be applied to single-stranded nucleotide synthesis. Therefore, it can be seen that the variants included in Table 1 or Table 3 that have the same function of incorporating modified nucleotides at the end of single-stranded oligonucleotides as the S100 variant can all be applied to single-stranded DNA synthesis.
      
      
         ä»¥ä¸ï¼å¯¹æ¬åæçå®æ½æ¹å¼è¿è¡äºè¯´æãä½æ¯ï¼æ¬åæä¸éå®äºä¸è¿°å®æ½æ¹å¼ãå¡å¨æ¬åæçç²¾ç¥åååä¹åï¼æåçä»»ä½ä¿®æ¹ãç­åæ¿æ¢ãæ¹è¿ç­ï¼ååºåå«å¨æ¬åæçä¿æ¤èå´ä¹åãThe above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
      
      
         SEQUENCE LISTINGSEQUENCE LISTING
      
      
         &lt;110&gt; ä¸­å½ç§å­¦é¢å¤©æ´¥å·¥ä¸çç©ææ¯ç ç©¶æ&lt;110&gt; Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences
      
      
         &lt;120&gt; å¯æ§åæåé¾DNAçæ«ç«¯è½¬ç§»é¶åä½ååºç¨&lt;120&gt; Terminal transferase variants for controllable synthesis of single-stranded DNA and their applications
      
      
         &lt;130&gt; CPCN21411298&lt;130&gt; CPCN21411298
      
      
         &lt;160&gt; 4&lt;160&gt; 4
      
      
         &lt;170&gt; PatentIn version 3.5&lt;170&gt; PatentIn version 3.5
      
      
         &lt;210&gt; 1&lt;210&gt; 1
      
      
         &lt;211&gt; 513&lt;211&gt; 513
      
      
         &lt;212&gt; PRT&lt;212&gt; PRT
      
      
         &lt;213&gt; äººå·¥åæ&lt;213&gt; Synthesis
      
      
         &lt;400&gt; 1&lt;400&gt; 1
      
      
         Met Asp Arg Phe Lys Ala Pro Ala Val Ile Ser Gln Arg Lys Arg GlnMet Asp Arg Phe Lys Ala Pro Ala Val Ile Ser Gln Arg Lys Arg Gln
      
      
         1               5                   10                  151 5 10 15
      
      
         Lys Gly Leu His Ser Pro Lys Leu Ser Cys Ser Tyr Glu Ile Lys PheLys Gly Leu His Ser Pro Lys Leu Ser Cys Ser Tyr Glu Ile Lys Phe
      
      
                     20                  25                  3020 25 30
      
      
         Ser Asn Phe Val Ile Phe Ile Met Gln Arg Lys Met Gly Leu Thr ArgSer Asn Phe Val Ile Phe Ile Met Gln Arg Lys Met Gly Leu Thr Arg
      
      
                 35                  40                  4535 40 45
      
      
         Arg Met Phe Leu Met Glu Leu Gly Arg Arg Lys Gly Phe Arg Val GluArg Met Phe Leu Met Glu Leu Gly Arg Arg Lys Gly Phe Arg Val Glu
      
      
             50                  55                  6050 55 60
      
      
         Ser Glu Leu Ser Asp Ser Val Thr His Ile Val Ala Glu Asn Asn SerSer Glu Leu Ser Asp Ser Val Thr His Ile Val Ala Glu Asn Asn Ser
      
      
         65                  70                  75                  8065 70 75 80
      
      
         Tyr Leu Glu Val Leu Asp Trp Leu Lys Gly Gln Ala Val Gly Asp SerTyr Leu Glu Val Leu Asp Trp Leu Lys Gly Gln Ala Val Gly Asp Ser
      
      
                         85                  90                  9585 90 95
      
      
         Ser Arg Phe Glu Leu Leu Asp Ile Ser Trp Phe Thr Ala Cys Met GluSer Arg Phe Glu Leu Leu Asp Ile Ser Trp Phe Thr Ala Cys Met Glu
      
      
                     100                 105                 110100 105 110
      
      
         Ala Gly Arg Pro Val Asp Ser Glu Val Lys Tyr Arg Leu Met Glu GlnAla Gly Arg Pro Val Asp Ser Glu Val Lys Tyr Arg Leu Met Glu Gln
      
      
                 115                 120                 125115 120 125
      
      
         Ser Gln Ser Leu Pro Leu Asn Met Pro Ala Leu Glu Met Pro Ala PheSer Gln Ser Leu Pro Leu Asn Met Pro Ala Leu Glu Met Pro Ala Phe
      
      
             130                 135                 140130 135 140
      
      
         Ile Ala Thr Lys Val Ser Gln Tyr Ser Cys Gln Arg Lys Thr Thr LeuIle Ala Thr Lys Val Ser Gln Tyr Ser Cys Gln Arg Lys Thr Thr Leu
      
      
         145                 150                 155                 160145 150 155 160
      
      
         Asn Asn Tyr Asn Lys Lys Phe Thr Asp Ala Phe Glu Val Met Ala GluAsn Asn Tyr Asn Lys Lys Phe Thr Asp Ala Phe Glu Val Met Ala Glu
      
      
                         165                 170                 175165 170 175
      
      
         Asn Tyr Glu Phe Lys Glu Asn Glu Ile Phe Cys Leu Glu Phe Leu ArgAsn Tyr Glu Phe Lys Glu Asn Glu Ile Phe Cys Leu Glu Phe Leu Arg
      
      
                     180                 185                 190180 185 190
      
      
         Ala Ala Ser Leu Leu Lys Ser Leu Pro Phe Ser Val Thr Arg Met LysAla Ala Ser Leu Leu Lys Ser Leu Pro Phe Ser Val Thr Arg Met Lys
      
      
                 195                 200                 205195 200 205
      
      
         Asp Ile Gln Gly Leu Pro Cys Val Gly Asp Gln Val Arg Asp Ile IleAsp Ile Gln Gly Leu Pro Cys Val Gly Asp Gln Val Arg Asp Ile Ile
      
      
             210                 215                 220210 215 220
      
      
         Glu Glu Ile Ile Glu Glu Gly Glu Ser Ser Arg Val Asn Glu Val LeuGlu Glu Ile Ile Glu Glu Gly Glu Ser Ser Arg Val Asn Glu Val Leu
      
      
         225                 230                 235                 240225 230 235 240
      
      
         Asn Asp Glu Arg Tyr Lys Ala Phe Lys Gln Phe Thr Ser Val Phe GlyAsn Asp Glu Arg Tyr Lys Ala Phe Lys Gln Phe Thr Ser Val Phe Gly
      
      
                         245                 250                 255245 250 255
      
      
         Val Gly Val Lys Thr Ser Glu Lys Trp Tyr Arg Met Gly Leu Arg ThrVal Gly Val Lys Thr Ser Glu Lys Trp Tyr Arg Met Gly Leu Arg Thr
      
      
                     260                 265                 270260 265 270
      
      
         Val Glu Glu Val Lys Ala Asp Lys Thr Leu Lys Leu Ser Lys Met GlnVal Glu Glu Val Lys Ala Asp Lys Thr Leu Lys Leu Ser Lys Met Gln
      
      
                 275                 280                 285275 280 285
      
      
         Lys Ala Gly Leu Leu Tyr Tyr Glu Asp Leu Val Ser Cys Val Ser LysLys Ala Gly Leu Leu Tyr Tyr Glu Asp Leu Val Ser Cys Val Ser Lys
      
      
             290                 295                 300290 295 300
      
      
         Ala Glu Ala Asp Ala Val Ser Leu Ile Val Lys Asn Thr Val Cys ThrAla Glu Ala Asp Ala Val Ser Leu Ile Val Lys Asn Thr Val Cys Thr
      
      
         305                 310                 315                 320305 310 315 320
      
      
         Phe Leu Pro Asp Ala Leu Val Thr Ile Thr Gly Gly Phe Arg Arg GlyPhe Leu Pro Asp Ala Leu Val Thr Ile Thr Gly Gly Phe Arg Arg Gly
      
      
                         325                 330                 335325 330 335
      
      
         Lys Asn Ile Gly His Asp Ile Asp Phe Leu Ile Thr Asn Pro Gly ProLys Asn Ile Gly His Asp Ile Asp Phe Leu Ile Thr Asn Pro Gly Pro
      
      
                     340                 345                 350340 345 350
      
      
         Arg Glu Asp Asp Glu Leu Leu His Lys Val Ile Asp Leu Trp Lys LysArg Glu Asp Asp Glu Leu Leu His Lys Val Ile Asp Leu Trp Lys Lys
      
      
                 355                 360                 365355 360 365
      
      
         Gln Gly Leu Leu Leu Tyr Cys Asp Ile Ile Glu Ser Thr Phe Val LysGln Gly Leu Leu Leu Tyr Cys Asp Ile Ile Glu Ser Thr Phe Val Lys
      
      
             370                 375                 380370 375 380
      
      
         Glu Gln Leu Pro Ser Arg Lys Val Asp Ala Met Asp His Phe Gln LysGlu Gln Leu Pro Ser Arg Lys Val Asp Ala Met Asp His Phe Gln Lys
      
      
         385                 390                 395                 400385 390 395 400
      
      
         Cys Phe Ala Ile Leu Lys Leu Tyr Gln Pro Arg Val Asp Asn Ser ThrCys Phe Ala Ile Leu Lys Leu Tyr Gln Pro Arg Val Asp Asn Ser Thr
      
      
                         405                 410                 415405 410 415
      
      
         Cys Asn Thr Ser Glu Gln Leu Glu Met Ala Glu Val Lys Asp Trp LysCys Asn Thr Ser Glu Gln Leu Glu Met Ala Glu Val Lys Asp Trp Lys
      
      
                     420                 425                 430420 425 430
      
      
         Ala Ile Arg Val Asp Leu Val Ile Thr Pro Phe Glu Gln Tyr Pro TyrAla Ile Arg Val Asp Leu Val Ile Thr Pro Phe Glu Gln Tyr Pro Tyr
      
      
                 435                 440                 445435 440 445
      
      
         Ala Leu Leu Gly Trp Thr Gly Ser Arg Gln Phe Gly Arg Asp Leu ArgAla Leu Leu Gly Trp Thr Gly Ser Arg Gln Phe Gly Arg Asp Leu Arg
      
      
             450                 455                 460450 455 460
      
      
         Arg Tyr Ala Ala His Glu Arg Lys Met Ile Leu Asp Asn His Gly LeuArg Tyr Ala Ala His Glu Arg Lys Met Ile Leu Asp Asn His Gly Leu
      
      
         465                 470                 475                 480465 470 475 480
      
      
         Tyr Asp Arg Arg Lys Arg Ile Phe Leu Lys Ala Gly Ser Glu Glu GluTyr Asp Arg Arg Lys Arg Ile Phe Leu Lys Ala Gly Ser Glu Glu Glu
      
      
                         485                 490                 495485 490 495
      
      
         Ile Phe Ala His Leu Gly Leu Asp Tyr Val Glu Pro Trp Glu Arg AsnIle Phe Ala His Leu Gly Leu Asp Tyr Val Glu Pro Trp Glu Arg Asn
      
      
                     500                 505                 510500 505 510
      
      
         AlaAla
      
      
         &lt;210&gt; 2&lt;210&gt; 2
      
      
         &lt;211&gt; 382&lt;211&gt; 382
      
      
         &lt;212&gt; PRT&lt;212&gt; PRT
      
      
         &lt;213&gt; äººå·¥åæ&lt;213&gt; Synthesis
      
      
         &lt;400&gt; 2&lt;400&gt; 2
      
      
         Leu Pro Leu Asn Met Pro Ala Leu Glu Met Pro Ala Phe Ile Ala ThrLeu Pro Leu Asn Met Pro Ala Leu Glu Met Pro Ala Phe Ile Ala Thr
      
      
         1               5                   10                  151 5 10 15
      
      
         Lys Val Ser Gln Tyr Ser Cys Gln Arg Lys Thr Thr Leu Asn Asn TyrLys Val Ser Gln Tyr Ser Cys Gln Arg Lys Thr Thr Leu Asn Asn Tyr
      
      
                     20                  25                  3020 25 30
      
      
         Asn Lys Lys Phe Thr Asp Ala Phe Glu Val Met Ala Glu Asn Tyr GluAsn Lys Lys Phe Thr Asp Ala Phe Glu Val Met Ala Glu Asn Tyr Glu
      
      
                 35                  40                  4535 40 45
      
      
         Phe Lys Glu Asn Glu Ile Phe Cys Leu Glu Phe Leu Arg Ala Ala SerPhe Lys Glu Asn Glu Ile Phe Cys Leu Glu Phe Leu Arg Ala Ala Ser
      
      
             50                  55                  6050 55 60
      
      
         Leu Leu Lys Ser Leu Pro Phe Ser Val Thr Arg Met Lys Asp Ile GlnLeu Leu Lys Ser Leu Pro Phe Ser Val Thr Arg Met Lys Asp Ile Gln
      
      
         65                  70                  75                  8065 70 75 80
      
      
         Gly Leu Pro Cys Val Gly Asp Gln Val Arg Asp Ile Ile Glu Glu IleGly Leu Pro Cys Val Gly Asp Gln Val Arg Asp Ile Ile Glu Glu Ile
      
      
                         85                  90                  9585 90 95
      
      
         Ile Glu Glu Gly Glu Ser Ser Arg Val Asn Glu Val Leu Asn Asp GluIle Glu Glu Gly Glu Ser Ser Arg Val Asn Glu Val Leu Asn Asp Glu
      
      
                     100                 105                 110100 105 110
      
      
         Arg Tyr Lys Ala Phe Lys Gln Phe Thr Ser Val Phe Gly Val Gly ValArg Tyr Lys Ala Phe Lys Gln Phe Thr Ser Val Phe Gly Val Gly Val
      
      
                 115                 120                 125115 120 125
      
      
         Lys Thr Ser Glu Lys Trp Tyr Arg Met Gly Leu Arg Thr Val Glu GluLys Thr Ser Glu Lys Trp Tyr Arg Met Gly Leu Arg Thr Val Glu Glu
      
      
             130                 135                 140130 135 140
      
      
         Val Lys Ala Asp Lys Thr Leu Lys Leu Ser Lys Met Gln Lys Ala GlyVal Lys Ala Asp Lys Thr Leu Lys Leu Ser Lys Met Gln Lys Ala Gly
      
      
         145                 150                 155                 160145 150 155 160
      
      
         Leu Leu Tyr Tyr Glu Asp Leu Val Ser Cys Val Ser Lys Ala Glu AlaLeu Leu Tyr Tyr Glu Asp Leu Val Ser Cys Val Ser Lys Ala Glu Ala
      
      
                         165                 170                 175165 170 175
      
      
         Asp Ala Val Ser Leu Ile Val Lys Asn Thr Val Cys Thr Phe Leu ProAsp Ala Val Ser Leu Ile Val Lys Asn Thr Val Cys Thr Phe Leu Pro
      
      
                     180                 185                 190180 185 190
      
      
         Asp Ala Leu Val Thr Ile Thr Gly Gly Phe Arg Arg Gly Lys Asn IleAsp Ala Leu Val Thr Ile Thr Gly Gly Phe Arg Arg Gly Lys Asn Ile
      
      
                 195                 200                 205195 200 205
      
      
         Gly His Asp Ile Asp Phe Leu Ile Thr Asn Pro Gly Pro Arg Glu AspGly His Asp Ile Asp Phe Leu Ile Thr Asn Pro Gly Pro Arg Glu Asp
      
      
             210                 215                 220210 215 220
      
      
         Asp Glu Leu Leu His Lys Val Ile Asp Leu Trp Lys Lys Gln Gly LeuAsp Glu Leu Leu His Lys Val Ile Asp Leu Trp Lys Lys Gln Gly Leu
      
      
         225                 230                 235                 240225 230 235 240
      
      
         Leu Leu Tyr Cys Asp Ile Ile Glu Ser Thr Phe Val Lys Glu Gln LeuLeu Leu Tyr Cys Asp Ile Ile Glu Ser Thr Phe Val Lys Glu Gln Leu
      
      
                         245                 250                 255245 250 255
      
      
         Pro Ser Arg Lys Val Asp Ala Met Asp His Phe Gln Lys Cys Phe AlaPro Ser Arg Lys Val Asp Ala Met Asp His Phe Gln Lys Cys Phe Ala
      
      
                     260                 265                 270260 265 270
      
      
         Ile Leu Lys Leu Tyr Gln Pro Arg Val Asp Asn Ser Thr Cys Asn ThrIle Leu Lys Leu Tyr Gln Pro Arg Val Asp Asn Ser Thr Cys Asn Thr
      
      
                 275                 280                 285275 280 285
      
      
         Ser Glu Gln Leu Glu Met Ala Glu Val Lys Asp Trp Lys Ala Ile ArgSer Glu Gln Leu Glu Met Ala Glu Val Lys Asp Trp Lys Ala Ile Arg
      
      
             290                 295                 300290 295 300
      
      
         Val Asp Leu Val Ile Thr Pro Phe Glu Gln Tyr Pro Tyr Ala Leu LeuVal Asp Leu Val Ile Thr Pro Phe Glu Gln Tyr Pro Tyr Ala Leu Leu
      
      
         305                 310                 315                 320305 310 315 320
      
      
         Gly Trp Thr Gly Ser Arg Gln Phe Gly Arg Asp Leu Arg Arg Tyr AlaGly Trp Thr Gly Ser Arg Gln Phe Gly Arg Asp Leu Arg Arg Tyr Ala
      
      
                         325                 330                 335325 330 335
      
      
         Ala His Glu Arg Lys Met Ile Leu Asp Asn His Gly Leu Tyr Asp ArgAla His Glu Arg Lys Met Ile Leu Asp Asn His Gly Leu Tyr Asp Arg
      
      
                     340                 345                 350340 345 350
      
      
         Arg Lys Arg Ile Phe Leu Lys Ala Gly Ser Glu Glu Glu Ile Phe AlaArg Lys Arg Ile Phe Leu Lys Ala Gly Ser Glu Glu Glu Ile Phe Ala
      
      
                 355                 360                 365355 360 365
      
      
         His Leu Gly Leu Asp Tyr Val Glu Pro Trp Glu Arg Asn AlaHis Leu Gly Leu Asp Tyr Val Glu Pro Trp Glu Arg Asn Ala
      
      
             370                 375                 380370 375 380
      
      
         &lt;210&gt; 3&lt;210&gt; 3
      
      
         &lt;211&gt; 896&lt;211&gt; 896
      
      
         &lt;212&gt; PRT&lt;212&gt; PRT
      
      
         &lt;213&gt; äººå·¥åæ&lt;213&gt; Synthesis
      
      
         &lt;400&gt; 3&lt;400&gt; 3
      
      
         Met Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp LysMet Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys
      
      
         1               5                   10                  151 5 10 15
      
      
         Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp ThrGly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr
      
      
                     20                  25                  3020 25 30
      
      
         Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys PheGly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe
      
      
                 35                  40                  4535 40 45
      
      
         Pro Gln Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp AlaPro Gln Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala
      
      
             50                  55                  6050 55 60
      
      
         His Asp Arg Phe Gly Gly Tyr Ala Gln Ser Gly Leu Leu Ala Glu IleHis Asp Arg Phe Gly Gly Tyr Ala Gln Ser Gly Leu Leu Ala Glu Ile
      
      
         65                  70                  75                  8065 70 75 80
      
      
         Thr Pro Asp Lys Ala Phe Gln Asp Lys Leu Tyr Pro Phe Thr Trp AspThr Pro Asp Lys Ala Phe Gln Asp Lys Leu Tyr Pro Phe Thr Trp Asp
      
      
                         85                  90                  9585 90 95
      
      
         Ala Val Arg Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val GluAla Val Arg Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu
      
      
                     100                 105                 110100 105 110
      
      
         Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro LysAla Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys
      
      
                 115                 120                 125115 120 125
      
      
         Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys GlyThr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly
      
      
             130                 135                 140130 135 140
      
      
         Lys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Trp ProLys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Trp Pro
      
      
         145                 150                 155                 160145 150 155 160
      
      
         Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly LysLeu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys
      
      
                         165                 170                 175165 170 175
      
      
         Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala GlyTyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly
      
      
                     180                 185                 190180 185 190
      
      
         Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala AspLeu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp
      
      
                 195                 200                 205195 200 205
      
      
         Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr AlaThr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr Ala
      
      
             210                 215                 220210 215 220
      
      
         Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser LysMet Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys
      
      
         225                 230                 235                 240225 230 235 240
      
      
         Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gln Pro SerVal Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gln Pro Ser
      
      
                         245                 250                 255245 250 255
      
      
         Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser ProLys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro
      
      
                     260                 265                 270260 265 270
      
      
         Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr AspAsn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp
      
      
                 275                 280                 285275 280 285
      
      
         Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val AlaGlu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala
      
      
             290                 295                 300290 295 300
      
      
         Leu Lys Ser Tyr Glu Glu Glu Leu Val Lys Asp Pro Arg Ile Ala AlaLeu Lys Ser Tyr Glu Glu Glu Leu Val Lys Asp Pro Arg Ile Ala Ala
      
      
         305                 310                 315                 320305 310 315 320
      
      
         Thr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro GlnThr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro Gln
      
      
                         325                 330                 335325 330 335
      
      
         Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala AlaMet Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala
      
      
                     340                 345                 350340 345 350
      
      
         Ser Gly Arg Gln Thr Val Asp Glu Ala Leu Lys Asp Ala Gln Thr AsnSer Gly Arg Gln Thr Val Asp Glu Ala Leu Lys Asp Ala Gln Thr Asn
      
      
                 355                 360                 365355 360 365
      
      
         Ser Ser Ser Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Leu Gly MetSer Ser Ser Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Leu Gly Met
      
      
             370                 375                 380370 375 380
      
      
         Asp Arg Phe Lys Ala Pro Ala Val Ile Ser Gln Arg Lys Arg Gln LysAsp Arg Phe Lys Ala Pro Ala Val Ile Ser Gln Arg Lys Arg Gln Lys
      
      
         385                 390                 395                 400385 390 395 400
      
      
         Gly Leu His Ser Pro Lys Leu Ser Cys Ser Tyr Glu Ile Lys Phe SerGly Leu His Ser Pro Lys Leu Ser Cys Ser Tyr Glu Ile Lys Phe Ser
      
      
                         405                 410                 415405 410 415
      
      
         Asn Phe Val Ile Phe Ile Met Gln Arg Lys Met Gly Leu Thr Arg ArgAsn Phe Val Ile Phe Ile Met Gln Arg Lys Met Gly Leu Thr Arg Arg
      
      
                     420                 425                 430420 425 430
      
      
         Met Phe Leu Met Glu Leu Gly Arg Arg Lys Gly Phe Arg Val Glu SerMet Phe Leu Met Glu Leu Gly Arg Arg Lys Gly Phe Arg Val Glu Ser
      
      
                 435                 440                 445435 440 445
      
      
         Glu Leu Ser Asp Ser Val Thr His Ile Val Ala Glu Asn Asn Ser TyrGlu Leu Ser Asp Ser Val Thr His Ile Val Ala Glu Asn Asn Ser Tyr
      
      
             450                 455                 460450 455 460
      
      
         Leu Glu Val Leu Asp Trp Leu Lys Gly Gln Ala Val Gly Asp Ser SerLeu Glu Val Leu Asp Trp Leu Lys Gly Gln Ala Val Gly Asp Ser Ser
      
      
         465                 470                 475                 480465 470 475 480
      
      
         Arg Phe Glu Leu Leu Asp Ile Ser Trp Phe Thr Ala Cys Met Glu AlaArg Phe Glu Leu Leu Asp Ile Ser Trp Phe Thr Ala Cys Met Glu Ala
      
      
                         485                 490                 495485 490 495
      
      
         Gly Arg Pro Val Asp Ser Glu Val Lys Tyr Arg Leu Met Glu Gln SerGly Arg Pro Val Asp Ser Glu Val Lys Tyr Arg Leu Met Glu Gln Ser
      
      
                     500                 505                 510500 505 510
      
      
         Gln Ser Leu Pro Leu Asn Met Pro Ala Leu Glu Met Pro Ala Phe IleGln Ser Leu Pro Leu Asn Met Pro Ala Leu Glu Met Pro Ala Phe Ile
      
      
                 515                 520                 525515 520 525
      
      
         Ala Thr Lys Val Ser Gln Tyr Ser Cys Gln Arg Lys Thr Thr Leu AsnAla Thr Lys Val Ser Gln Tyr Ser Cys Gln Arg Lys Thr Thr Leu Asn
      
      
             530                 535                 540530 535 540
      
      
         Asn Tyr Asn Lys Lys Phe Thr Asp Ala Phe Glu Val Met Ala Glu AsnAsn Tyr Asn Lys Lys Phe Thr Asp Ala Phe Glu Val Met Ala Glu Asn
      
      
         545                 550                 555                 560545 550 555 560
      
      
         Tyr Glu Phe Lys Glu Asn Glu Ile Phe Cys Leu Glu Phe Leu Arg AlaTyr Glu Phe Lys Glu Asn Glu Ile Phe Cys Leu Glu Phe Leu Arg Ala
      
      
                         565                 570                 575565 570 575
      
      
         Ala Ser Leu Leu Lys Ser Leu Pro Phe Ser Val Thr Arg Met Lys AspAla Ser Leu Leu Lys Ser Leu Pro Phe Ser Val Thr Arg Met Lys Asp
      
      
                     580                 585                 590580 585 590
      
      
         Ile Gln Gly Leu Pro Cys Val Gly Asp Gln Val Arg Asp Ile Ile GluIle Gln Gly Leu Pro Cys Val Gly Asp Gln Val Arg Asp Ile Ile Glu
      
      
                 595                 600                 605595 600 605
      
      
         Glu Ile Ile Glu Glu Gly Glu Ser Ser Arg Val Asn Glu Val Leu AsnGlu Ile Ile Glu Glu Gly Glu Ser Ser Arg Val Asn Glu Val Leu Asn
      
      
             610                 615                 620610 615 620
      
      
         Asp Glu Arg Tyr Lys Ala Phe Lys Gln Phe Thr Ser Val Phe Gly ValAsp Glu Arg Tyr Lys Ala Phe Lys Gln Phe Thr Ser Val Phe Gly Val
      
      
         625                 630                 635                 640625 630 635 640
      
      
         Gly Val Lys Thr Ser Glu Lys Trp Tyr Arg Met Gly Leu Arg Thr ValGly Val Lys Thr Ser Glu Lys Trp Tyr Arg Met Gly Leu Arg Thr Val
      
      
                         645                 650                 655645 650 655
      
      
         Glu Glu Val Lys Ala Asp Lys Thr Leu Lys Leu Ser Lys Met Gln LysGlu Glu Val Lys Ala Asp Lys Thr Leu Lys Leu Ser Lys Met Gln Lys
      
      
                     660                 665                 670660 665 670
      
      
         Ala Gly Leu Leu Tyr Tyr Glu Asp Leu Val Ser Cys Val Ser Lys AlaAla Gly Leu Leu Tyr Tyr Glu Asp Leu Val Ser Cys Val Ser Lys Ala
      
      
                 675                 680                 685675 680 685
      
      
         Glu Ala Asp Ala Val Ser Leu Ile Val Lys Asn Thr Val Cys Thr PheGlu Ala Asp Ala Val Ser Leu Ile Val Lys Asn Thr Val Cys Thr Phe
      
      
             690                 695                 700690 695 700
      
      
         Leu Pro Asp Ala Leu Val Thr Ile Thr Gly Gly Phe Arg Arg Gly LysLeu Pro Asp Ala Leu Val Thr Ile Thr Gly Gly Phe Arg Arg Gly Lys
      
      
         705                 710                 715                 720705 710 715 720
      
      
         Asn Ile Gly His Asp Ile Asp Phe Leu Ile Thr Asn Pro Gly Pro ArgAsn Ile Gly His Asp Ile Asp Phe Leu Ile Thr Asn Pro Gly Pro Arg
      
      
                         725                 730                 735725 730 735
      
      
         Glu Asp Asp Glu Leu Leu His Lys Val Ile Asp Leu Trp Lys Lys GlnGlu Asp Asp Glu Leu Leu His Lys Val Ile Asp Leu Trp Lys Lys Gln
      
      
                     740                 745                 750740 745 750
      
      
         Gly Leu Leu Leu Tyr Cys Asp Ile Ile Glu Ser Thr Phe Val Lys GluGly Leu Leu Leu Tyr Cys Asp Ile Ile Glu Ser Thr Phe Val Lys Glu
      
      
                 755                 760                 765755 760 765
      
      
         Gln Leu Pro Ser Arg Lys Val Asp Ala Met Asp His Phe Gln Lys CysGln Leu Pro Ser Arg Lys Val Asp Ala Met Asp His Phe Gln Lys Cys
      
      
             770                 775                 780770 775 780
      
      
         Phe Ala Ile Leu Lys Leu Tyr Gln Pro Arg Val Asp Asn Ser Thr CysPhe Ala Ile Leu Lys Leu Tyr Gln Pro Arg Val Asp Asn Ser Thr Cys
      
      
         785                 790                 795                 800785 790 795 800
      
      
         Asn Thr Ser Glu Gln Leu Glu Met Ala Glu Val Lys Asp Trp Lys AlaAsn Thr Ser Glu Gln Leu Glu Met Ala Glu Val Lys Asp Trp Lys Ala
      
      
                         805                 810                 815805 810 815
      
      
         Ile Arg Val Asp Leu Val Ile Thr Pro Phe Glu Gln Tyr Pro Tyr AlaIle Arg Val Asp Leu Val Ile Thr Pro Phe Glu Gln Tyr Pro Tyr Ala
      
      
                     820                 825                 830820 825 830
      
      
         Leu Leu Gly Trp Thr Gly Ser Arg Gln Phe Gly Arg Asp Leu Arg ArgLeu Leu Gly Trp Thr Gly Ser Arg Gln Phe Gly Arg Asp Leu Arg Arg
      
      
                 835                 840                 845835 840 845
      
      
         Tyr Ala Ala His Glu Arg Lys Met Ile Leu Asp Asn His Gly Leu TyrTyr Ala Ala His Glu Arg Lys Met Ile Leu Asp Asn His Gly Leu Tyr
      
      
             850                 855                 860850 855 860
      
      
         Asp Arg Arg Lys Arg Ile Phe Leu Lys Ala Gly Ser Glu Glu Glu IleAsp Arg Arg Lys Arg Ile Phe Leu Lys Ala Gly Ser Glu Glu Glu Ile
      
      
         865                 870                 875                 880865 870 875 880
      
      
         Phe Ala His Leu Gly Leu Asp Tyr Val Glu Pro Trp Glu Arg Asn AlaPhe Ala His Leu Gly Leu Asp Tyr Val Glu Pro Trp Glu Arg Asn Ala
      
      
                         885                 890                 895885 890 895
      
      
         &lt;210&gt; 4&lt;210&gt; 4
      
      
         &lt;211&gt; 765&lt;211&gt; 765
      
      
         &lt;212&gt; PRT&lt;212&gt; PRT
      
      
         &lt;213&gt; äººå·¥åæ&lt;213&gt; Synthesis
      
      
         &lt;400&gt; 4&lt;400&gt; 4
      
      
         Met Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp LysMet Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys
      
      
         1               5                   10                  151 5 10 15
      
      
         Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp ThrGly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr
      
      
                     20                  25                  3020 25 30
      
      
         Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys PheGly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe
      
      
                 35                  40                  4535 40 45
      
      
         Pro Gln Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp AlaPro Gln Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala
      
      
             50                  55                  6050 55 60
      
      
         His Asp Arg Phe Gly Gly Tyr Ala Gln Ser Gly Leu Leu Ala Glu IleHis Asp Arg Phe Gly Gly Tyr Ala Gln Ser Gly Leu Leu Ala Glu Ile
      
      
         65                  70                  75                  8065 70 75 80
      
      
         Thr Pro Asp Lys Ala Phe Gln Asp Lys Leu Tyr Pro Phe Thr Trp AspThr Pro Asp Lys Ala Phe Gln Asp Lys Leu Tyr Pro Phe Thr Trp Asp
      
      
                         85                  90                  9585 90 95
      
      
         Ala Val Arg Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val GluAla Val Arg Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu
      
      
                     100                 105                 110100 105 110
      
      
         Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro LysAla Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys
      
      
                 115                 120                 125115 120 125
      
      
         Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys GlyThr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly
      
      
             130                 135                 140130 135 140
      
      
         Lys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Trp ProLys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Trp Pro
      
      
         145                 150                 155                 160145 150 155 160
      
      
         Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly LysLeu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys
      
      
                         165                 170                 175165 170 175
      
      
         Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala GlyTyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly
      
      
                     180                 185                 190180 185 190
      
      
         Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala AspLeu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp
      
      
                 195                 200                 205195 200 205
      
      
         Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr AlaThr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr Ala
      
      
             210                 215                 220210 215 220
      
      
         Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser LysMet Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys
      
      
         225                 230                 235                 240225 230 235 240
      
      
         Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gln Pro SerVal Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gln Pro Ser
      
      
                         245                 250                 255245 250 255
      
      
         Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser ProLys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro
      
      
                     260                 265                 270260 265 270
      
      
         Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr AspAsn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp
      
      
                 275                 280                 285275 280 285
      
      
         Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val AlaGlu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala
      
      
             290                 295                 300290 295 300
      
      
         Leu Lys Ser Tyr Glu Glu Glu Leu Val Lys Asp Pro Arg Ile Ala AlaLeu Lys Ser Tyr Glu Glu Glu Leu Val Lys Asp Pro Arg Ile Ala Ala
      
      
         305                 310                 315                 320305 310 315 320
      
      
         Thr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro GlnThr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro Gln
      
      
                         325                 330                 335325 330 335
      
      
         Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala AlaMet Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala
      
      
                     340                 345                 350340 345 350
      
      
         Ser Gly Arg Gln Thr Val Asp Glu Ala Leu Lys Asp Ala Gln Thr AsnSer Gly Arg Gln Thr Val Asp Glu Ala Leu Lys Asp Ala Gln Thr Asn
      
      
                 355                 360                 365355 360 365
      
      
         Ser Ser Ser Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Leu Gly LeuSer Ser Ser Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Leu Gly Leu
      
      
             370                 375                 380370 375 380
      
      
         Pro Leu Asn Met Pro Ala Leu Glu Met Pro Ala Phe Ile Ala Thr LysPro Leu Asn Met Pro Ala Leu Glu Met Pro Ala Phe Ile Ala Thr Lys
      
      
         385                 390                 395                 400385 390 395 400
      
      
         Val Ser Gln Tyr Ser Cys Gln Arg Lys Thr Thr Leu Asn Asn Tyr AsnVal Ser Gln Tyr Ser Cys Gln Arg Lys Thr Thr Leu Asn Asn Tyr Asn
      
      
                         405                 410                 415405 410 415
      
      
         Lys Lys Phe Thr Asp Ala Phe Glu Val Met Ala Glu Asn Tyr Glu PheLys Lys Phe Thr Asp Ala Phe Glu Val Met Ala Glu Asn Tyr Glu Phe
      
      
                     420                 425                 430420 425 430
      
      
         Lys Glu Asn Glu Ile Phe Cys Leu Glu Phe Leu Arg Ala Ala Ser LeuLys Glu Asn Glu Ile Phe Cys Leu Glu Phe Leu Arg Ala Ala Ser Leu
      
      
                 435                 440                 445435 440 445
      
      
         Leu Lys Ser Leu Pro Phe Ser Val Thr Arg Met Lys Asp Ile Gln GlyLeu Lys Ser Leu Pro Phe Ser Val Thr Arg Met Lys Asp Ile Gln Gly
      
      
             450                 455                 460450 455 460
      
      
         Leu Pro Cys Val Gly Asp Gln Val Arg Asp Ile Ile Glu Glu Ile IleLeu Pro Cys Val Gly Asp Gln Val Arg Asp Ile Ile Glu Glu Ile Ile
      
      
         465                 470                 475                 480465 470 475 480
      
      
         Glu Glu Gly Glu Ser Ser Arg Val Asn Glu Val Leu Asn Asp Glu ArgGlu Glu Gly Glu Ser Ser Arg Val Asn Glu Val Leu Asn Asp Glu Arg
      
      
                         485                 490                 495485 490 495
      
      
         Tyr Lys Ala Phe Lys Gln Phe Thr Ser Val Phe Gly Val Gly Val LysTyr Lys Ala Phe Lys Gln Phe Thr Ser Val Phe Gly Val Gly Val Lys
      
      
                     500                 505                 510500 505 510
      
      
         Thr Ser Glu Lys Trp Tyr Arg Met Gly Leu Arg Thr Val Glu Glu ValThr Ser Glu Lys Trp Tyr Arg Met Gly Leu Arg Thr Val Glu Glu Val
      
      
                 515                 520                 525515 520 525
      
      
         Lys Ala Asp Lys Thr Leu Lys Leu Ser Lys Met Gln Lys Ala Gly LeuLys Ala Asp Lys Thr Leu Lys Leu Ser Lys Met Gln Lys Ala Gly Leu
      
      
             530                 535                 540530 535 540
      
      
         Leu Tyr Tyr Glu Asp Leu Val Ser Cys Val Ser Lys Ala Glu Ala AspLeu Tyr Tyr Glu Asp Leu Val Ser Cys Val Ser Lys Ala Glu Ala Asp
      
      
         545                 550                 555                 560545 550 555 560
      
      
         Ala Val Ser Leu Ile Val Lys Asn Thr Val Cys Thr Phe Leu Pro AspAla Val Ser Leu Ile Val Lys Asn Thr Val Cys Thr Phe Leu Pro Asp
      
      
                         565                 570                 575565 570 575
      
      
         Ala Leu Val Thr Ile Thr Gly Gly Phe Arg Arg Gly Lys Asn Ile GlyAla Leu Val Thr Ile Thr Gly Gly Phe Arg Arg Gly Lys Asn Ile Gly
      
      
                     580                 585                 590580 585 590
      
      
         His Asp Ile Asp Phe Leu Ile Thr Asn Pro Gly Pro Arg Glu Asp AspHis Asp Ile Asp Phe Leu Ile Thr Asn Pro Gly Pro Arg Glu Asp Asp
      
      
                 595                 600                 605595 600 605
      
      
         Glu Leu Leu His Lys Val Ile Asp Leu Trp Lys Lys Gln Gly Leu LeuGlu Leu Leu His Lys Val Ile Asp Leu Trp Lys Lys Gln Gly Leu Leu
      
      
             610                 615                 620610 615 620
      
      
         Leu Tyr Cys Asp Ile Ile Glu Ser Thr Phe Val Lys Glu Gln Leu ProLeu Tyr Cys Asp Ile Ile Glu Ser Thr Phe Val Lys Glu Gln Leu Pro
      
      
         625                 630                 635                 640625 630 635 640
      
      
         Ser Arg Lys Val Asp Ala Met Asp His Phe Gln Lys Cys Phe Ala IleSer Arg Lys Val Asp Ala Met Asp His Phe Gln Lys Cys Phe Ala Ile
      
      
                         645                 650                 655645 650 655
      
      
         Leu Lys Leu Tyr Gln Pro Arg Val Asp Asn Ser Thr Cys Asn Thr SerLeu Lys Leu Tyr Gln Pro Arg Val Asp Asn Ser Thr Cys Asn Thr Ser
      
      
                     660                 665                 670660 665 670
      
      
         Glu Gln Leu Glu Met Ala Glu Val Lys Asp Trp Lys Ala Ile Arg ValGlu Gln Leu Glu Met Ala Glu Val Lys Asp Trp Lys Ala Ile Arg Val
      
      
                 675                 680                 685675 680 685
      
      
         Asp Leu Val Ile Thr Pro Phe Glu Gln Tyr Pro Tyr Ala Leu Leu GlyAsp Leu Val Ile Thr Pro Phe Glu Gln Tyr Pro Tyr Ala Leu Leu Gly
      
      
             690                 695                 700690 695 700
      
      
         Trp Thr Gly Ser Arg Gln Phe Gly Arg Asp Leu Arg Arg Tyr Ala AlaTrp Thr Gly Ser Arg Gln Phe Gly Arg Asp Leu Arg Arg Tyr Ala Ala
      
      
         705                 710                 715                 720705 710 715 720
      
      
         His Glu Arg Lys Met Ile Leu Asp Asn His Gly Leu Tyr Asp Arg ArgHis Glu Arg Lys Met Ile Leu Asp Asn His Gly Leu Tyr Asp Arg Arg
      
      
                         725                 730                 735725 730 735
      
      
         Lys Arg Ile Phe Leu Lys Ala Gly Ser Glu Glu Glu Ile Phe Ala HisLys Arg Ile Phe Leu Lys Ala Gly Ser Glu Glu Glu Ile Phe Ala His
      
      
                     740                 745                 750740 745 750
      
      
         Leu Gly Leu Asp Tyr Val Glu Pro Trp Glu Arg Asn AlaLeu Gly Leu Asp Tyr Val Glu Pro Trp Glu Arg Asn Ala
      
      
                 755                 760                 765755 760 765
      
    
  
  
  

  
    ## Claims (10)
    
    
     
      1. A variant of a terminal deoxynucleotidyl transferase (TdT), characterized in that the mutant comprises at least one mutation selected from the group consisting of a residue at least one position of Y178, F186, I210, I228, V302, D324, R353, D324, T330, G332, F333, R335, K337, I329, I339, G340, H341, I343, R435, G452, W453, T454, G455, S456, R457, N477, H478 or a functionally equivalent residue, the position being determined by alignment with SEQ ID No. 1.
      Preferably, the amino acid sequence of the mutant comprises at least one mutation of a residue or a functionally equivalent residue at least one position selected from the group consisting of Y178, F186, I210, I228, V302, T330, R335, K337, I339, G340, R435, T454, G455, S456, R457, N477, H478. 
      More preferably, the amino acid sequence of the mutant comprises at least one mutation selected from the group consisting of a residue at least one position in Y178A, F R, I210L, I228L, V G, T330A, R335A, R335L, K337L, I339 46329 340G, G340L, R435L, T454A, G455V, S456 457G, N477L, H G or a functionally equivalent residue.
      Preferably, the amino acid sequence of the mutant comprises a mutation of the amino acid residues at any two of positions Y178, F186, I210, I228, V302, D324, R353, D324, T330, G332, F333, R335, K337, I329, I339, G340, H341, I343, R435, G452, W453, T454, G455, S456, R457, N477, H478, N477.
      Preferably, the amino acid sequence of the mutant comprises a mutation of the amino acid residues at any two positions of Y178, F186, I210, I228, V302, T330, R335, K337, I339, G340, R435, T454, G455, S456, R457, N477, H478.
      More preferably, the amino acid sequence of the mutant comprises a mutation of the amino acid residues at two positions in Y178, F186, I210, I228, V302, T330, R335, K337, I339, G340, R435, T454, G455, S456, R457, N477, H478. 
      Preferably, the amino acid sequence of the mutant comprises mutations at two positions: Y178/F186, I210/I228, R335/K337, I339/G340, S456/R457.
      Preferably, the amino acid sequence of the mutant comprises mutations at two positions: Y178A/F186R, I L/I228L, R335A/K337G, R L/K337L, I339V/G340V, S456V/R457L.
      Preferably, the variant has at least 80% identity with SEQ ID No.1 or a functionally equivalent sequence, more preferably at least 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID No.1 or a functionally equivalent sequence.
    
      
      
         
      
      2. The variant according to claim 1, characterized in that it further comprises at least one mutation of a residue in at least a semi-conserved region of the sequence from position 330 to position 343X 1X2X3X4RX5GX6NX7X8X9DX10 (SEQ ID NO: 1), wherein,
      x1 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      x2 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      x3 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      x4 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      x5 represents a residue selected from A, I, L, V, P, Q, T, K, E, 
      X6 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      x7 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      x8 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      x9 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      x10 represents a residue selected from G, L, V, F, Y, C, H, R, D.
    
      
      
         
         
      
      3. The variant according to claim 1 or 2, further comprising at least one mutation of a residue in at least a semi-conserved region of ALLX1X2X3X4X5X6QFG in sequence 449 to 460, wherein,
      x1 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      x2 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      x3 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      x4 represents a residue selected from G, L, V, F, Y, C, H, R, D,
      x5 represents a residue selected from A, I, L, V, P, Q, T, K, E,
      x6 represents a residue selected from G, L, V, F, Y, C, H, R, D.
      Preferably, the variants include variants that add or delete part of the amino acids based on SEQ ID NO. 1, yet still utilize the function of 3&#39; O-modified nucleotides to synthesize nucleic acids. Preferably, the sequence of the variant is SEQ ID NO.2.
      Preferably, variants of said TdT, including variants that do not affect protein activity, e.g. comprising a tag sequence such as MBP tag, HIS tag, GST, etc. at the N-and/or C-terminus of the above variants or functionally equivalent sequences. Preferably, the sequence of the variant is SEQ ID NO.3 or SEQ ID NO.4.
      Preferably, variants of TdT are capable of incorporating modified nucleotides, preferably modified 3 &#39;o-nucleotides, and more preferably 3&#39; o-blocked nucleotides.
      The variants comprise at least one combination of substitutions or functionally equivalent residues selected from the combinations of substitutions disclosed in table 1.
    
      
      4. A nucleic acid molecule encoding a variant as in any one of claims 1 to 3.
    
      
      5. An expression vector comprising the nucleic acid molecule of claim 4.
    
      
      6. A host cell comprising the nucleic acid molecule of claim 4 or the expression vector of claim 5.
    
      
      7. A method for producing a variant as claimed in any one of claims 1 to 3, wherein a host cell as claimed in claim 6 is cultured under culture conditions allowing expression of a nucleic acid encoding the variant, and wherein the variant is optionally recovered. 
    
      
      
         
         
         
      
      8. Use of a variant as claimed in any one of claims 1 to 3 for the synthesis of a nucleic acid molecule with 3&#39; o-modified nucleotides in the absence of a template.
    
      
      9. A method for synthesizing a nucleic acid molecule in the absence of a template, the method comprising the step of contacting a nucleic acid primer with both at least one nucleotide, preferably at least one 3&#39; o-modified nucleotide, and a variant as defined in any one of claims 1-3.
    
      
      10. A kit, enzyme or composition for performing a nucleotide incorporation reaction, characterized by comprising a variant of TdT as defined in any one of claims 1 to 9.
      Preferably, one or more nucleotides or nucleic acid molecules are also included. More preferably, one or more 3&#39; O-modified nucleotides are also included.
      More preferably, also optionally at least one DNA template or nucleic acid primer.
    
   
  
  

  

    
      CN202210107337.7A
      2022-01-28
      2022-01-28
      Terminal transferase variant for controllable synthesis of single-stranded DNA and application 
       
      Pending
      
      
        CN116555216A
        (en)
      
    

    ## Priority Applications (4)
    
      
        
          Application Number
          Priority Date
          Filing Date
          Title
        
      
      
        
          
            CN202210107337.7A
            
            
              CN116555216A
                (en)
            
          
          2022-01-28
          2022-01-28
          Terminal transferase variant for controllable synthesis of single-stranded DNA and application 
       
        
        
          
            US18/730,931
            
            
              US20250101479A1
                (en)
            
          
          2022-01-28
          2023-01-13
          Terminal transferase variants for controllably synthesizing single-stranded dna and use thereof 
     
        
        
          
            EP23746005.0A
            
            
              EP4450620A4
                (en)
            
          
          2022-01-28
          2023-01-13
          Terminal transferase variant for controllable synthesis of single-stranded dna and use thereof 
       
        
        
          
            PCT/CN2023/072086
            
            
              WO2023143123A1
                (en)
            
          
          2022-01-28
          2023-01-13
          Terminal transferase variant for controllable synthesis of single-stranded dna and use thereof 
       
        
      
    

    ## Applications Claiming Priority (1)
    
      
        
          Application Number
          Priority Date
          Filing Date
          Title
        
      
      
        
          
            CN202210107337.7A
            
              CN116555216A
                (en)
            
          
          2022-01-28
          2022-01-28
          Terminal transferase variant for controllable synthesis of single-stranded DNA and application 
       
        
      
    

    

    

    ## Publications (1)
    
      
        
          Publication Number
          Publication Date
        
      
      
        
          
            CN116555216A
            
            true
            
              CN116555216A
              (en)
            
          
          2023-08-08
        
      
    

  

  
    # Family
    ## ID=87470459

    ## Family Applications (1)
    
      
        
          Application Number
          Title
          Priority Date
          Filing Date
        
      
      
        
          
            CN202210107337.7A
            Pending
            
            
              CN116555216A
                (en)
            
          
          2022-01-28
          2022-01-28
          Terminal transferase variant for controllable synthesis of single-stranded DNA and application 
       
        
      
    

    

    

    ## Country Status (4)
    
      
        
          Country
          Link
        
      
      
        
          
            US
            (1)
            
          
          
            
              US20250101479A1
              (en)
            
          
        
        
          
            EP
            (1)
            
          
          
            
              EP4450620A4
              (en)
            
          
        
        
          
            CN
            (1)
            
          
          
            
              CN116555216A
              (en)
            
          
        
        
          
            WO
            (1)
            
          
          
            
              WO2023143123A1
              (en)
            
          
        
      
    

    

    ## Families Citing this family (1)
    
      * Cited by examiner, â  Cited by third party
      
        
          Publication number
          Priority date
          Publication date
          Assignee
          Title
        
      
      
        
          
            
              CN119193526B
              (en)
            
            *
            
          
          2024-10-09
          2025-08-26
          æµæ±å¤§å­¦
          
        Terminal deoxynucleotidyl transferase mutant and its application
       
       
        
      
    

    

    ## Family Cites Families (12)
    
      * Cited by examiner, â  Cited by third party
      
        
          Publication number
          Priority date
          Publication date
          Assignee
          Title
        
      
      
        
          
            
              US5808045A
              (en)
            
            
            
          
          1994-09-02
          1998-09-15
          Andrew C. Hiatt
          Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides 
       
        
        
          
            
              FR3020071B1
              (en)
            
            
            
          
          2014-04-17
          2017-12-22
          Dna Script
          
        PROCESS FOR THE SYNTHESIS OF NUCLEIC ACIDS, IN PARTICULAR LARGE NUCLEIC ACIDS, USE OF THE METHOD AND KIT FOR IMPLEMENTING THE METHOD
       
     
        
        
          
            
              FR3025201B1
              (en)
            
            
            
          
          2014-09-02
          2018-10-12
          Dna Script
          
  MODIFIED NUCLEOTIDES FOR THE SYNTHESIS OF NUCLEIC ACIDS, A KIT COMPRISING SUCH NUCLEOTIDES AND THEIR USE FOR GENERATING SYNTHETIC NUCLEIC ACID GENES OR SEQUENCES
 
     
        
        
          
            
              EP3699283A1
              (en)
            
            *
            
          
          2014-10-20
          2020-08-26
          Molecular Assemblies Inc.
          Modified template-independent enzymes for polydeoxynucleotide systhesis 
       
        
        
          
            
              FR3052462A1
              (en)
            
            *
            
          
          2016-06-14
          2017-12-15
          Dna Script
          
        POLYMERASE DNA VARIANTS OF THE POLX FAMILY
       
       
        
        
          
            
              AU2019205606A1
              (en)
            
            *
            
          
          2018-01-08
          2020-07-30
          Centre National De La Recherche Scientifique
          Variants of Terminal deoxynucleotidyl Transferase and uses thereof 
     
        
        
          
            
              SG11202104601PA
              (en)
            
            *
            
          
          2018-11-14
          2021-06-29
          Dna Script
          Terminal deoxynucleotidyl transferase variants and uses thereof 
     
        
        
          
            
              CA3122494A1
              (en)
            
            *
            
          
          2018-12-13
          2020-06-18
          Dna Script
          Direct oligonucleotide synthesis on cells and biomolecules 
       
        
        
          
            
              GB201901501D0
              (en)
            
            *
            
          
          2019-02-04
          2019-03-27
          Nuclera Nucleics Ltd
          Modified terminal deoxynucleotidyl transferase (TdT) enzymes 
     
        
        
          
            
              CN114207140A
              (en)
            
            *
            
          
          2019-05-28
          2022-03-18
          Dnaæ¯åçæ®ç¹å¬å¸
          
        Terminal deoxynucleotidyl transferase variants and uses thereof
       
       
        
        
          
            
              EP3744854A1
              (en)
            
            *
            
          
          2019-05-28
          2020-12-02
          DNA Script
          Variants of terminal deoxynucleotidyl transferase and uses thereof 
       
        
        
          
            
              CN112746063B
              (en)
            
            *
            
          
          2019-10-29
          2021-12-31
          ä¸­å½ç§å­¦é¢å¤©æ´¥å·¥ä¸çç©ææ¯ç ç©¶æ
          New function and application of nucleoside transferase 
       
        
      
    

    
      
        2022
        
          
            2022-01-28
            CN
            CN202210107337.7A
            patent/CN116555216A/en
            active
            Pending
            
          
        
      
      
        2023
        
          
            2023-01-13
            WO
            PCT/CN2023/072086
            patent/WO2023143123A1/en
            active
            Application Filing
            
          
          
            2023-01-13
            US
            US18/730,931
            patent/US20250101479A1/en
            active
            Pending
            
          
          
            2023-01-13
            EP
            EP23746005.0A
            patent/EP4450620A4/en
            active
            Pending
            
          
        
      
    

    

  

  

  

  
    ## Also Published As
    
      
        
          Publication number
          Publication date
        
      
      
        
          
            
              WO2023143123A1
              (en)
            
          
          2023-08-03
        
        
          
            
              US20250101479A1
              (en)
            
          
          2025-03-27
        
        
          
            
              EP4450620A4
              (en)
            
          
          2025-06-25
        
        
          
            
              EP4450620A1
              (en)
            
          
          2024-10-23
        
      
    
  

  
    ## Similar Documents
    
      
        
          Publication
          Publication Date
          Title
        
      
      
        
          
            
              
                US10435676B2
                (en)
              
            
            
          
          
            2019-10-08
            
            
          
          Variants of terminal deoxynucleotidyl transferase and uses thereof 
       
        
        
          
            
              
                US12286652B2
                (en)
              
            
            
          
          
            2025-04-29
            
            
          
          Variants of terminal deoxynucleotidyl transferase and uses thereof 
       
        
        
          
            
              
                US11859217B2
                (en)
              
            
            
          
          
            2024-01-02
            
            
          
          Terminal deoxynucleotidyl transferase variants and uses thereof 
       
        
        
          
            
              
                US12173333B2
                (en)
              
            
            
          
          
            2024-12-24
            
            
          
          Variants of family a DNA polymerase and uses thereof 
       
        
        
          
            
              
                JP2022543569A
                (en)
              
            
            
          
          
            2022-10-13
            
            
          
          
        Templateless Enzymatic Synthesis of Polynucleotides Using Poly(A) and Poly(U) Polymerases
       
     
        
        
          
            
              
                JP2023522234A
                (en)
              
            
            
          
          
            2023-05-29
            
            
          
          
        Terminal deoxynucleotidyl transferase mutants and uses thereof
       
     
        
        
          
            
              
                AU2020281709B2
                (en)
              
            
            
          
          
            2024-08-08
            
            
          
          Variants of terminal deoxynucleotidyl transferase and uses thereof. 
       
        
        
          
            
              
                WO2023143123A1
                (en)
              
            
            
          
          
            2023-08-03
            
            
          
          Terminal transferase variant for controllable synthesis of single-stranded dna and use thereof 
       
        
        
          
            
              
                EP3744854A1
                (en)
              
            
            
          
          
            2020-12-02
            
            
          
          Variants of terminal deoxynucleotidyl transferase and uses thereof 
       
        
        
          
            
              
                JP2023501651A
                (en)
              
            
            
          
          
            2023-01-18
            
            
          
          
        Highly efficient template-free enzymatic synthesis of polynucleotides
       
     
        
      
    
  

  
    ## Legal Events
    
      
        
          Date
          Code
          Title
          Description
        
      
      
        
          2023-08-08
          PB01
          Publication
          
          
        
        
          2023-08-08
          PB01
          Publication
          
          
        
        
          2023-08-25
          SE01
          Entry into force of request for substantive examination
          
          
        
        
          2023-08-25
          SE01
          Entry into force of request for substantive examination
          
          
        
      
    
  



    
    
    
    
    
    
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    
    
  



## 资源文件

无资源文件
